var title_f7_2_7200="Obesity all-cause mortality";
var content_f7_2_7200=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F73156&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F73156&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 600px\">",
"   <div class=\"ttl\">",
"    All-cause mortality versus BMI for each sex in the range 15 to 50 kg/m",
"    <sup>",
"     2",
"    </sup>",
"    (excluding the first five years of follow-up)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 580px; height: 697px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relative risks at age 35 to 89 years, adjusted for age at risk, smoking, and study, were multiplied by a common factor (ie, floated) to make the weighted average match the PSC mortality rate at ages 35 to 79 years. Floated mortality rates shown above each square and numbers of deaths below. Area of square is inversely proportional to the variance of the log risk. Boundaries of BMI groups are indicated by tick marks. 95% CIs for floated rates reflect uncertainty in the log risk for each single rate. Dotted vertical line indicates 25 kg/m",
"    <sup>",
"     2",
"    </sup>",
"    (boundary between upper and lower BMI ranges in this report). Above 25 kg/m",
"    <sup>",
"     2",
"    </sup>",
"    , mortality was on average approximately 30 percent higher for every 5 kg/m",
"    <sup>",
"     2",
"    </sup>",
"    higher BMI.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373:1083. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_2_7200=[""].join("\n");
var outline_f7_2_7200=null;
var title_f7_2_7201="Wing block";
var content_f7_2_7201=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74358&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74358&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Wing block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Holding the syringe at a 45 degree angle to the plane of the table and perpendicular to the long axis of the digit, insert the needle a short distance to enter the deep intradermal tissue of the dorsum of the digit at a point approximately 3 mm proximal to an imaginary point where a linear extension of the lateral and proximal nail folds would intersect. Inject the anesthetic into the intradermal tissue, first infiltrating the proximal nail fold; the needle can be advanced to allow infiltration along the proximal nail fold. The needle is then partially withdrawn and redirected to allow infiltration of the intradermal tissue along the lateral nail fold. As the anesthetic is injected, the folds blanch and distend creating a wing-like appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_2_7201=[""].join("\n");
var outline_f7_2_7201=null;
var title_f7_2_7202="Lower leg fasciotomy landmarks";
var content_f7_2_7202=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F80994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F80994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 515px\">",
"   <div class=\"ttl\">",
"    Incisions for four compartment lower extremity fasciotomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 495px; height: 573px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The two incision four-compartment fasciotomy uses medial and lateral longitudinal incisions that are 12 to 20 cm in length. The lateral incision is centered between the fibular shaft and the spine of the tibia. The medial incision is placed 1 to 2 cm medial to the tibial margin. A single incision fasciotomy uses the lateral of these incisions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_2_7202=[""].join("\n");
var outline_f7_2_7202=null;
var title_f7_2_7203="Ultrasound-guided breast biopsy PI";
var content_f7_2_7203=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F86543&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F86543&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Ultrasound-guided breast biopsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 629px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During an ultrasound-guided breast biopsy, the doctor uses an ultrasound, which uses sound waves, to create a picture of your breast. It lets the doctor see where to place the needle for the biopsy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_2_7203=[""].join("\n");
var outline_f7_2_7203=null;
var title_f7_2_7204="Doppler ultrasound nuchal cord";
var content_f7_2_7204=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Doppler ultrasound of the nuchal cord",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Professor Josef Wisser, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_2_7204=[""].join("\n");
var outline_f7_2_7204=null;
var title_f7_2_7205="Enfuvirtide: Drug information";
var content_f7_2_7205=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Enfuvirtide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/33/21013?source=see_link\">",
"    see \"Enfuvirtide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/39/6774?source=see_link\">",
"    see \"Enfuvirtide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F165005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fuzeon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F165006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fuzeon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F165024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiretroviral Agent, Fusion Protein Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F165009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Use is not recommended in antiretroviral therapy na&iuml;ve patients (DHHS, 2013).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      HIV treatment:",
"     </b>",
"     SubQ: 90 mg twice daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F165018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/39/6774?source=see_link\">",
"      see \"Enfuvirtide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Use is not recommended in antiretroviral therapy na&iuml;ve patients (DHHS, 2013).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      HIV treatment:",
"     </b>",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6-16 years: 2 mg/kg twice daily (maximum dose: 90 mg twice daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents &ge;16 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F165010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F165011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;35 mL/minute: Clearance not affected; no dosage adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;35 mL/minute: Limited data showed decreased clearance; however, no dosage adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     End-stage renal disease (on dialysis): Limited data showed decreased clearance; however, no dosage adjustment recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F3441194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment required.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F164985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fuzeon&reg;: 108 mg [90 mg/mL following reconstitution]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F164973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F164987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inject subcutaneously into upper arm, abdomen, or anterior thigh. Do not inject into moles, the navel, over a blood vessel or skin abnormalities such as scar tissue, surgical scars,  bruises, or tattoos. In addition, do not inject in or near sites where large nerves are close to the skin including the elbow, knee, groin, or buttocks. Rotate injection site, give injections at a site different from the preceding injection site; do not inject into any site where an injection site reaction is evident. Bioequivalence was found to be similar in a study comparing standard administration using a needle versus a needle-free device.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F164986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV-1 infection in combination with other antiretroviral agents in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F165022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (20%), insomnia (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (32%), nausea (23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site infection (children 11%), injection site reactions (98%; may include pain, erythema, induration, pruritus, ecchymosis, nodule or cyst formation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Folliculitis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Weight loss (7%), abdominal pain (4%), appetite decreased (3%), pancreatitis (3%), anorexia (2%), xerostomia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Eosinophilia (2% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases increased (4%, grade 4: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site infection (adults 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: CPK increased (3% to 7%), limb pain (3%), myalgia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctivitis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Sinusitis (6%), cough (4%), bacterial pneumonia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infections (4% to 6%), herpes simplex (4%), flu-like syndrome (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abacavir hypersensitivity worsening, amylase increased, angina, anxiety, constipation, depression, GGT increased, glomerulonephritis, Guillain-Barr&eacute; syndrome, hepatic steatosis, hyperglycemia; hypersensitivity reactions (symptoms may include rash, fever, nausea, vomiting, hypotension, and transaminase increases); insomnia, lipase increased, lymphadenopathy, neutropenia, peripheral neuropathy, pneumopathy, renal failure, renal insufficiency, respiratory distress, sepsis, sixth nerve palsy, suicide attempt, taste disturbances, thrombocytopenia, toxic hepatitis, triglycerides increased, tubular necrosis, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F164990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to enfuvirtide or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F164976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: May cause hypersensitivity reactions (symptoms may include rash, fever, nausea, vomiting, hypotension, and elevated transaminases).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injection site reactions: Local injection site reactions are common.  Administration using a needle-free device has been associated with nerve pain (including neuralgia and/or paresthesia lasting up to 6 months), bruising, and hematomas when administered at sites where large nerves are close to the skin; only administer medication in recommended sites.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pneumonia: Monitor closely for signs/symptoms of pneumonia; associated with an increased incidence during clinical trials, particularly in patients with a low CD4 cell count, high initial viral load, I.V. drug use, smoking, or a history of lung disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with coagulation disorders (eg, hemophilia) or receiving anticoagulants; increased risk of bleeding at injection site.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV: Appropriate use: Use is not recommended in antiretroviral therapy-naive patients (DHHS, 2013).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;6 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F164980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: Enfuvirtide may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Enfuvirtide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F164982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F164992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. Limited data suggest that enfuvirtide does not cross the placenta. The DHHS Perinatal HIV Guidelines note that data are insufficient to recommend use during pregnancy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum antiretroviral (ARV) drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV, also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F165013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F164993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal or infant antiretroviral therapy does not completely eliminate the risk of postnatal HIV transmission. In addition, multiclass-resistant virus has been detected in breast-feeding infants despite maternal therapy. Therefore, in the United States, where formula is accessible, affordable, safe, and sustainable, and the risk of infant mortality due to diarrhea and respiratory infections is low, complete avoidance of breast-feeding by HIV-infected women is recommended to decrease potential transmission of HIV (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Fuzeon Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     90 mg (1): $3346.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Fuzeon Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     90 mg (1): $55.77",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F164994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Fuzeon (AR, AT, AU, BE, BG, BR, CH, CN, CO, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HN, IE, IL, IT, MT, MX, NL, NO, NZ, PE, PL, PT, RU, SE, SG, SK, TH, TR, TW, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F164975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein. Inhibits the fusion of HIV-1 virus with CD4 cells by blocking the conformational change in gp41 required for membrane fusion and entry into CD4 cells",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F164989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 5.5 L; CSF concentrations (2-18 hours after administration): nondetectable (&lt;0.025 mcg/mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 92%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Proteolytic hydrolysis (CYP isoenzymes do not appear to contribute to metabolism)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Adults: 24.8 mL/hour/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 84% &plusmn; 16%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 3.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 4-8 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services,&rdquo; February 12, 2013;1-267. Available at",
"      <a href=\"file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7&amp;ClassID=1\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,\"  July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      True AL, Chiu YY, Demasi RA, et al, &ldquo;Pharmacokinetic Bioequivalence of Enfuvirtide Using a Needle-Free Device Versus Standard Needle Administration,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2006, 26(12):1679-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/2/7205/abstract-text/17125431/pubmed\" id=\"17125431\" target=\"_blank\">",
"        17125431",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, &ldquo;Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,&rdquo; August 16, 2010. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8609 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-61.234.146.186-C2D6B77659-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_2_7205=[""].join("\n");
var outline_f7_2_7205=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165005\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165006\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165024\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165009\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165018\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165010\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165011\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3441194\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164985\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164973\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164987\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164986\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165022\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164990\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164976\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299263\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164980\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164982\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164992\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165013\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164993\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323128\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164994\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164975\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164989\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8609\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8609|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/33/21013?source=related_link\">",
"      Enfuvirtide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/39/6774?source=related_link\">",
"      Enfuvirtide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_2_7206="Cabergoline: Drug information";
var content_f7_2_7206=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cabergoline: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/43/6837?source=see_link\">",
"    see \"Cabergoline: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F143938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      CO Cabergoline;",
"     </li>",
"     <li>",
"      Dostinex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F143967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Ergot Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F143941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hyperprolactinemia:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     Initial dose: 0.25 mg twice weekly; the dose may be increased by 0.25 mg twice weekly up to a maximum of 1 mg twice weekly according to the patient's serum prolactin level. Dosage increases should not occur more rapidly than every 4 weeks. Once a normal serum prolactin level is maintained for 6 months, the dose may be discontinued and prolactin levels monitored to determine if cabergoline is still required. The durability of efficacy beyond 24 months of therapy has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Initial dose: 0.5 mg once weekly or 0.25 mg twice weekly; weekly dose may be increased by 0.5 mg per week at 4 week intervals until optimal therapeutic response. Therapeutic dose: Usual: 1 mg/week (range 0.25-2 mg/week).",
"     <b>",
"      Note:",
"     </b>",
"     May divide weekly dose into 2 or more divided doses per week (recommended for doses &gt;1 mg/week) based on tolerability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lactation inhibition",
"     </b>",
"     <i>",
"      (Canadian labeling; not in U.S. labeling):",
"     </i>",
"     Oral: 1 mg single dose on first day postpartum",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F143942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. No dosage recommendations suggested; however, start at the low end of the dosage range.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F4117136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No dosage adjustment required; pharmacokinetics not altered with moderate-severe renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F4117137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate dysfunction (Child-Pugh class B or C): No dosage adjustment required; no effect on C",
"     <sub>",
"      max",
"     </sub>",
"     or AUC.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe dysfunction (Child-Pugh class C): There are no dosage adjustments provided in manufacturer's labeling; use caution; significant increase in AUC.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F143922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 0.5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F143909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13267702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with meals (may increase tolerability).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F143923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional use (not in U.S. labeling): Prevention of the onset of physiological lactation in the puerperium when clinically indicated (eg, still born baby or neonatal death, conditions that interfere with suckling, severe acute or chronic mental illness).",
"     <b>",
"      Note:",
"     </b>",
"     Not indicated for suppression of established postpartum lactation.",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F143965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (26%), dizziness (15% to 17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (27% to 29%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Orthostatic hypotension (4%), hypotension (1%), dependent edema (1%), edema (peripheral 1%), palpitation (1%), syncope (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (5% to 7%), vertigo (1% to 4%), depression (3%), somnolence (2% to 5%), nervousness (1% to 2%), anxiety (1%), insomnia (1%), concentration impaired (1%), malaise (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Acne (1%), pruritus (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine: Hot flashes (1% to 3%), breast pain (1% to 2%), dysmenorrhea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (7% to 10%), abdominal pain (5%), dyspepsia (2% to 5%), vomiting (2% to 4%), xerostomia (2%), diarrhea (2%), flatulence (2%), anorexia (1%), throat irritation (1%), toothache (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (6% to 9%), pain (2%), paresthesia (1% to 2%), arthralgia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Abnormal vision (1%), periorbital edema (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Aggression, alopecia, cardiac fibrosis, duodenal ulcer (in PD patients), gastric ulcer (in PD patients), pleural effusion, psychosis, pulmonary fibrosis, valvular regurgitation, valvulopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Aggression, alopecia, cardiac fibrosis, confusion (in patients with Parkinson's disease [PD]), constrictive pericarditis (in PD patients), duodenal ulcer (in PD patients), dyskinesia (in PD patients), epistaxis, facial edema, gastric ulcer (in PD patients), hallucinations (in PD patients), heart failure (in PD patients), hypersexuality, libido increased, pathological gambling, pleural effusion (in PD patients), psychosis, pulmonary fibrosis (in PD patients), valvulopathy, weight gain/loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F143927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ergot derivatives; uncontrolled hypertension; history of pulmonary, pericardial, or retroperitoneal fibrotic disorders; history of cardiac valvular disorders",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F143913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac valvulopathy: Cardiac valvular disease (mitral, aortic, tricuspid regurgitation) has been associated with cabergoline (a potent 5-HT",
"     <sub>",
"      2B",
"     </sub>",
"     agonist). Cardiovascular evaluation (including ECG) is necessary prior to initiating treatment. Treatment should not be initiated if valvular disease is detected. The lowest effective dose should be utilized; incidence may be higher for daily doses &gt;2 mg and for duration of use &ge;6 months. Use with caution if patients are using concomitant medications associated with valvulopathy. Following diagnosis of valvulopathy, discontinuation of cabergoline may result in improvement of condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause somnolence; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: Initial doses &gt;1 mg may cause orthostatic hypotension. Concurrent use with antihypertensives may increase risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pleural/retroperitoneal fibrosis: Rare cases of pleural or retroperitoneal fibrosis have been reported with prolonged daily use. Treatment should not be initiated in patients with a history of fibrotic disorders. Following diagnosis of fibrosis, discontinuation of cabergoline may result in improvement of condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disorders: Pathological gambling, increased libido, and hypersexuality have been reported with use; generally reversible with dose reduction or discontinuation of treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution and carefully monitor patients with hepatic impairment; extensively metabolized by the liver.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peptic ulcer disease (PUD): Use with caution in patients with PUD or GI bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy-induced hypertension: Should not be used in patients with pregnancy-induced hypertension unless benefit outweighs potential risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Raynaud's syndrome: Use with caution in patients with Raynaud's syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: In the U.S. labeling, not indicated for the inhibition or suppression of physiologic lactation; other dopamine agonists are associated with cases of hypertension, stroke, and seizures.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F143918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Ergot Derivatives may enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Ergot Derivatives may enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lorcaserin: May enhance the adverse/toxic effect of Ergot Derivatives. Specifically, use of these drugs together may increase the risk of developing valvular heart disease. Lorcaserin may enhance the serotonergic effect of Ergot Derivatives. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroglycerin: Ergot Derivatives may diminish the vasodilatory effect of Nitroglycerin. This is of particular concern in patients being treated for angina. Nitroglycerin may increase the serum concentration of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin 5-HT1D Receptor Agonists: Ergot Derivatives may enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5648625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid products that enhance serotonin activity (includes SAMe [S-adenosylmethionine] and St John's wort); may increase the risk of serotonin syndrome.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F143919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4116767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in most animal studies when administered in maternally nontoxic doses. Treatment of hyperprolactinemia may restore fertility in a previously infertile woman. Because information concerning the use of cabergoline in pregnancy is limited, bromocriptine is generally recommended to treat hyperprolactinemia in women who wish to conceive. Based on preliminary data, cabergoline has not been shown to increase the risk of congenital malformations or miscarriages when used early in pregnancy (treatment was generally stopped once pregnancy was diagnosed). Not recommended for use in patients with pregnancy-induced hypertension unless benefit outweighs potential risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling (not in U.S. labeling): Exclude pregnancy prior to use; prevent pregnancy for &ge;1 month following discontinuation of treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F4116769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F4116770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with lactation and should not be given to women postpartum who are breast-feeding or who are planning to breast-feed. In the U.S. labeling, not indicated for the suppression of physiologic lactation.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F13267701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F143930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cabergoline Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (8): $293.27",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F4117138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure (both sitting/supine and standing); serum prolactin level (monthly until normalized); echocardiogram (at baseline and every 6-12 months or as needed during therapy); erythrocyte sedimentation rate, chest x-ray, and serum creatinine (at baseline and during therapy as needed)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F143931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cabaser (AR, AU, CH, DK, FI, GB, IE, IL, IT, SE);",
"     </li>",
"     <li>",
"      Cabergoline-Pharmacia (LU);",
"     </li>",
"     <li>",
"      Caberlin (IN);",
"     </li>",
"     <li>",
"      Cabotrim (IL);",
"     </li>",
"     <li>",
"      Dostinex (AE, AT, AU, BE, BG, BH, BR, CH, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, FI, FR, GB, GR, GT, HK, HN, IE, IL, IQ, IR, IT, JO, KW, LB, LU, LY, MT, MX, MY, NI, NL, NO, NZ, OM, PA, PE, PL, PT, QA, RU, SA, SE, SG, SK, SV, SY, TR, TW, UY, VE, YE, ZA);",
"     </li>",
"     <li>",
"      Lactinese (PE);",
"     </li>",
"     <li>",
"      Prolastat (CO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F143912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cabergoline is a long acting dopamine receptor agonist with a high affinity for D",
"     <sub>",
"      2",
"     </sub>",
"     receptors; prolactin secretion by the anterior pituitary is predominantly under hypothalamic inhibitory control exerted through the release of dopamine. It is a potent 5-HT",
"     <sub>",
"      2B",
"     </sub>",
"     -receptor agonist, which may contribute to observed fibrotic/valvulopathic events.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F143926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Extensive, particularly to the pituitary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 40% to 42%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via hydrolysis; minimal CYP mediated metabolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 63-69 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily feces (~60%); urine (~22%, &lt;4% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bronstein MD, &ldquo;Prolactinomas and Pregnancy,&rdquo;",
"      <i>",
"       Pituitary",
"      </i>",
"      , 2005, 8(1):31-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/2/7206/abstract-text/16411066/pubmed\" id=\"16411066\" target=\"_blank\">",
"        16411066",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      European Multicentre Study Group for Cabergoline in Lactation Inhibition, &ldquo;Single Dose Cabergoline Versus Bromocriptine in Inhibition of Puerperal Lactation: Randomised, Double-Blind, Multicentre Study,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1991, 302(6789):1367-71.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferrari C, Paracchi A, Mattei AM, et al, &ldquo;Cabergoline in the Long-Term Therapy of Hyperprolactinemic Disorders,&rdquo;",
"      <i>",
"       Acta Endocrinol (Copenh)",
"      </i>",
"      , 1992, 126(6):489-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/2/7206/abstract-text/1642081/pubmed\" id=\"1642081\" target=\"_blank\">",
"        1642081",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Giusti M, Porcella E, Carraro A, et al, &ldquo;A Cross-Over Study With the Two Novel Dopaminergic Drugs Cabergoline and Quinagolide in Hyperprolactinemic Patients,&rdquo;",
"      <i>",
"       J Endocrinol Invest",
"      </i>",
"      , 1994, 17(1):51-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/2/7206/abstract-text/7911813/pubmed\" id=\"7911813\" target=\"_blank\">",
"        7911813",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rains CP, Bryson HM, and Fitton A, &ldquo;Cabergoline: A Review of Its Pharmacological Properties and Therapeutic Potential in the Treatment of Hyperprolactinemia and Inhibition of Lactation,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1995, 49(2):255-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/2/7206/abstract-text/7729332/pubmed\" id=\"7729332\" target=\"_blank\">",
"        7729332",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ricci E, Parazzini F, Motta T, et al, &ldquo;Pregnancy Outcome After Cabergoline Treatment in Early Weeks of Gestation,&rdquo;",
"      <i>",
"       Reprod Toxicol",
"      </i>",
"      , 2002, 16(6):791-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/2/7206/abstract-text/12401507/pubmed\" id=\"12401507\" target=\"_blank\">",
"        12401507",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Robert E, Musatti L, Piscitelli G, et al, &ldquo;Pregnancy Outcome After Treatment With the Ergot Derivative, Cabergoline,&rdquo;",
"      <i>",
"       Reprod Toxicol",
"      </i>",
"      , 1996, 10(4):333-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/2/7206/abstract-text/8829257/pubmed\" id=\"8829257\" target=\"_blank\">",
"        8829257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roth BL, &ldquo;Drugs and Valvular Heart Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 356(1):6-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/2/7206/abstract-text/17202450/pubmed\" id=\"17202450\" target=\"_blank\">",
"        17202450",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schade R, Andersohn F, Suissa S, et al, &ldquo;Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 356(1):29-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/2/7206/abstract-text/17202453/pubmed\" id=\"17202453\" target=\"_blank\">",
"        17202453",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Webster J, Piscitelli G, Polli A, et al, &ldquo;A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1994, 331(14):904-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/2/7206/abstract-text/7915824/pubmed\" id=\"7915824\" target=\"_blank\">",
"        7915824",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Webster J, Piscitelli G, Polli A, et al, &ldquo;Dose-Dependent Suppression of Serum Prolactin by Cabergoline in Hyperprolactinaemia: A Placebo Controlled, Double Blind, Multicentre Study,&rdquo;",
"      <i>",
"       Clin Endocrinol (Oxf)",
"      </i>",
"      , 1992, 37(6):534-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/2/7206/abstract-text/1286524/pubmed\" id=\"1286524\" target=\"_blank\">",
"        1286524",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Webster J, Piscitelli G, Polli A, et al, &ldquo;The Efficacy and Tolerability of Long-Term Cabergoline Therapy in Hyperprolactinaemic Disorders: An Open, Uncontrolled, Multicentre Study,&rdquo;",
"      <i>",
"       Clin Endocrinol (Oxf)",
"      </i>",
"      , 1993, 39(3):323-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/2/7206/abstract-text/7900937/pubmed\" id=\"7900937\" target=\"_blank\">",
"        7900937",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zanettini R, Antonini A, Gatto G, et al, &ldquo;Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson&rsquo;s Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      2007, 356(1):39-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/2/7206/abstract-text/17202454/pubmed\" id=\"17202454\" target=\"_blank\">",
"        17202454",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8600 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-6EBEB1F6CE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_2_7206=[""].join("\n");
var outline_f7_2_7206=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143938\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143967\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143941\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143942\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4117136\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4117137\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143922\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143909\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13267702\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143923\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143965\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143927\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143913\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298921\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143918\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5648625\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143919\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4116767\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4116769\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4116770\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13267701\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143930\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4117138\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143931\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143912\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143926\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8600\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8600|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/43/6837?source=related_link\">",
"      Cabergoline: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_2_7207="Prevention of necrotizing enterocolitis in newborns";
var content_f7_2_7207=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of necrotizing enterocolitis in newborns",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/2/7207/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/2/7207/contributors\">",
"     Richard J Schanler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/2/7207/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/2/7207/contributors\">",
"     Steven A Abrams, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/2/7207/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/2/7207/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/2/7207/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Necrotizing enterocolitis (NEC) is one of the most common gastrointestinal emergencies in the newborn infant. It is a disorder characterized by ischemic necrosis of the intestinal mucosa, which is associated with inflammation, invasion of enteric gas forming organisms, and dissection of gas into the muscularis and portal venous system [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/1\">",
"     1",
"    </a>",
"    ]. Although early recognition and aggressive treatment of this disorder has improved clinical outcomes, NEC accounts for substantial long-term morbidity in survivors of neonatal intensive care, particularly in premature very low birth weight infants (birth weight below 1500 g). As a result, research efforts have focused on finding interventions that will reduce the risk and severity of this disorder.",
"   </p>",
"   <p>",
"    The prevention of NEC will be reviewed here. The pathology, pathogenesis, clinical features, diagnosis, and management of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28105?source=see_link\">",
"     \"Pathology and pathogenesis of necrotizing enterocolitis in newborns\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41591?source=see_link\">",
"     \"Clinical features and diagnosis of necrotizing enterocolitis in newborns\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35928?source=see_link\">",
"     \"Management of necrotizing enterocolitis in newborns\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efforts to minimize the frequency or severity of necrotizing enterocolitis (NEC) are directed at reducing exposure to risk factors and finding interventions that will prevent the disorder. The use of human milk versus formula has been shown to reduce the risk of NEC. Other commonly used preventive measures, most of which have less support, include having a neonatal intensive care unit (NICU) feeding protocol [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/2\">",
"     2",
"    </a>",
"    ], judicious advancement of enteral feeding (between 15 and 25",
"    <span class=\"nowrap\">",
"     mL/kg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/3\">",
"     3",
"    </a>",
"    ], the avoidance of hypertonic formulas, hypertonic medications or contrast agents that may injure the intestinal mucosa, and prompt treatment of polycythemia. These measures are routinely performed in the management of infants cared for in the neonatal intensive care unit (NICU). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28105?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathology and pathogenesis of necrotizing enterocolitis in newborns\", section on 'Medications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HUMAN MILK FEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human milk compared to formula is the most important strategy associated with a lower risk of necrotizing enterocolitis (NEC) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28105?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathology and pathogenesis of necrotizing enterocolitis in newborns\", section on 'Milk feeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/28/458?source=see_link\">",
"     \"Nutritional composition of human milk and preterm formula for the premature infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This was illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of five randomized controlled trials demonstrated that the risk of NEC was increased 2.5 times in infants who were fed formula compared to those who were breast fed (RR 2.5, 95% CI 1.2-5.1) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a subsequent study from the National Institute of Child Health and Human Developmental Neonatal Network, the risk of NEC was decreased by a factor of 0.8 for each 10 percent increase in the proportion of enteral intake that comprised human milk [",
"      <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a trial of 207 preterm infants (birth weight 500 to 1250 g), the rate of NEC was lower in the two groups randomly assigned to an exclusively human milk diet (donor human milk-based human milk fortifier added to mothers&rsquo; own milk and pasteurized donor milk if no mothers&rsquo; milk was available) compared to the group receiving bovine milk-based human milk fortifier added to mothers&rsquo; own milk and preterm formula if no mothers&rsquo; milk was available (6 versus 16 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/10\">",
"       10",
"      </a>",
"      ]. Only two of eight infants with NEC who were fed an exclusively human milk diet required surgery compared to 7 of 11 infants with NEC who received bovine milk-based products. These findings demonstrate the significant benefits of an exclusive human milk diet that is appropriately fortified compared with a diet containing bovine milk-based products for extremely preterm infants.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of exclusive human milk diets, appropriately fortified, has resulted in lower rates of NEC. Thus, in many units if mothers&rsquo; own milk is unavailable, pasteurized donor human milk is used. This approach is consistent with the 2012 American Academy of Pediatrics breastfeeding policy statement [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23655?source=see_link&amp;anchor=H10#H10\">",
"     \"Human milk feeding and fortification of human milk for premature infants\", section on 'Preterm formula versus donor milk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11354162\">",
"    <span class=\"h1\">",
"     TIMING OF INITIAL FEED",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal timing of initiation of minimal enteral (trophic) feeding remains uncertain and its association with NEC is lacking. A systematic review of very low birth weight infants (birth weight &lt;1500 g) concluded that available data were insufficient to determine whether early feeds (before 96 hours postnatal) were associated with either beneficial or harmful effects [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/12\">",
"     12",
"    </a>",
"    ]. Another systemic review that compared early versus delayed enteral feedings concluded that late initiation of feeds (greater than 4 days postnatal) did not appear to reduce the risk of NEC and was associated with a longer time period to full enteral feeds compared to early feeding [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our institution, enteral feedings with unfortified human milk, if available, are initiated in the first two to five days after birth to prime the gastrointestinal (GI) tract (trophic feeding) in the very low birth weight infant (birth weight &lt;1500 g), who is at the greatest risk for NEC, and to begin feeds in the more mature infant. The volume is advanced to provide enteral nutrition when the infant is clinically stable and minimal feedings are tolerated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/8/19593?source=see_link\">",
"     \"Approach to enteral nutrition in the premature infant\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28105?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathology and pathogenesis of necrotizing enterocolitis in newborns\", section on 'Prematurity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28105?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathology and pathogenesis of necrotizing enterocolitis in newborns\", section on 'Human milk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PROBIOTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Probiotics are defined as live nonpathogenic microbial preparations that colonize the intestine [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Probiotic therapy appears to be a promising strategy to prevent necrotizing enterocolitis (NEC) in premature infants. Probiotic microorganisms commonly used are strains of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/5/1108?source=see_link\">",
"     Lactobacillus",
"    </a>",
"    , Bifidobacterium, Streptococcus salivarius, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/39/25203?source=see_link\">",
"     Saccharomyces boulardii",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The following are the proposed mechanisms why probiotic reduce NEC in neonates. These are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=see_link\">",
"     \"Probiotics for gastrointestinal diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28105?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathology and pathogenesis of necrotizing enterocolitis in newborns\", section on 'Microbial colonization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Improvement of intestinal barrier function",
"     </li>",
"     <li>",
"      Modulation of the immune system",
"     </li>",
"     <li>",
"      Suppression of growth or epithelial",
"      <span class=\"nowrap\">",
"       binding/invasion",
"      </span>",
"      by pathogenic bacteria",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Randomized controlled trials and systematic reviews have demonstrated that probiotic therapy reduces the rate NEC [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/17-22\">",
"     17-22",
"    </a>",
"    ]. The following findings were noted in a 2011 systematic review of 2842 infants [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants who received probiotics versus controls were less likely to develop severe NEC (stage II or higher) (relative risk [RR] 0.35, 95% CI 0.24-0.52).",
"     </li>",
"     <li>",
"      Infants who received probiotics had a lower mortality rate (RR 0.40, 95% CI 0.27-0.60).",
"     </li>",
"     <li>",
"      There was no difference in the rate of nosocomial sepsis between infants who received probiotics and controls (RR 0.90, 95% CI 0.76-1.07).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A follow-up study of one of the included study in the above systematic review demonstrated no differences in the growth, and neurodevelopmental and sensory outcomes between the probiotic and placebo groups at three years corrected age [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/18,20\">",
"     18,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a subsequent trial of 750 preterm infants (birth weight &lt;2000 g) did not find a statistical difference between the daily administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/5/1108?source=see_link\">",
"     Lactobacillus",
"    </a>",
"    <em>",
"     reuteri",
"    </em>",
"    and placebo during the first 48 hours of life on the risk of NEC (2.4 versus 4 percent), or nosocomial pneumonia (2.4 versus 5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/21\">",
"     21",
"    </a>",
"    ]. However, this study may have been underpowered because number of patients enrolled was lower than the calculated sample size of 1100 using an estimated rate of 28 percent for the composite outcome of death and nosocomial outcome, which was higher than the observed rate of 18 percent in the placebo group.",
"   </p>",
"   <p>",
"    Although the potential reduction in NEC with probiotic therapy is exciting, caution should be used in general application of these findings [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/23\">",
"     23",
"    </a>",
"    ]. Because these clinical trials used different probiotics and varied in study design (eg, timing, duration and dosing of probiotic therapy), the optimal strain(s) and dosing regimen remain uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Considerable differences exist in composition, doses, and biologic activity among various commercial preparations so that results with one preparation may not be applied to all probiotic preparations. In addition, the above studies evaluated mostly more mature infants and not extremely low birth weight (ELBW) infants (birth weight &lt;1000 g), which is the most vulnerable population for NEC.",
"   </p>",
"   <p>",
"    In a subsequent small trial of 101 ELBW infants, there were no differences in the risk of NEC and mean weight at 34 weeks postmenstrual age between infants who received probiotic therapy and controls [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/27\">",
"     27",
"    </a>",
"    ]. However, the authors cautioned that the number of patients was small and larger trials are needed to determine the efficacy and safety of probiotics in ELBW infants.",
"   </p>",
"   <p>",
"    Despite the above concerns, some experts suggest that probiotic therapy should be offered in locations where they are licensed or available by special access to infants who meet eligibility criteria from published trials and there is adequate quality control of the administered product [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/28\">",
"     28",
"    </a>",
"    ]. However, we suggest that the current use of probiotics be limited to clinical trials until the most effective regimen for premature infants (especially ELBW infants) is identified (eg, bacterial strain, dosing, and timing and duration of therapy, and combinations with mother's own or pasteurized donor human milk) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/23-26,29,30\">",
"     23-26,29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, one of the included studies in the meta-analysis from Taiwan reported a higher rate of sepsis in the probiotic group [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/18\">",
"     18",
"    </a>",
"    ]. It is unclear as to the etiology but it should be noted that the usual probiotic organisms are not cultured in routine microbiology laboratories. Thus, it is prudent to wait for further clarification and",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    analyses before routine use of probiotic therapy in preterm infants can be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     IMMUNOGLOBULINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral immunoglobulins may reduce necrotizing enterocolitis (NEC) by inhibiting the release of proinflammatory cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/31\">",
"     31",
"    </a>",
"    ]. However, data are conflicting on their efficacy in reducing NEC.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial, oral administration of IgA and IgG in amounts similar to human milk reduced the incidence of NEC in formula-fed premature infants compared to controls (0 versus 7 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, all other data demonstrate that immunoglobulins do not reduce the risk of NEC [",
"      <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. In a meta-analysis of five trials (including the above study), the oral administration of IgG or",
"      <span class=\"nowrap\">",
"       IgG/IgA",
"      </span>",
"      combination did not reduce the incidence of definite NEC (RR 0.84, 95% CI 0.57-1.25), suspected NEC (RR 0.84, 95% CI 0.49-1.46), need for surgery (RR 0.21, 95% CI 0.02-1.75), or death from NEC (RR 1.1, 95% CI 0.47-2.59) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon the currently available evidence, immunoglobulin therapy should",
"    <strong>",
"     not",
"    </strong>",
"    be used because there is lack of evidence demonstrating any benefit from this therapy",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     NUTRITIONAL SUPPLEMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is uncertain whether nutritional supplements of arginine or glutamine reduce the rate of necrotizing enterocolitis (NEC).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arginine &ndash; In one study of 152 premature infants with birth weight &le;1250 g and gestational age &le;32 weeks, the rate of NEC was lower in those who were randomly assigned to arginine supplementation compared to infants who received placebo at two to five days of age (6.7 versus 27.3 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/35\">",
"       35",
"      </a>",
"      ]. However, the interpretation of this study may be limited by the high prevalence of NEC in the control group, even when stage I disease is excluded [",
"      <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Glutamine &ndash; In a randomized multicenter trial, parenteral glutamine supplementation was found not to be effective in decreasing the rate of NEC in 721 preterm infants with birth weight &le;1000 g [",
"      <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result, glutamine and arginine should not be given routinely to prevent NEC. Further investigations are needed to determine whether either glutamine or arginine is effective in preventing NEC.",
"   </p>",
"   <p>",
"    Other supplements have been studied in animals and only theoretically discussed or infrequently studied in NICU infants. These include polyunsaturated fatty acids, erythropoietin, epidermal growth factor, acetylhydrolase, and oligosaccharides.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H249738918\">",
"    <span class=\"h1\">",
"     OTHER STRATEGIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Avoidance of histamine 2 blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Innate gastrointestinal immunity provided by gastric acid may be important in preventing the cascade of infectious and inflammatory events leading to necrotizing enterocolitis (NEC). Histamine 2 blockers (H2 blockers), such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/58/43943?source=see_link\">",
"     cimetidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/1/33815?source=see_link\">",
"     ranitidine",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/61/29655?source=see_link\">",
"     famotidine",
"    </a>",
"    , suppress gastric acidity and are associated with an increase risk of NEC [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was illustrated in a report from the National Institute of Child Health and Human Development (NICHD) Neonatal Research Network [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/38\">",
"     38",
"    </a>",
"    ]. In this study of 11,072 very low birth weight infants (range of birth weight 401 to 1500 g) from 1998 to 2001, the incidence of NEC was 7.1 percent. Infants with NEC compared to matched controls were more likely to have received H2-antagonists (OR 1.71, 95% CI 1.34-2.19).",
"   </p>",
"   <p>",
"    As a result, the use of H2 blockers in very low birth weight infants should be avoided, if at all possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23657?source=see_link&amp;anchor=H25#H25\">",
"     \"Gastroesophageal reflux in premature infants\", section on 'Acid suppression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Avoidance of prolonged empirical antibiotic use",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bacterial colonization of the gastrointestinal tract may be altered by the use of prolonged initial empirical antibiotic therapy, resulting in an increased risk of necrotizing enterocolitis (NEC). Results from a retrospective study from the NICHD of 5693 extremely low birth weight (ELBW) infants (birth weight below 1000 g) supported this association [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/40\">",
"     40",
"    </a>",
"    ]. In this cohort, 96 percent of neonates received empirical antibiotic therapy, and the median duration of antibiotic therapy was five days. The use of prolonged initial empiric antibiotic (&ge;5 days duration) started in the first three days of life was associated with an increased risk of NEC or death (61 versus 51 percent). Each additional day of antibiotic therapy beyond five days was associated with additional increased risks of NEC or death. Patients who received prolonged antibiotic therapy in the absence of positive culture results were more likely to have a lower gestational age, birth weight, and Apgar scores, be black, and be born more than 24 hours after rupture of membranes.",
"   </p>",
"   <p>",
"    The authors acknowledge that these findings must be balanced by the observation that sterile culture results may not be reliable as the required blood culture volumes, for reliable detection for bacteremia may not be consistently available in these extremely small infants. However, these findings suggest that limiting the duration of antibiotic therapy in infants with sterile culture results reduces the risk of NEC and death in ELBW infants.",
"   </p>",
"   <p>",
"    Similar findings were noted in a retrospective case-control study from a single center that demonstrated the risk of NEC rose with increasing duration of initial antibiotic exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7207/abstract/41\">",
"     41",
"    </a>",
"    ]. In this cohort, antibiotic exposure &gt;10 days resulted in a nearly threefold increase in the risk of NEC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current efforts to minimize the frequency or severity of necrotizing enterocolitis (NEC) are directed at reducing exposure to risk factors and encouraging early feeding of human milk.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Human milk compared to formula is associated with a lower risk of NEC. In premature infants who are at risk for developing NEC, we recommend initiation of enteral feeds with human milk, if available (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).In our institution, enteral feedings with unfortified human milk are initiated in the first two to five days after birth to prime the gastrointestinal (GI) tract in low birth weight premature infants (birth weight &lt;1500 g) and to begin feeds in the more mature infant. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Human milk feeding'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/8/19593?source=see_link\">",
"       \"Approach to enteral nutrition in the premature infant\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although data have shown that probiotic therapy appears to reduce the risk of NEC, we suggest probiotic therapy to prevent NEC in premature infants be limited to clinical trials (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Further studies are required to confirm the optimal administration (type, timing, duration and dosing of probiotic therapy) of this intervention before it can be routinely recommended. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Probiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that histamine 2 blockers should be avoided in premature infants to reduce the incidence of NEC (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We recommend not to use oral immunoglobulins to prevent NEC in premature infants (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We recommend not to use nutritional supplements, such as arginine or glutamine, to prevent NEC in premature infants (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Although unproven as measures to prevent NEC, routine management for infants admitted to the neonatal intensive care unit include use of feeding protocols, judicious advancement of feeding, avoidance of hypertonic formulas and contrast agents, and prompt treatment of polycythemia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Background'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/1\">",
"      Neu J. Necrotizing enterocolitis: the search for a unifying pathogenic theory leading to prevention. Pediatr Clin North Am 1996; 43:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/2\">",
"      Patole S, Rao S, Doherty D. Erythromycin as a prokinetic agent in preterm neonates: a systematic review. Arch Dis Child Fetal Neonatal Ed 2005; 90:F301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/3\">",
"      Morgan J, Young L, McGuire W. Slow advancement of enteral feed volumes to prevent necrotising enterocolitis in very low birth weight infants. Cochrane Database Syst Rev 2011; :CD001241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/4\">",
"      Lucas A, Cole TJ. Breast milk and neonatal necrotising enterocolitis. Lancet 1990; 336:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/5\">",
"      Schanler RJ, Shulman RJ, Lau C. Feeding strategies for premature infants: beneficial outcomes of feeding fortified human milk versus preterm formula. Pediatrics 1999; 103:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/6\">",
"      Contreras-Lemus J, Flores-Huerta S, Cisneros-Silva I, et al. [Morbidity reduction in preterm newborns fed with milk of their own mothers]. Bol Med Hosp Infant Mex 1992; 49:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/7\">",
"      Sisk PM, Lovelady CA, Dillard RG, et al. Early human milk feeding is associated with a lower risk of necrotizing enterocolitis in very low birth weight infants. J Perinatol 2007; 27:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/8\">",
"      Quigley MA, Henderson G, Anthony MY, McGuire W. Formula milk versus donor breast milk for feeding preterm or low birth weight infants. Cochrane Database Syst Rev 2007; :CD002971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/9\">",
"      Meinzen-Derr J, Poindexter B, Wrage L, et al. Role of human milk in extremely low birth weight infants' risk of necrotizing enterocolitis or death. J Perinatol 2009; 29:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/10\">",
"      Cristofalo EA, Schanler RJ, Blanco CL, et al. Exclusive human milk vs preterm formula: Randomized trial in extremely preterm infants. Pediatr Res 2011; 70:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/11\">",
"      Section on Breastfeeding. Breastfeeding and the use of human milk. Pediatrics 2012; 129:e827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/12\">",
"      Bombell S, McGuire W. Early trophic feeding for very low birth weight infants. Cochrane Database Syst Rev 2009; :CD000504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/13\">",
"      Morgan J, Young L, McGuire W. Delayed introduction of progressive enteral feeds to prevent necrotising enterocolitis in very low birth weight infants. Cochrane Database Syst Rev 2011; :CD001970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/14\">",
"      Caplan MS, Jilling T. Neonatal necrotizing enterocolitis: possible role of probiotic supplementation. J Pediatr Gastroenterol Nutr 2000; 30 Suppl 2:S18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/15\">",
"      Hammerman C, Bin-Nun A, Kaplan M. Germ warfare: probiotics in defense of the premature gut. Clin Perinatol 2004; 31:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/16\">",
"      Agostoni C, Axelsson I, Braegger C, et al. Probiotic bacteria in dietetic products for infants: a commentary by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr 2004; 38:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/17\">",
"      Deshpande G, Rao S, Patole S, Bulsara M. Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Pediatrics 2010; 125:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/18\">",
"      Lin HC, Hsu CH, Chen HL, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial. Pediatrics 2008; 122:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/19\">",
"      Alfaleh K, Anabrees J, Bassler D, Al-Kharfi T. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2011; :CD005496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/20\">",
"      Chou IC, Kuo HT, Chang JS, et al. Lack of effects of oral probiotics on growth and neurodevelopmental outcomes in preterm very low birth weight infants. J Pediatr 2010; 156:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/21\">",
"      Rojas MA, Lozano JM, Rojas MX, et al. Prophylactic probiotics to prevent death and nosocomial infection in preterm infants. Pediatrics 2012; 130:e1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/22\">",
"      Fern&aacute;ndez-Carrocera LA, Solis-Herrera A, Cabanillas-Ay&oacute;n M, et al. Double-blind, randomised clinical assay to evaluate the efficacy of probiotics in preterm newborns weighing less than 1500 g in the prevention of necrotising enterocolitis. Arch Dis Child Fetal Neonatal Ed 2013; 98:F5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/23\">",
"      Caffarelli C, Bernasconi S. Preventing necrotising enterocolitis with probiotics. Lancet 2007; 369:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/24\">",
"      Soll RF. Probiotics: are we ready for routine use? Pediatrics 2010; 125:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/25\">",
"      Neu J. Routine probiotics for premature infants: let's be careful! J Pediatr 2011; 158:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/26\">",
"      Millar M, Wilks M, Fleming P, Costeloe K. Should the use of probiotics in the preterm be routine? Arch Dis Child Fetal Neonatal Ed 2012; 97:F70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/27\">",
"      Al-Hosni M, Duenas M, Hawk M, et al. Probiotics-supplemented feeding in extremely low-birth-weight infants. J Perinatol 2012; 32:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/28\">",
"      Tarnow-Mordi WO, Wilkinson D, Trivedi A, Brok J. Probiotics reduce all-cause mortality and necrotizing enterocolitis: it is time to change practice. Pediatrics 2010; 125:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/29\">",
"      Kliegman RM, Willoughby RE. Prevention of necrotizing enterocolitis with probiotics. Pediatrics 2005; 115:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/30\">",
"      Bell EF. Preventing necrotizing enterocolitis: what works and how safe? Pediatrics 2005; 115:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/31\">",
"      Wolf HM, Eibl MM. The anti-inflammatory effect of an oral immunoglobulin (IgA-IgG) preparation and its possible relevance for the prevention of necrotizing enterocolitis. Acta Paediatr Suppl 1994; 396:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/32\">",
"      Eibl MM, Wolf HM, F&uuml;rnkranz H, Rosenkranz A. Prevention of necrotizing enterocolitis in low-birth-weight infants by IgA-IgG feeding. N Engl J Med 1988; 319:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/33\">",
"      Lawrence G, Tudehope D, Baumann K, et al. Enteral human IgG for prevention of necrotising enterocolitis: a placebo-controlled, randomised trial. Lancet 2001; 357:2090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/34\">",
"      Foster J, Cole M. Oral immunoglobulin for preventing necrotizing enterocolitis in preterm and low birth-weight neonates. Cochrane Database Syst Rev 2004; :CD001816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/35\">",
"      Amin HJ, Zamora SA, McMillan DD, et al. Arginine supplementation prevents necrotizing enterocolitis in the premature infant. J Pediatr 2002; 140:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/36\">",
"      Neu J. Arginine supplementation and the prevention of necrotizing enterocolitis in very low birth weight infants. J Pediatr 2002; 140:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/37\">",
"      Poindexter BB, Ehrenkranz RA, Stoll BJ, et al. Parenteral glutamine supplementation does not reduce the risk of mortality or late-onset sepsis in extremely low birth weight infants. Pediatrics 2004; 113:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/38\">",
"      Guillet R, Stoll BJ, Cotten CM, et al. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2006; 117:e137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/39\">",
"      Terrin G, Passariello A, De Curtis M, et al. Ranitidine is associated with infections, necrotizing enterocolitis, and fatal outcome in newborns. Pediatrics 2012; 129:e40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/40\">",
"      Cotten CM, Taylor S, Stoll B, et al. Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. Pediatrics 2009; 123:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7207/abstract/41\">",
"      Alexander VN, Northrup V, Bizzarro MJ. Antibiotic exposure in the newborn intensive care unit and the risk of necrotizing enterocolitis. J Pediatr 2011; 159:392.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5040 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-1745D172DA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_2_7207=[""].join("\n");
var outline_f7_2_7207=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HUMAN MILK FEEDING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11354162\">",
"      TIMING OF INITIAL FEED",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PROBIOTICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      IMMUNOGLOBULINS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      NUTRITIONAL SUPPLEMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H249738918\">",
"      OTHER STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Avoidance of histamine 2 blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Avoidance of prolonged empirical antibiotic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/8/19593?source=related_link\">",
"      Approach to enteral nutrition in the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41591?source=related_link\">",
"      Clinical features and diagnosis of necrotizing enterocolitis in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23657?source=related_link\">",
"      Gastroesophageal reflux in premature infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23655?source=related_link\">",
"      Human milk feeding and fortification of human milk for premature infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35928?source=related_link\">",
"      Management of necrotizing enterocolitis in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/28/458?source=related_link\">",
"      Nutritional composition of human milk and preterm formula for the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28105?source=related_link\">",
"      Pathology and pathogenesis of necrotizing enterocolitis in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=related_link\">",
"      Probiotics for gastrointestinal diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_2_7208="Use of array comparative genomic hybridization (aCGH) in obstetrics";
var content_f7_2_7208=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Use of array comparative genomic hybridization (aCGH) in obstetrics",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/2/7208/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/2/7208/contributors\">",
"     David T Miller, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/2/7208/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/2/7208/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/2/7208/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/2/7208/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/2/7208/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H18810847\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal diagnosis and postnatal evaluation of pregnancy loss often involves cytogenetic analysis of amniocytes, chorionic villi, or fetal cells. Although conventional Giemsa(G)-banding of metaphase chromosomes detects aneuploidies and large structural changes, this approach also has limitations: it does not consistently identify microscopic gene defects (&lt;3 to 10 million base pairs per G-band) and requires cell culture, which takes a minimum of seven days to obtain an adequate number of dividing cells. The use of fluorescent in situ hybridization (FISH) reduces the time to obtain a result and is less labor intensive, but can only detect a limited number of prespecified targets.",
"   </p>",
"   <p>",
"    Array comparative genomic hybridization (aCGH) can overcome these limitations. This technique compares the genomic content (DNA) of a patient (target) with that of a normal control individual (or individuals) and detects not only aneuploidies and large structural changes, but also submicroscopic gains, losses, and unbalanced rearrangements in genes (",
"    <a class=\"graphic graphic_figure graphicRef58888 \" href=\"UTD.htm?28/63/29687\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Different laboratories perform aCGH using different technology platforms and with different array design and content. Testing is offered under various names such as &ldquo;chromosomal microarray&rdquo; (CMA) and &ldquo;molecular karyotyping&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7208/abstract/1-6\">",
"     1-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will discuss the use of aCGH in obstetrics. Basic principles of genetics are reviewed separately, and include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21097?source=see_link\">",
"       \"Basic principles of genetic disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17846?source=see_link\">",
"       \"Principles of molecular genetics\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39799?source=see_link\">",
"       \"Tools for genetics and genomics: Gene expression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=see_link\">",
"       \"Cytogenetic and molecular genetic diagnostic tools\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28087?source=see_link&amp;anchor=H3390507#H3390507\">",
"       \"Genomic disorders: An overview\", section on 'Array comparative genomic hybridization'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39799?source=see_link&amp;anchor=H3544103#H3544103\">",
"       \"Tools for genetics and genomics: Gene expression\", section on 'Microarray analysis and interpretation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12423065\">",
"    <span class=\"h1\">",
"     BENEFITS AND LIMITATIONS OF aCGH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Array comparative genomic hybridization (aCGH) has advantages and disadvantages compared with conventional G-banding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18811338\">",
"    <span class=\"h2\">",
"     Benefits",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18811391\">",
"    <span class=\"h3\">",
"     Higher diagnostic yield",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the resolution of the array is dependent upon the type of array used and the average spacing of the probes on the array, the minimum resolution is 50,000 to 200,000 base pairs compared with 3 to 10 million base pairs for G-banding. The ability of aCGH to detect extremely small changes in the genome results in a higher rate of detection of abnormalities compared with conventional G-banding [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7208/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. The following studies are examples of the higher diagnostic yield of aCGH compared with karyotype in various clinical settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multi-center prospective study of 4406 women undergoing prenatal diagnosis because of advanced maternal age (47 percent), abnormal result on maternal serum screening (19 percent), abnormal ultrasound (25 percent), or other indications (9 percent), following a negative karyotype result, aCGH revealed clinically significant results in 6.0 percent of fetuses with a structural anomaly and 1.7 percent of fetuses tested because of advanced maternal age or positive maternal serum screening [",
"      <a class=\"abstract\" href=\"UTD.htm?7/2/7208/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective study of 532 stillborn fetuses that compared diagnostic yield with aCGH versus traditional karyotype, aCGH resulted in a positive finding, 42 percent more often than karyotype in all stillbirths, 35 percent more often in antepartum stillbirths, and 54 percent more often in stillbirths with anomalies [",
"      <a class=\"abstract\" href=\"UTD.htm?7/2/7208/abstract/8\">",
"       8",
"      </a>",
"      ]. The actual yields of positive results for aCGH and karyotype were: all stillbirths 8.3 versus 5.8 percent (P = 0.007), antepartum stillbirths 8.8 versus 6.5 percent (P = 0.02), and stillbirths with congenital anomalies 29.9 versus 19.4 percent, (P = 0.008). Importantly, aCGH was successful (from a technical standpoint) more often than karyotype (87.4 versus 70.5 percent, P&lt;0.001), since karyotype requires cell culture, which is often unsuccessful in this setting.",
"     </li>",
"     <li>",
"      In a large retrospective study of over 5000 prenatal cases, 5.3 percent had clinically significant results, with the number increasing to 6.5 percent and 8.2 percent for cases referred for abnormal ultrasounds and fetal demise, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?7/2/7208/abstract/9\">",
"       9",
"      </a>",
"      ]. Those diagnostic yields excluded cases with an abnormal karyotype or family history of a parental rearrangement due to potential upward bias in yield. In a companion retrospective study of the 2858 pregnancies with abnormal ultrasounds, the same authors stratified cases to gain additional insight into features that predict yield from aCGH [",
"      <a class=\"abstract\" href=\"UTD.htm?7/2/7208/abstract/10\">",
"       10",
"      </a>",
"      ]. The frequency of clinically significant genomic abnormalities by subset analysis was: single ultrasound anomaly (n =",
"      <span class=\"nowrap\">",
"       99/1773,",
"      </span>",
"      5.6 percent), anomalies in two or more organ systems (n =",
"      <span class=\"nowrap\">",
"       77/808,",
"      </span>",
"      9.5 percent), isolated growth abnormalities (n =",
"      <span class=\"nowrap\">",
"       2/76,",
"      </span>",
"      2.6 percent), and soft markers (n =",
"      <span class=\"nowrap\">",
"       2/77,",
"      </span>",
"      2.6 percent). In addition, the following anomalies in isolation or with additional anomalies had very high detection rates: holoprosencephaly (n =",
"      <span class=\"nowrap\">",
"       9/85,",
"      </span>",
"      10.6 percent), posterior fossa defects (n =",
"      <span class=\"nowrap\">",
"       21/144,",
"      </span>",
"      14.6 percent), skeletal anomalies (n =",
"      <span class=\"nowrap\">",
"       15/140,",
"      </span>",
"      10.7 percent), ventricular septal defect (n =",
"      <span class=\"nowrap\">",
"       14/132,",
"      </span>",
"      10.6 percent), hypoplastic left heart (n =",
"      <span class=\"nowrap\">",
"       11/68,",
"      </span>",
"      16.2 percent), and cleft",
"      <span class=\"nowrap\">",
"       lip/palate",
"      </span>",
"      (n =",
"      <span class=\"nowrap\">",
"       14/136,",
"      </span>",
"      10.3 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18811433\">",
"    <span class=\"h3\">",
"     Faster turnaround time",
"    </span>",
"    &nbsp;&mdash;&nbsp;G-banding requires cell culture to obtain sufficient DNA from dividing cells, which results in a turnaround time of one to two weeks. aCGH can be performed directly on high quality DNA extracted from isolated cells; results can be available in as little as one day since time for culture is not required. aCGH is also more amenable to automation in the laboratory, which provides objective interpretation and decreases labor costs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18812072\">",
"    <span class=\"h2\">",
"     Limitations/disadvantages",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18812086\">",
"    <span class=\"h3\">",
"     Inability to detect balanced structural rearrangements",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to G-banding,",
"    <strong>",
"    </strong>",
"    aCGH is unable to detect balanced structural rearrangements because there is no change in copy number. Although this is a disadvantage of the technique, it is not always of clinical significance because:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The likelihood that a truly balanced rearrangement would interrupt a gene is low. Even those that have breakpoints within a gene are not necessarily pathogenic.",
"     </li>",
"     <li>",
"      When the parent and fetus have the same balanced rearrangement, it is generally considered benign if the parent is unaffected.",
"     </li>",
"     <li>",
"      Although there is greater concern that a de novo balanced rearrangement may be clinically significant (ie, associated with an abnormal phenotype), de novo balanced rearrangements are rare and represent a small proportion of the abnormalities detected by G-banding.",
"      <br/>",
"      <br/>",
"      In one study including 269,371 analyses, the rate of prenatally diagnosed de novo balanced chromosome rearrangements in amniocytes, chorionic villus samples, and fetal blood samples was 0.09, 0.08 and 0.05 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?7/2/7208/abstract/12\">",
"       12",
"      </a>",
"      ]. In another study of 377,357 amniocenteses, de novo reciprocal translocations were detected in approximately 0.05 percent and a balanced Robertsonian translocation in 0.01 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?7/2/7208/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    De novo cytogenetic rearrangements that appear balanced by G-banding may have submicroscopic genomic differences in the number of copies of one or more sections of DNA. These copy number variants may be known to be benign or associated with phenotypic consequences, or their significance may be unknown. Although most apparently balanced reciprocal translocations in phenotypically normal individuals do not contain genomic imbalance and are benign [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7208/abstract/14\">",
"     14",
"    </a>",
"    ], there is a 6 percent probability that an apparently balanced translocation identified on prenatal G-banding has phenotypic consequences [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7208/abstract/15\">",
"     15",
"    </a>",
"    ]. As a result, the overall ability to predict abnormalities (eg, developmental delay, malformation) is more strongly correlated with findings on array CGH than G-banding [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7208/abstract/16-18\">",
"     16-18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18812954\">",
"    <span class=\"h3\">",
"     Poor ability to detect triploidy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard aCGH does not recognize triploidy because the relative gene content is balanced. The poor ability of standard aCGH to detect most triploidies does not represent a significant limitation as a clinical test because triploidy is rare, the diagnosis is often suspected by prenatal ultrasound examination after the first trimester, and most cases result in fetal demise or neonatal death rather than long-term disability. Although fetal 69,XXX may be missed, fetal 69,XXY will be detected because of the sex chromosome imbalance in the latter case.",
"   </p>",
"   <p>",
"    Some laboratories incorporate specific algorithms in their processing to better detect triploidy, either through the use of single nucleotide polymorphisms (SNP) arrays [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7208/abstract/19\">",
"     19",
"    </a>",
"    ] or through an initial assessment of a limited number of cells by fluorescence in situ hybridization (FISH).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1897070\">",
"    <span class=\"h3\">",
"     Variable ability to detect low level mosaicism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low levels of mosaicism are difficult to detect, but generally result in a milder phenotypic abnormality than the same but non-mosaic genomic imbalance. G-banding performs somewhat better than most clinical aCGH platforms for detection of low level mosaicism: a typical 20-cell G-banded karyotype detects mosaicism at approximately 14 percent of cells or more, while most clinical aCGH platforms typically detect mosaicism at 20 to 30 percent of cells or more. Laboratories that use SNP array platforms for aCGH can detect lower levels of mosaicism (~10 percent), but this test is not commonly used in the clinical setting. If there is suspicion of lower level mosaicism on G-banding or postnatally, a cytogenetics laboratory can be asked to count additional cells to improve the detection of mosaicism below 10 percent of cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1897120\">",
"    <span class=\"h3\">",
"     Detection of variants of uncertain significance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Copy number variants of uncertain significance (VUS) are copy number changes that have not been reported and thus have an unknown phenotype. These small changes are not detectable by G-banding, but are identified by aCGH in 1 to 2 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7208/abstract/7,8,19,20\">",
"     7,8,19,20",
"    </a>",
"    ]. The additional information provided by aCGH can be challenging to interpret, particularly if a phenotypically normal parent carries the same change. In the absence of clear prognostic information, parents may find it difficult to make a decision about continuing the pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5112?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of genetic variation\", section on 'Copy number variations (CNVs)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the large prospective study discussed above and performed from 2008 to mid 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7208/abstract/7\">",
"     7",
"    </a>",
"    ], aCGH detected VUS in 3.4 percent (130 of 3822) of all cases that were normal by karyotype. Although this degree of uncertainty is concerning, the authors pointed out that collective knowledge in this field continues to improve, thereby decreasing the frequency of VUS. If the VUS identified in this study were reanalyzed in 2012, the overall VUS rate would be approximately 1.5 percent (56 of 3822). &nbsp;",
"   </p>",
"   <p>",
"    Detection of VUS has raised the question of whether it is ethically justifiable to withhold these test results from the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7208/abstract/21\">",
"     21",
"    </a>",
"    ]. VUS should become less problematic in the future as the International Standards for Cytogenomic Arrays (ISCA) is creating a database of array results and associated phenotypes for the National Institutes of Health (NIH).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1897387\">",
"    <span class=\"h3\">",
"     Expense",
"    </span>",
"    &nbsp;&mdash;&nbsp;aCGH is relatively expensive, like many genetic tests, although costs are declining.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16315619\">",
"    <span class=\"h3\">",
"     Variable clinical sensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical sensitivity refers to the proportion of patients who have the clinical symptoms of a disorder and are detectable by the testing method. Some genetic conditions are primarily caused by a change in genomic copy number (eg, a microdeletion or microduplication syndrome). An example of a relatively common genomic disorder is velocardiofacial syndrome, also known as 22q11.2 deletion syndrome. Among individuals with",
"    <span class=\"nowrap\">",
"     signs/symptoms",
"    </span>",
"    of this condition, a microdeletion will be detected by chromosomal microarray (CMA) in over 90 percent. When the microdeletion is not detected, the patient usually does not have all of the symptoms and may have another diagnosis that is similar. In contrast, neurofibromatosis type-1 (NF1) can be caused by a genomic deletion that includes the NF1 gene, but less than 5 percent of NF1 patients have a deletion; most of these patients have a sequence change in the gene that is undetectable by aCGH. If a patient has a genetic condition in which a subset of cases are caused by sequence changes, then other testing should be considered either in place of, or in addition to, aCGH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1898090\">",
"    <span class=\"h1\">",
"     PROCEDURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1898181\">",
"    <span class=\"h2\">",
"     Specimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal array comparative genomic hybridization (aCGH) can be performed on uncultured amniocytes, chorionic villus cells, fetal cells (eg, skin, blood), or cell free fetal DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7208/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1898188\">",
"    <span class=\"h2\">",
"     Targeted versus whole genome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal aCGH may assess the whole genome or may be targeted to evaluate known",
"    <span class=\"nowrap\">",
"     microdeletion/microduplication",
"    </span>",
"    syndromes and other known loci of inherited Mendelian disorders. For targeted aCGH, probes are selected to target regions of the genome known or highly suspected to cause specific phenotypes when deleted or duplicated. A typical microarray contains thousands of different probes representing targeted areas of the genome. Oligonucleotide probes are typically used, although some laboratories still use bacterial artificial chromosome (BAC) clones. Oligonucleotide probes are smaller and can better define the breakpoints compared to BAC probes, but their ability to detect small copy number variations (CNVs) makes them more likely to detect variants of uncertain clinical significance.",
"   </p>",
"   <p>",
"    Compared to whole genome aCGH, targeted aCGH lowers the chance of identifying variants of uncertain significance, but also potentially results in a lower diagnostic yield as unique chromosomal imbalances that could be clinically significant may be missed.",
"   </p>",
"   <p>",
"    However, whole genome aCGH also may raise challenging counseling issues. Because copy number variants related to late-onset diseases may be identified in genomic regions other than those specifically targeted, the additional information provided by whole genome aCGH can have implications for both the parent and offspring. For example, a prenatal diagnostic procedure to detect Down syndrome may exclude Down syndrome, but identify an inherited BRCA 1 or 2 mutation or the gene for Huntington disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1897463\">",
"    <span class=\"h1\">",
"     CLINICAL INDICATIONS FOR aCGH IN OBSTETRICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical guidelines for use of array comparative genomic hybridization (aCGH) are evolving as more data on the benefits and limitations of this technique are published [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7208/abstract/23-26\">",
"     23-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American College of Obstetrics and Gynecology (ACOG) practice guidelines recommend G-banded karyotyping as the first-tier cytogenetic test in the prenatal setting, with targeted aCGH in certain situations, including [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7208/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fetal congenital anomalies and normal G-banded karyotype",
"     </li>",
"     <li>",
"      Fetal demise with congenital anomalies and inability to obtain G-banded karyotype",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whole genome array CGH is not recommended as the first-tier cytogenetic test, in part due to concerns about identification of variants of unknown significance. However, worldwide, some centers have begun to offer whole genome array analysis as a replacement for karyotyping in the prenatal diagnostic evaluation of fetuses with structural anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7208/abstract/27\">",
"     27",
"    </a>",
"    ], advanced maternal age, or parental anxiety [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7208/abstract/24\">",
"     24",
"    </a>",
"    ]. In addition, some guidelines have included additional indications for aCGH (targeted or whole genome), such as G-banding showing a marker chromosome (in order to characterize the origin and genetic content) or a de novo balanced translocation (in order to confirm the absence of small deletions that could be clinically significant) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7208/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the postnatal setting, American College of Medical Genetics (ACMG) guidelines recommend aCGH as the first-tier test for patients with [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7208/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unexplained developmental",
"      <span class=\"nowrap\">",
"       delay/intellectual",
"      </span>",
"      disability (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5257?source=see_link\">",
"       \"Intellectual disability (mental retardation) in children: Evaluation\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Autism spectrum disorders (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38969?source=see_link\">",
"       \"Diagnosis of autism spectrum disorders\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Multiple congenital anomalies not explained by a specific syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19161?source=see_link\">",
"       \"Approach to congenital malformations\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12423086\">",
"    <span class=\"h2\">",
"     Prenatal ultrasound showing fetal structural abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal structural abnormalities detectable by ultrasound should raise suspicion of a chromosomal abnormality in the fetus. In a study that karyotyped 2086 fetuses after ultrasonographic examination revealed fetal malformations, growth restriction, or both, chromosomal abnormalities by G-banding were detected in 301 cases (14 percent), and were more common among fetuses with multisystem malformations (29 percent) than among those with isolated defects (2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7208/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among fetuses presenting with an ultrasound structural abnormality and a normal G-banded karyotype, a 2011 meta-analysis reported that aCGH was abnormal in 5.2 percent (95% CI 1.9&ndash;13.9) when the referral indication was structural malformation on ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7208/abstract/20\">",
"     20",
"    </a>",
"    ]. This number is higher than the 1 to 3 percent previously thought to have a genetic imbalance (eg, microdeletion, microduplication) on aCGH [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7208/abstract/30-32\">",
"     30-32",
"    </a>",
"    ], but the lower prevalence was based on earlier studies. The increased yield reported by the meta-analysis included data from some subsequent studies and was likely due to increased coverage of aCGH probes since the detection of abnormalities on the array increases as the density of the array increases, as well as when there are multiple anomalies present. Postnatal studies of neonates with structural anatomical abnormalities confirm these findings [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7208/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We agree with expert opinion that prenatal aCGH is an appropriate adjunctive test in the presence of fetal structural anatomical abnormalities and a normal G-banded karyotype [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7208/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12423093\">",
"    <span class=\"h2\">",
"     Fetal demise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not specifically advocated in current guidelines, aCGH can provide benefit if used on all cases of fetal demise because of increased diagnostic yield. It is also beneficial in cases of culture failure. Chromosomal abnormalities identifiable by G-banded karyotype are identified in about 50 percent of spontaneous abortions, 5 percent of stillborn fetuses in the absence of an anatomical malformation, and 35 to 40 percent of stillborns when structural abnormalities are present [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7208/abstract/15,35\">",
"     15,35",
"    </a>",
"    ]. Culture failure is common when the",
"    <span class=\"nowrap\">",
"     embryo/fetus",
"    </span>",
"    has died, and thus prevents the accurate diagnosis of a karyotypic abnormality in these cases, aCGH can overcome this difficulty.",
"   </p>",
"   <p>",
"    As discussed above, in a study of samples from 532 stillbirths, SNP oligonucleotide microarray analysis was more likely to yield results than karyotype analysis (87.4 versus 70.5 percent, P&lt;0.001), provided better detection of genetic abnormalities (aneuploidy or pathogenic copy number variants, 8.3 versus 5.8 percent; P = 0.007), and identified more genetic abnormalities among the 443 antepartum stillbirths (8.8 versus 6.5 percent, P = 0.02) and the 67 stillbirths with congenital anomalies (29.9 versus 19.4 percent, P = 0.008) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7208/abstract/8,36\">",
"     8,36",
"    </a>",
"    ]. A copy-number VUS was reported in 2.6 percent (12 of 465) of the samples.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1897951\">",
"    <span class=\"h2\">",
"     Marker chromosome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A marker chromosome refers to small chromosome fragments that may be observed with a G-banded karyotype. Because of the small size of the marker, the chromosome of origin cannot always be determined. aCGH is often able to identify the chromosomal origin of a marker chromosome and thus allow prognostic counseling based on its origin and gene content. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=see_link&amp;anchor=H11375661#H11375661\">",
"     \"Congenital cytogenetic abnormalities\", section on 'Supernumerary marker chromosome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1897960\">",
"    <span class=\"h2\">",
"     Potential indications for prenatal aCGH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal aCGH may be useful after a normal karyotype in the following situations, but data are limited and the diagnostic yield of aCGH in these settings is not known:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intrauterine growth restriction (IUGR)",
"     </li>",
"     <li>",
"      Increased nuchal lucency",
"     </li>",
"     <li>",
"      Abnormal maternal serum screening showing an increased risk for Down syndrome and normal karyotype",
"     </li>",
"     <li>",
"      One or more soft markers for aneuploidy on ultrasound (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=see_link\">",
"       \"Sonographic findings associated with fetal aneuploidy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Oligohydramnios or polyhydramnios",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12423100\">",
"    <span class=\"h1\">",
"     PATIENT COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Couples considering aCGH testing should receive pre-test and post-test genetic counseling that is nondirective and clearly explains that testing is voluntary. Nondirective information enables the parents to balance the risks, benefits, and limitations of this approach to prenatal diagnosis. Genetic counseling should involve a provider with specific expertise in the area of prenatal genetic testing, usually a genetic counselor, medical geneticist, or provider with relevant experience, given the range of potential results from aCGH and the variable clinical effects of particular genomic imbalance disorders.",
"   </p>",
"   <p>",
"    Pre-test counseling should provide the following information [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7208/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Risks associated with prenatal diagnosis (eg, procedure-related fetal loss)",
"     </li>",
"     <li>",
"      Potential psychological implications of prenatal diagnosis (eg, uncertainty, anxiety, need for consideration of pregnancy termination or other intervention, genetic information about risk of long-term disease in parent or offspring)",
"     </li>",
"     <li>",
"      Implications of having a child with a genomic disorder",
"     </li>",
"     <li>",
"      Advantages and disadvantages of prenatal aCGH (see",
"      <a class=\"local\" href=\"#H12423065\">",
"       'Benefits and limitations of aCGH'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Detection rate for chromosomal abnormalities that is higher than with G-banding",
"     </li>",
"     <li>",
"      Possibility and clinical implications of an undetected balanced rearrangement",
"     </li>",
"     <li>",
"      Possibility and clinical implications of detecting a variant of unknown significance",
"     </li>",
"     <li>",
"      Possibility of detecting a carrier state for genetic disease within the parent",
"     </li>",
"     <li>",
"      Possibility of identifying",
"      <span class=\"nowrap\">",
"       non-paternity/consanguinity",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Information about the length of time necessary to obtain aCGH results",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Results may be available one week after biopsy with direct cell preparation (eg, chorionic villus biopsy, biopsy of fetal tissue, amniocytes)",
"     </li>",
"     <li>",
"      If amniocytes are cultured initially for G-banding and then aCGH is performed, results may be available three weeks after amniocentesis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Post-test counseling is best provided through consultation with a genetic counselor or a medical geneticist, particularly after a diagnosis of a genomic imbalance disorder, to provide the following information:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Normal/negative",
"      </span>",
"      results do not rule out the presence of a genetic disorder, because many disorders are not caused by microdeletions or microduplications. Other genetic testing may be warranted based on the clinical presentation.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Abnormal/positive",
"      </span>",
"      results allow a better understanding of the etiology of clinical features present in the fetus, but not necessarily an ability to predict the medical or developmental outcome of a child born with that genomic disorder. The couple should be told about:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The spectrum of medical and intellectual issues associated with the identified genomic disorder",
"     </li>",
"     <li>",
"      The difficulty in predicting phenotype due to variable penetrance and expressivity",
"     </li>",
"     <li>",
"      How mutations arise (de novo versus inherited)",
"     </li>",
"     <li>",
"      Recurrence risks for future pregnancies",
"     </li>",
"     <li>",
"      Information about pregnancy termination. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4453?source=see_link\">",
"       \"Surgical termination of pregnancy: First trimester\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28409?source=see_link\">",
"       \"Termination of pregnancy: Second trimester\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12423107\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Advantages of array comparative genomic hybridization (aCGH) over conventional G-banding in the prenatal setting include higher diagnostic yield and faster turnaround time. (See",
"      <a class=\"local\" href=\"#H18811391\">",
"       'Higher diagnostic yield'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Certain types of chromosomal changes are not detectable or are poorly detectable by aCGH, such as balanced translocations, triploidy, and low level mosaicism; however, these represent a smaller number of cases as compared to those with genomic imbalance. (See",
"      <a class=\"local\" href=\"#H18812072\">",
"       'Limitations/disadvantages'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      aCGH detects variants of unknown significance in about 1 to 2 percent of cases. Counseling patients with these findings can be difficult. (See",
"      <a class=\"local\" href=\"#H1897120\">",
"       'Detection of variants of uncertain significance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the obstetrical setting, aCGH is a reasonable option for further evaluation of fetuses with structural abnormalities and a normal karyotype, after fetal demise (particularly when chromosomal analysis is desired but G-banding is not possible due to failure of cell culture), and when a marker chromosome is identified. It is equivalent to G-banding when the primary goal is to detect aneuploidy, as in Down syndrome screening. (See",
"      <a class=\"local\" href=\"#H1897463\">",
"       'Clinical indications for aCGH in obstetrics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic counseling by a qualified provider should always be offered before and after prenatal aCGH. Pre-test counseling should include a discussion of the medical and psychological risks and the advantages and disadvantages of this approach compared with conventional G-banding. The genetic principles of variants of uncertain significance and variable expressivity and penetrance should be explained. Post-test counseling should include interpretation of the findings and an explanation of possible follow-up studies.(See",
"      <a class=\"local\" href=\"#H12423100\">",
"       'Patient counseling'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/1\">",
"      Rauch A, R&uuml;schendorf F, Huang J, et al. Molecular karyotyping using an SNP array for genomewide genotyping. J Med Genet 2004; 41:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/2\">",
"      de Vries BB, Pfundt R, Leisink M, et al. Diagnostic genome profiling in mental retardation. Am J Hum Genet 2005; 77:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/3\">",
"      Hochstenbach R, Ploos van Amstel HK, Poot M. Microarray-based genome investigation: molecular karyotyping or segmental aneuploidy profiling? Eur J Hum Genet 2006; 14:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/4\">",
"      Vermeesch JR, Rauch A. Reply to Hochstenbach et al. 'Molecular karyotyping'. Eur J Hum Genet 2006; 14:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/5\">",
"      Vermeesch JR, Fiegler H, de Leeuw N, et al. Guidelines for molecular karyotyping in constitutional genetic diagnosis. Eur J Hum Genet 2007; 15:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/6\">",
"      Hoyer J, Dreweke A, Becker C, et al. Molecular karyotyping in patients with mental retardation using 100K single-nucleotide polymorphism arrays. J Med Genet 2007; 44:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/7\">",
"      Wapner RJ, Martin CL, Levy B, et al. Chromosomal microarray versus karyotyping for prenatal diagnosis. N Engl J Med 2012; 367:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/8\">",
"      Reddy UM, Page GP, Saade GR, et al. Karyotype versus microarray testing for genetic abnormalities after stillbirth. N Engl J Med 2012; 367:2185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/9\">",
"      Shaffer LG, Dabell MP, Fisher AJ, et al. Experience with microarray-based comparative genomic hybridization for prenatal diagnosis in over 5000 pregnancies. Prenat Diagn 2012; 32:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/10\">",
"      Shaffer LG, Rosenfeld JA, Dabell MP, et al. Detection rates of clinically significant genomic alterations by microarray analysis for specific anomalies detected by ultrasound. Prenat Diagn 2012; 32:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/11\">",
"      Scott F, Murphy K, Carey L, et al. Prenatal diagnosis using combined qf-PCR and array CGH analysis as a first line test: results from over 1000 consecutive cases. Ultrasound Obstet Gynecol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/12\">",
"      Giardino D, Corti C, Ballarati L, et al. De novo balanced chromosome rearrangements in prenatal diagnosis. Prenat Diagn 2009; 29:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/13\">",
"      Warburton D. De novo balanced chromosome rearrangements and extra marker chromosomes identified at prenatal diagnosis: clinical significance and distribution of breakpoints. Am J Hum Genet 1991; 49:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/14\">",
"      Baptista J, Prigmore E, Gribble SM, et al. Molecular cytogenetic analyses of breakpoints in apparently balanced reciprocal translocations carried by phenotypically normal individuals. Eur J Hum Genet 2005; 13:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/15\">",
"      Savage MS, Mourad MJ, Wapner RJ. Evolving applications of microarray analysis in prenatal diagnosis. Curr Opin Obstet Gynecol 2011; 23:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/16\">",
"      Gribble SM, Prigmore E, Burford DC, et al. The complex nature of constitutional de novo apparently balanced translocations in patients presenting with abnormal phenotypes. J Med Genet 2005; 42:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/17\">",
"      De Gregori M, Ciccone R, Magini P, et al. Cryptic deletions are a common finding in \"balanced\" reciprocal and complex chromosome rearrangements: a study of 59 patients. J Med Genet 2007; 44:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/18\">",
"      Feenstra I, Hanemaaijer N, Sikkema-Raddatz B, et al. Balanced into array: genome-wide array analysis in 54 patients with an apparently balanced de novo chromosome rearrangement and a meta-analysis. Eur J Hum Genet 2011; 19:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/19\">",
"      Breman A, Pursley AN, Hixson P, et al. Prenatal chromosomal microarray analysis in a diagnostic laboratory; experience with &gt;1000 cases and review of the literature. Prenat Diagn 2012; 32:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/20\">",
"      Hillman SC, Pretlove S, Coomarasamy A, et al. Additional information from array comparative genomic hybridization technology over conventional karyotyping in prenatal diagnosis: a systematic review and meta-analysis. Ultrasound Obstet Gynecol 2011; 37:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/21\">",
"      McGillivray G, Rosenfeld JA, McKinlay Gardner RJ, Gillam LH. Genetic counselling and ethical issues with chromosome microarray analysis in prenatal testing. Prenat Diagn 2012; 32:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/22\">",
"      Brady PD, Vermeesch JR. Genomic microarrays: a technology overview. Prenat Diagn 2012; 32:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/23\">",
"      ACOG Committee Opinion No. 446: array comparative genomic hybridization in prenatal diagnosis. Obstet Gynecol 2009; 114:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/24\">",
"      Lee CN, Lin SY, Lin CH, et al. Clinical utility of array comparative genomic hybridisation for prenatal diagnosis: a cohort study of 3171 pregnancies. BJOG 2012; 119:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/25\">",
"      Duncan A, Langlois S, SOGC Genetics Committee, CCMG Prenatal Diagnosis Committee. Use of array genomic hybridization technology in prenatal diagnosis in Canada. J Obstet Gynaecol Can 2011; 33:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/26\">",
"      Novelli A, Grati FR, Ballarati L, et al. Microarray application in prenatal diagnosis: a position statement from the cytogenetics working group of the Italian Society of Human Genetics (SIGU), November 2011. Ultrasound Obstet Gynecol 2012; 39:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/27\">",
"      Faas BH, Feenstra I, Eggink AJ, et al. Non-targeted whole genome 250K SNP array analysis as replacement for karyotyping in fetuses with structural ultrasound anomalies: evaluation of a one-year experience. Prenat Diagn 2012; 32:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/28\">",
"      Manning M, Hudgins L, Professional Practice and Guidelines Committee. Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. Genet Med 2010; 12:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/29\">",
"      Nicolaides KH, Snijders RJ, Gosden CM, et al. Ultrasonographically detectable markers of fetal chromosomal abnormalities. Lancet 1992; 340:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/30\">",
"      Sahoo T, Cheung SW, Ward P, et al. Prenatal diagnosis of chromosomal abnormalities using array-based comparative genomic hybridization. Genet Med 2006; 8:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/31\">",
"      Shaffer LG, Coppinger J, Alliman S, et al. Comparison of microarray-based detection rates for cytogenetic abnormalities in prenatal and neonatal specimens. Prenat Diagn 2008; 28:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/32\">",
"      Kleeman L, Bianchi DW, Shaffer LG, et al. Use of array comparative genomic hybridization for prenatal diagnosis of fetuses with sonographic anomalies and normal metaphase karyotype. Prenat Diagn 2009; 29:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/33\">",
"      Lu XY, Phung MT, Shaw CA, et al. Genomic imbalances in neonates with birth defects: high detection rates by using chromosomal microarray analysis. Pediatrics 2008; 122:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/34\">",
"      Goemaere N, Douben H, Van Opstal D, et al. The use of comparative genomic hybridization and fluorescent in situ hybridization in postmortem pathology investigation of congenital malformations. Pediatr Dev Pathol 2010; 13:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/35\">",
"      Warburton D, Susser M, Stein Z, Kline J. Genetic and epidemiologic investigation of spontaneous abortion: relevance to clinical practice. Birth Defects Orig Artic Ser 1979; 15:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/36\">",
"      Reddy UM, Page GP, Saade GR. The role of DNA microarrays in the evaluation of fetal death. Prenat Diagn 2012; 32:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7208/abstract/37\">",
"      Wapner RJ, Driscoll DA, Simpson JL. Integration of microarray technology into prenatal diagnosis: counselling issues generated during the NICHD clinical trial. Prenat Diagn 2012; 32:396.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16683 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-ED3CA7AB47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_2_7208=[""].join("\n");
var outline_f7_2_7208=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12423107\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18810847\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12423065\">",
"      BENEFITS AND LIMITATIONS OF aCGH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18811338\">",
"      Benefits",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18811391\">",
"      - Higher diagnostic yield",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18811433\">",
"      - Faster turnaround time",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18812072\">",
"      Limitations/disadvantages",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18812086\">",
"      - Inability to detect balanced structural rearrangements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18812954\">",
"      - Poor ability to detect triploidy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1897070\">",
"      - Variable ability to detect low level mosaicism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1897120\">",
"      - Detection of variants of uncertain significance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1897387\">",
"      - Expense",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16315619\">",
"      - Variable clinical sensitivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1898090\">",
"      PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1898181\">",
"      Specimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1898188\">",
"      Targeted versus whole genome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1897463\">",
"      CLINICAL INDICATIONS FOR aCGH IN OBSTETRICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12423086\">",
"      Prenatal ultrasound showing fetal structural abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12423093\">",
"      Fetal demise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1897951\">",
"      Marker chromosome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1897960\">",
"      Potential indications for prenatal aCGH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12423100\">",
"      PATIENT COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12423107\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/16683\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/16683|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/63/29687\" title=\"figure 1\">",
"      Schematic CGH for microarray setup",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19161?source=related_link\">",
"      Approach to congenital malformations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21097?source=related_link\">",
"      Basic principles of genetic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=related_link\">",
"      Congenital cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=related_link\">",
"      Cytogenetic and molecular genetic diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38969?source=related_link\">",
"      Diagnosis of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28087?source=related_link\">",
"      Genomic disorders: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5257?source=related_link\">",
"      Intellectual disability (mental retardation) in children: Evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5112?source=related_link\">",
"      Overview of genetic variation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17846?source=related_link\">",
"      Principles of molecular genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=related_link\">",
"      Sonographic findings associated with fetal aneuploidy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4453?source=related_link\">",
"      Surgical termination of pregnancy: First trimester",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28409?source=related_link\">",
"      Termination of pregnancy: Second trimester",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39799?source=related_link\">",
"      Tools for genetics and genomics: Gene expression",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_2_7209="Organ scoring of chronic GVHD";
var content_f7_2_7209=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F69017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F69017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 632px\">",
"   <div class=\"ttl\">",
"    NIH consensus criteria for organ scoring of chronic GVHD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 612px; height: 1354px; background-image: url(data:image/gif;base64,R0lGODlhZAJKBcQAAP///+bm5gAAAIiIiERERLu7uyIiIpmZmd3d3WZmZjMzMxEREe7u7szMzFVVVXd3d6qqqkBAQLGxsQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABkAkoFAAX/YASMZGmeaKqubOu+MCDGdG3fuDrnfO//u59wSEwFi8hkLyJQOp+2JnRKVUmr2Ow1y31uu+Ci4Bsu+8jm9A2tbsfY7vgKLq+bxvb8XM8/0ftyf4BtgoNpeIZ8hYlhi4xgjo9aknaIlHGRl1OZmlCcnUqfoEiWo2WipkOoqUKrrD2urzmlslixtVG4Xbe6b722vL8uwcIsxMV7yF7KXsfMd8+h0dLTYtViztXZ09vc10Tdz7TfPOHM5ufkreo/4+y57+XxsPOz9Tju98P68Pw06MgAFsvnz0pBXwdhCBS28BfBhNAgtmjosAoEAmMIPGCA5MCCMQoaUKGo66HEERQv/2bciIQBRgEKIHgyo1KARo5JMA5IIrCBAAMIADQgILJIgp0FBCwYedIYSVwNfQIVShQJxgMMFizASQ2M1KBDixIZMEbATlJUyCrgOmLAR6VUQYp8YBMjg6FjDMhM8VGsk5QvbyIhO2bB2b9PazVUyxaA28JxYc6tK+DuS70lEIzheHVZGMYmHsPFKxkAXQJ2SWM+4cAsTyo+yzqQSZYAiawCGiDQyoBuWQYGDNyFiyIB8ZlVvlL1K8TBAaFjgiJumgx2WQGzHdu83Xf3Vt+bgw9fSsIn+daHX4eJPSZ7be65vfe+Dly4eRTo1U9pAD63AgHPjXDATyP8dwBdDgh43f8YzAFgnGubYAFaCaItRVpIplFmWV57nSCVJ4nJQhF/1zVgIAkDGlAggAgquKBY9wGQ319mkFiWiQCiSCAABrYIwIAvsgahNVz8N8CJCqrII4vYJamCS+1VEdV17m03Am668dZffeN5WFaHoYT4SohGIvnjjj02eaaSJ2hWGQCd0dhGmTk6ueSBaqbIwoxEQjFAAkEBl9t7V3anpZq47YQAAWz9J0ACtmRhI4Nm6nmnj0CWiAKWzVBnUBV/BmrAoFYCgKV8PiYKwKJsXSWfZ2CEauqoDRBqqqHfIfqRoowKmZ4qsD0wqk17VRgZhj5GpiYJjpb1QIRg0BngmivimSD/tS38ByYpYrISlbAZFfuWhS8huyxpy15Z7rZorQcusW2Ne+xk1ypbb1sLNnaGpyksBuispNpWaHyHXqsqq7dV1QBvnfLrh8MPQxyRxChhwd+wBIgL2YX0lvdSunCWVVXDFAPQbSono1xyxSubdFLKo8Ac88om0+yyRDJ3krPONtu88yU/UxK00D23PPQjRzOStNJFl3wzREsbErXUTVM8RgBYZ6311lx37fXXYIct9thkl2322WinrfbabLft9ttwxy333HTXbffdeJd9dd589+3334AHLvjghBdu+OGIy7134ow37vjjkEcu+eSUV0724pZnrvnmnHfu+eeg1415/+ikl2766ainrjrco6/u+uuwxy777IU/ndDUgOCee9US236Q7orQXHPLPvMOMfDBE2+08Q4jr4fzlRSvvNPCQ1+H9YFgjwnzzXPvqe8FobHgdeGjMH5Zv5t/vvawlrA++9P9gMCovwZk/v3fJPXpxO7XQtgJA7ANAerXL/zx7x7iM6A+TPIxApbgAQLzRsQOSJdp/UB/PAhgWyKYAwwqkAQJLI+jFGDBGngQBxp0DAefJIACoECDA3xBCPkHngToKwYxLIcLTbZDKX2QZSPAEUxKSIMT3iCFKZTSHwgAqaQ0qAQOcOBAfji8QqGGCEa0QRIvCIcZ9o9Zz3IMpHCQxf8abNEFPkkBDKV4QCB+EQAQWABYFCCdG+RwFj3kghdBWAIFhPFPHYzFGYHBAiaOYAEHIIwBRAKgYUUnMAxISlJSNIYHKWBVZVlLUv6zAJEUYFgDQICjxhhERyWIMLkpwEcQCacAAmWUI7jiPib4xh/JUQBzbE8CBKaRpIxqAa0RwLMGYICPrGVYKoKkL5USzGdlClBlOYptPjmGw7gJJhyByRieQ02C7NGNCuCgRzhyJJMNy5IA2ORPGoDMkNkkkj9h5hicGc1rSjOdoETBOQ2gKFyucZyOuSQVZxjHPPLzVhAgJkgcJRMCjDJTB1ClUp5DAIz9MijIbMCDcNlCGUH/pn18pGU4SwDQcsbzUSBJpzYX2U5lxhOY8zxTJe2pwW6y8QxLhNSAFjaXBKkphsRkAAMUMICknMU1CQCKZnqoGQhIEk6QMgwJHACp3YilnEHs6CF3Mk6HBoWqq+oknFa4v1qGNJbPAqpAMYkAzSDgqQawzYAcIxzgFFUKQR3qXV0Y1zORtDJItI1UU9BUk+2EmACQahndeNZaajQjIjHAcyRrWAcptYVOlJEDMJhXosJVrlsYEAMCm1g2YvCgbl0jAChL2YEq8EhK4aqKDqAiYrYVqQJMkE+GchapdhW0fE2PAZ6l1Rbalim0bOxjbRLZyT4HqZctQGYdsFm81tWz/x3t61x1NFqBaXCwICpkWQ6QKQJpNYYJGOOfPNjRFLYQXRGVQnrdSgJH1mlVrSEhbUlAX5Mt6iz2JaIxXDuCaxIIAfml6AAe0EQpxFB/KWQiBtPblgRg8MFNOECzEBDY/pYAvjz8EVBwqdKyNvbEJEjAJQMIASW1V2CYte6E1WthByMlwxvuMIlVcNp+cliAh80Ym5LL2CILZQEQyEoBSKhClLhQtSY7QAz7i0sMx3IADNgopIpbAAojt41VNIGKVdhiJzeZh5w1wIwrfOEb/yjH3iWAh0mWAkMGUawg3CFQ68pP9j4Zxl2+JAMAtGbwglUFxPRJD6XqFpec5dAkkP/lRAgc0EJ1CLGfFGubS6zB3cSXnHy+65VLPFw4+lOg363fmAf9XBful9FdpDSPArTLWxHVzO6VrhQUUGNQC7XPNib1syBw6g2WtgTgLTFUtfPjVtpait+s4p84srAnK4A8uW5yDIm9qDAyeitWbqVoebTlvRh3KvG64b6IHGYmO8g2Wbl1iHONQV4nxdd23bT+Ss1trKYa2TfFR04pFM0QO9udjPLzmTH7kVHFdwQUlqhZRFmWOqLyOahsgERZmUOKR2esMlTf+ep7mAREcbwFEpi+m4DKBA2VQC4dNYTzgsuFPaqmbzmMRB0e4v0C6T8mRsn6HphJ6TxgK7gGdFL/QIKAlyczI/CUOctpjgCb31PiA1gYWzC49P80O4dHV3eYQTj0ESy5LGcZ9FmyDUO0yzSiq1SwsgfocQNA6kFLdedSotgV95V9BOChI+CRPm+lF93pCI+6s2cez6p/5Oo51zpP4KeGbSi5BYOUBDHuyGOSPCDgK+A8u2+gSrFHGvRDyIrp5SEE0aNgsU74fJi8x4MHrHUFmUeaEIi9emUngvfV6YEfXeB6UAQD+CyAPdAofwjaU4f5ZoD+KaTfCOc3hfqQkF6/3sf97nuf+8lDwfyGlGflP6HFT9yFD3Kf54rAIo8AJKsbOM/+AqbA/FGAP+5tM37U65EOMpM0cABB//2iazmQQ8W3AphhYCrCAMEkTKtyGQGSZbLhFx4nYGBmRvLnPvqHf0OQRSAYCbegVWokfwmIBfS3gUFHAhCmgk6GfySIebZBgM8DgG4ggCrAd+ZjgDhwgiygYQW2YwWyFul0SQpAhGQhEl6FXxZEXaa2erdQfwZXAh4oBFVYhUZWAzEYfyjgg1SQgv/QeTEAg/qHaLahg3nwEAEYfiYAUfK1ZQZ4UFkBJhmlHdU0XgPkEW1xScFEhCkWRh7mE2whiFP1AD5RRyeAZGYmaRmISSABT7/UTHRlTAywXRTWQtd0THmReJIEIEiHVSYwQBXlcTqVc8gUQGQxVx7nAO00S//FgXIVlREXZTKOMlk+pkEbRV7jtXEKVlFyqIhCAhd1qE05kotwAks1NSwYiGIsyHICZFFKERQt1E59yAAeF4PgoRvISACZgogZZ4yi+EqVNHnBF31sGIpc9YZolmGzNWQlMFyKdnpXlhXPgUhHwhHyFksBwoCf1IZbkF7b9RIWVFwUtYGC0FSf5Vd5xU+WCIf8JQBOZV1ChV0A5lxdKHhgZVUa0YxtoWYl5gARNGHjuIJidklXNCDBVVlusVq3yEFjlkO+BW6C53Pu2JGIOAKl5hormWImqVuDIljPEUcDdn/OCHIoyZLruIf4OAAgaWYg1CEZ2Umq9SAJEI8leYz/X1VVeAYONkgI51gCMdSQSalk7nYlWrZf8uhsLKYiG/UoYLmPQniIH/YmI+AAhiiErXVI5laGZvVhH/Nwi1eUUCWW7/WXayZGHrSWdQZg1xFR/0EUnKVyTZCXWDh2FPIWyeRmztZRSTE/LekYmOlsVPZfhbJkAuZlpqJlIdaZopGZKJFIcrYgN9mILRiYoxZjEHcdSRUgMahQNhRgUIYiQ9aaBxdg3FKOp/CV8tiZogSHnHVt/oiPVUmCGymaP3FYfihmgCiEPCJ4S7ZaSJgb3VkUrDRVCQJ8wmJ/xSFohBZstelpzMlrPLRq7YlvwMYdt9ZoYPlopARFvXZm+tOU/2ZHl65oAoWVnuEWQx2FoJBCFj92oMnkbYcFbodxJOSRbMd1JtIZYsICoc7Wb0AZckSpbZqpoLpGTtnphFZpAogEaSRqAlbpoTnkosfWCl1Zeco5aiGzAPKJm6ZCfqviKHZnh7kBJFJ2FglAeA9oQUDoiJu4KIXxLFD6ExO4UQ5ggbVYIBgIBzvXnlJHpNeCETzqnA0HIIgXcyQQdjLyKx23YZfRAE6XQvqziohXoKGYF665aWXhkV3nTwKEp2/Hiwf3ozsheWBZGHW3ZXnhQpfxdNXUZN1Uk7RZlAm6Ey2EeEvKTtrUQ7iBTdf4dfWTcY16cJ9qqO1wo833PD5Qev9YsBpUoHrq2QcxBKuBMAisKntvwJfrEA24aqPIWX2qKnxhZBGL5JWAgHxpOAjDtwa62g7aR0XZF6zUY30486yjp37SajXVQ61Qg6rmmK29YwNeaAKV6QLlSnyW2qzQKn708wKd1q4l8Qv/Q2fXqkc56iBj5FUNJBQjtIwqgJZC9xOu9hYj00cV+ojp1HDpt6s0MK5U+AdbmHyRMK4mGoYvQIPuOoMuuH76JDJBuk3ggHuviD4XKCXqOmjqeqq/Gq3JmgIU5gBEaEhOtKyARAMAG2WgOWgy4YAWtHRnsVs88ixSZXsg9QIOy5Ef6AwVixAugIYuoEFOiwR0Maw42YT/50mg65YCUytm/emEyOoF6ppGm+CtyQmuJZBeKoYTdoZIIyV+jvIsnTgtN5sjuwWk6LiHG0SI52qxKVCNHvWo/PW2dDUqmjSZOzGHHKhOWzmJ2KS4DVBSa/ESSwFUNwKO6VprcEK168qL3ZimN0KKKtS5JPCNsOhKoPskxmFDOMl0ibWXwLICFKi6DrKoreuUsQRLoBuOq/i3hctJyyWEHvcs5xReJImtLTuyHWJIA1J1D1KwmnVkuvYrc/scSfUjLyG7+2lsdMV13NknAESERHVcnKeiC1AAtkWP+kOTd6BrjNqfC7lXy8Zan3Z6K8qTm1kAbjVn6xqTjnYHUKmV/7UCZLP7KPULcSaJkQDcAqNSAkPlUzt0X1nLAgt8tktBkGDpkw0QlUOBkRF0jzwCv4a0heTLg8Qbq996vCegYh5RFH95lfUVINyYRXObF34xVJp7cP5GFG+yt0ybwrrpZZzXWtyYQpKlP2RZQj6KmmcmYeqomBkiVXk4nKFZsQPEYJMmfjtWZb/im4IyXsEpIFK8iTlknCkQu43xXa7LsGWcuo2hP8AYgznUSI05xtPSljUGcQ75jjAMmCW8rvZqtinWoHK0bMxCaxykoj5KUkN2XwVQFXp1AjkEtMM3tLfXLi+Une8LRT5pvgJTxHgFnet7mMYGn+oYb+lxiAMUo/8QaRquyZnFtLDMuFU5m4At6r4CPJc7JKP8yaK/srUsyCiP7LVYSw8q4MvMIhK1JsytshPc5qIz2sHZuWarrMnQQcL02oh/jMJc25FD0Z+Bh4jB63s6gnb3hWCyQa57ii/YlLDrVLRQNF4vtwAHFbgxRcSAqXZ+wINK3HLK5mVqunRuSbkMMqpL27ZD+XpxN6i38oif+sXqnBsEfRalSnij2yaO0isl+7pqhB9y8bEQ7E6u8altGiVLumZ4R88QyMNaCIDf19IuDX6AzC8Uwao0IIUK3QOXd8WJ0Ks36ARHa3zYZ7zaigXLWtMb+7U9QLR2ejw+7X86E9TZPNTTI9X/VgPVkzDVVB2uy4PVXACKmmDVV20H8woDKo0PPFDWZ6YFKZvW28cCQExH+ypEZWkC9hUUtAUST/YWDoATojHXejy655whldR7fIuCh/HT2jwHaw0JD9yBghmyXOCFKGtCW4DWS11ElZ0JNl0DXhixL7SxJvGyMdtgJvJH/fnXJEBstDYAqh2kp+SRpnHaLzy6KuKZcTRHs8l6WXBHZcYzMrTYu7DWm62FXeCFYovZUW0DaD3c4CDcoP0HaOuHa6thG7taTai5dlkelVGeEjwtiCUjCVBQfReKuLuNDhpMS6FIGqdNnQRRPwrLu5MCQkRVFddIFqaMxziOmEtZkCSW/9n4jjRMpB+zVCaHVp0pMpw5zMRdZ+U9jqiIS+hth4vkuO4daVA3vIB3L0eSiVHHTqJGTITLEQ/o1Ov6ABpOR5nU4fcJ4us84hQSHOtMGCGRd/sVjh4BuLeZpe6Tpeot4E7h1mOQvDpVc82bfnXNjXRtTRz1ZCN5AnmJWAuDcZxE4pcdSxiswcT0ZOjGU6ZRXe2r0LANNIh2e8V1LawklFfUmfudSNc1AITJLu94lz3EZZ15iLWJr3iu25B85QCc5XQlHVxu4k9lSKLXWaJWAkKZzEoekezkQhAGFPToFkGB2Oua6Ge46E7EpywH6fY4yPTH6QcAtLtE48kkeNV5t/866Y462UliZeLxKIWhTUJ41sJnW8mzPVWnnd1ZRY+BnAJPXnAfBoxqfLdRBpwCg5rlpWbqGMTAHT2ElWAG11EGpsVsteZe9idiycW3cZaL3NitZMV3rkr62w+QfFR37cXHTkrJvmaid+13zMAQqRErDF9JsQBhdOeSBcRU3og6K++dRO9Kce+Cme/5mh72jJafROoHd3bOW7E3u5oAch2SpSSwDt2CPOn96W6Y6+QWRGxI6uY5IkoJcnQBQqO3TlcUorrVBtldyMwQbss2eWdiwe7DOmjw3QeCgFjTrFXcbZ0cpiKqxOa/dldtJZ8kwN3jxmsruvMDW76ctlYOdS//Zr2YpoZgMP/nMo+0FHbqHTn0WeQAiLQwS0Gf8aVKbmbPmWwPORj2WuEg7Fn2ijXwQm9XFNLJoS6eTZkjFXXTzpyuIra+rMzlWSUSAmoFFs/NdgZ4Refr1xEUokEAed0efP0Wfl1f1/HdZtcs+37QkOx2DR1Bkkuk705hRgpHkso0aoRyeKdVkerz43dtFAV1O8prnZqdiUqky5V3qyWZR+aWxNbsxbuvn2/hcIFKoz/kEIyml7mhXfpwC3PH9vxy16nnAIR08tn8+vP8+I4VQmrwdm+HGCLjrulOxSqPHfXwe8rk+g0Sz+09lG5Hm9/T38DcnE/svwAc/lrlSoD//yICAgIwkqV5oqm6sq37woCYEkN8k4OC8z08+4LCIQCxgBBlqlqy6ZQJBIQh8ImKSq3aW3Tr/Qar4DFZJS6j0+c0+7tuw5/dOF37ruN79zw/tu8DrvwFEprMFSIKJi6m/CkkMALeMSEWRBWQCGC2DEzJsTxG8h2KMg6W5u0d7AAkYAkcABwYRClgDixEOTCMrEYZ2JhA7CVAAhAoIBBg2TQo1MbezJZgGWAe5Eo1XC0Fp1GuKHiPaLp0WqmyumLFztbeZu/2PgsAlzBkJ5ecu1iOlyAQgACAvwFYHABgsEzAgn8vSKFCdCoinT0GkLQyNmJYtAQDOBZRgNDfCH4kFv+uKAbAgQJeBCBZcvagpEYY0zLFwsVAABIGDqIZ6tYGnIoFmzIdXWGyiUWMKkmAbPURVsiRAoItLaFgZg5PLBrkcjgiIIIGVAcYKALsAasDXv1MpAgnrlw2dwLyyljCAVcSfEmY9VkThaWUxVqOeDliwaq3AOnNtGQJ6E1yscyaFUttCT1ICCDLmqESloEED7Bsy1GrQcBrBg6wK7GQAIN1aTPRi1WA1lksjoncFZD36Yi/e/sGdjAYBYPXJAJGSfA5St+xjO2hCAiBccnbytkO9AGxbh+65Mvc2U1iXRS3QEdgLyLQnqV6JwqrWIfxGCTYZdcRkFpxCIFVAEklVCb/QywJpOVWdHkFRcMUliDgAIFGwTbCaAjJsB9gAmyTAAGtyZIWUQCgxQAD4siQlAw24AIAd9uZdctvVKignoavuGdCfGTR98sJrjjGj4UAFPicPfGZAB0rKKYF1gG15aLAez+Yd94YWWrpRo636eXXYMYhKZxyJCQ4An4pJGDlAqktRFUJbZbg3DEHrIkmmFDUI2BCW3FDgw1ARkPAARnqVQ6UAiQA4U27kTjNiU8NAImiSBEk0CuklXSjEOmBSdxKYyJnpkZpirmPJ3YaiuamYgW0ijEGRWcCbBBi2aUkupanAl4a1jRMMB7BFstnCA3DFVr3AaHTnJDgMpBiJFip/+FbR9aYZy97yklQgH+KNcmgAmGrCYWfWeoidyNgttIUVBFgYnVQqmjPpeRg8kBa65a5jQOehuGrcMCWIKyGAxRbFQDJdocghyLtw0q5LsIXTEMACdTcTMv6FQw2uD7EJa/ojJzKChftGBsuURAAjy55+VLPP3HG4sA/lBrQwLQjnFZLeGOBpm1ozHRb4UGNCEXWdAJwtcwCoZSDTy240qrANlU32J5sLPNyL5/WEMRbWusoALB4JzvFI4rZtLz2y/P8Mo4zPpcAFqNLz0uCPWDhSpZaHu2J1i8UuzBeyXYdXkc6aeADMioiJw7cCqtQ9IBmYBgeORmQax5wOMt1jv9j6GqAAvroenB+Oheqo8d6665jDjvmqcvOAu21m4G7F7frfgLvvVPzO/DkDO+E8HIhgLLkKkCQc/EPPd9C8h5ecTzw1ve+hwOrEZSL89QQ/hh1JU1dxpoFLOA4D03JV01C24+vzC/R1HaQn9honZ1AmQ5QnwD69IxR6mOBnVB0NIVE4WK+E0KC4tQMelRLBcGQXznQ1yc0KAp9AyQH9nTXQdzdYTsDCcXF2GKI8PkFIdNrF6DIkKcIfkoFlJPPzwCgAMQUYAc35IVBtoGMgVToPQ/IyQJSQBaz6GZ/BHCACJGkjxsUcFnJG4AJZXGj1DUQJiBqYaWY44pgGAAxi7H/QRU3dxQYVi96y1Oj5/RngxoEJlNzwgICquYniK3EcqxYiiWe4TxaOY80CdhNFAawNEggo1Zi4xmHYsgmrviNXQP7EIT4YpYapmA7RuTJuigEpe2Ez47H6MSeougd0zwRaUvgmmS6lcXFNMZXCVhAX7YDoThq639aIyS8SLk0hMCvJWihRUvYM5AHNDKNbGzjMte3AgvdEAH48SSm2iWiEvCSlvzgmJpAtBIHgGUbyJQBhxQ4qiK8iQATEkie3LLGE7SqfYPbU2iehaiFXEkt1HtOLUhAoRVB6xnm7FcrpvBDHwFlWVKi0v/yqYQUpGhF/buKrfakGP80AEB+Cgg9/1fGEAPNgJrkgFERZ1TEg/4rB4gRB1oQgI9YXMqdZvhg7WgquzvooCRWG1guXaMmepKgITlF0VvwgxbYuK8ckQQAb9rDBLK002w/WEI0lnrJuk0yj1eFz5WkJDBZdbN8gDmCnn46yhNEEQuDudUC2TSrQZ6hgbGZ05PGMsu+8ENfuBRDBTX1CmWAESjsYRQ/nBNTs2WumYVTrB4kuICB0KmEde0QQVMKz/SxsDr4eUQ4wTfGVJ1kXNLM6jhFhwLTjGV/1NJHDpmKmB7a0Gqw3Mf3PstPlxogMqpFUaOQZJQP+cugDjHlXjyWvraiIKLAENorqdWRG9WvGW8CgAkle/9C6u7rPZSwLIrESFSuUpaRgrAp7Mjruj0sRLYWrG3K6sg9fv4vNVXDlf/0QStGtUhN2TAkPQTy1Iz5cQRoPFsKZggdIVGQlkVYiJ3qpws/NRUWfMMYEEsj0hwywwSiPBFTX8HNRdWDcOhlZVw9vDPqYiGVySVffLt3weCFOGxCosQvV8KOwi4oCiN0aCbMyzofqw7IMRCaFjT4TrTu8wuWI4+Q0YHCJhh5pox15pRXVwgiP2F6SdhD8/xU5SbL4clE0PJ4q2xlM0MPzVNV82LZ3ILEujkTcbbdnOlcZ1Xe2Xdg7tyeNddnPw9vqKbNc/AIjVxDEw/Rm3FsFo5RK1X/seDAOl4aj7UADg5TWdFQ0HSiNf3nyN0hYd1hgBE8lBWlpOVIw9jgE8DRvCMbGs5z/vThaF1rFbDIL03zxoGlA5oTvFRGGLlXIvF7SKIaxGgMMWCf+siQBiCVKjvxcqYVLes423pk2da2Gdh2Vv5A+pu+pVgVFdWtYxAIRGcyQgPQcgsDhKezyJQMuIkCNkd6etu60neX+N3vomDCCAcwDlFwnJgrkUjY+JJNMEjDI34QJ9ohFg0ix3FvZiL62m7293k43nEVrPsIKSp1xAZUJhdxV9VZPeswKlSTbcKbXdPtJsEI0JdpDzrjHq/LzuXSc5/76tcLGYzdfD0+bHoT/2j5O0mGlyYQkyykiPeFK8GQGotX5zzWP4/I1h/H6U4HAtNWEPuZrd31UpxdFGlXOyLI3gRB49vsX1+7Kb7+UE/Pne6L0Hsi+N73uecd8Jz2u0QEn2/DW9vuhCfE4gOhcTY3fleIz3jgBz95ylt+8JHvVeY7n3jNX57Qm+c83kHvecyfPtaVLz3rW496uade9IoPfZ6jEIDb4z73ut8973vv+98DP/jCHz7xi2/84yM/+cpfPvOb7/znQz/60p8+9atv/esT3/bY3z73u+/974M//OIfP/nLb/7zR1/76F8/+9vv/vfDP/7ynz/9h6/++uM///rfP//77///U9/9Af/gABJgARrgASJgAj6fACpgAzrgA0JgBEog+T2emo2eydDenV0gHlQgmm2g4sxe7NXeB1ZEBmqgCc4aCcaBCs5FCLqe1qEgtrng5x2eCJ5gDG7c6tHgDvKg6pneC8oeDkKeDr5ej21KB4JQ9RwhCzKFEh6hma3BEiJhTTEh4hyanH1ZoERIFl4h2ClWFGohY8kaBTHB9iABkZgFatAKEpzG5XBbF96dJRgAL1yTGRUeHN7FUTyAVwQTtW2B0LwCh+CPNvDMuaXZFi4aVAABL82L15yApNnAevlhkYkMGB5aA1AbJDKbd4EBIB6NLLBNapxGpTWCI3gTBEyBGRqEJ+z/RBExW1q04elY4hbKISTU4ZaI2QqGIRaaQAM4wG9BgSc0USi40BlQRUzsRE/8REIsgDrhwCwmoqMBAaC0nGetwFLJCBlNlhdg2ZvtItg5gy1QGHDZUN78oTEmUQMk4/vEAj44I1ywQC54hF8wzf/kRSuSDy2YBkWNDjTy4mRowjVZEL84kS58THfJAG+QTab4UUbRkSjVQ3T009wIQDJ9Ah6aQAEgwz/wQ0C80Tg42x/9wjYIEi/xV60UGyQsEk4szBzuxD9gAza2GSLyIs1piNXsBoQYkyjBV0WWCS/kSUhezUgqiIXxxkni1zDZ40r6wTfeHZrcUFUdzVDxkS6J/+QFleRRHltKdph9sGTzqAg/oslj7Vbh/IHEpWKGjQA+GpAOSIFY8plTLqJ/lcYUXMxB6lSdxIJh2QCDIEBrxIS4lYM1vUtfwltrwN0W+CPYwQbomAQ0qVhgWoi8IYRPZmOqsJszUognPpgVPcgxzITbyeUuns8jwGV+ESYKgMVEddPPSCY4Tdc4WaY5hVy7wdtLdaOd0aQXuorcCJUnfNhrUiY52dY5ZeY6jZaedaaDCBBoflvIuEAD6IsmbM8v8sRaLltb+o8b8spixqFApOGIqNZuGU21dALWlQM/mMsMLEs5PEpapKcnaEJ5kmLc1eR9amSudUVeIqQ/sedrvP8CfAbcbkWYW4gWIEYDS9zDVkgaUOlmNOInEJAVPniIe96GjsDTAOwV0nWHxAkoDenNw60KnlTiaNpKVGYoVRbVf3pofi1Vgf5XchpCgtbVijxAg8KjCihENDyD0UAAbDxWQmSnQZBRIcmiiWYKZGXBxTiLhqUFPuRafOLLZlkKErRLSklpfjWMYiJp3fziUWxTkNKJfwpYAnQWplxmcdREjFoCyMjJv2jkNkjUUFFoU2Ikhy7GTIBFhVqpN3EXiujpb1kXmdqQmc7cwqXpOe0nU5Eoq+XOnbLLDSUFFY1bZuEpZx2qltLmmh7oyilIcbTMt8wpK9QpdK7AHtYCEpj/YSvE1yu0Gz/SAnfumxNuin8CURYM5HvcVzQ8wHHll3qCFN2sg3u1WJZqwq7uDq2+gq9swl9Jo2z5J91MnZZa0FU4HWDR0Ip4JQethrL5ZHwkgEU+qBE+IdPtUjbMy7Dy5E8dnSQinbSqFbXu17XimLY66Lhya7myC7UxIotxYn0NxLRm0Lz2F7aShb3CWHx5K0KAq7hKmQ1+gWjKEdrFQW7ynFxYbAvCQcZyXRWSDhusWgtw7ChU7Afq3ch+bBugrNp5LAYJ4RBCbAq+rAfOYBHCIA7YzBBkavKcJsXGrDlIlZaGzgU6ostawam9XdDaxSA4GNPISAG0Sy8mnQqY/4UJ2JwLaJLjzeyUsmfQrmcZIG2y0kCKDcQgfguKOZRHjUiZYAFBCq0f5GIQhO1T3gcEDSXdJJfS9sDcQhRw6m2O6qgB0IYVxZHc1ujUnqrDguDPpoBReW3caskkQAI+DMA6+kQ7NuNvGMSFzKFZ7IBZuCIVQO7eAsxdLIAxxAsDcEwLnQDfCoHrtu7frs8f7OGJUpcOEZM2lkh7RFtfVgf8OMDSYAJ7FMAwRMF29Cl20cKr4upREhSsBSEKlFZeaoLYKCUnOh1IgaKRBhMDRFt/7JeN2WMJBFC7TUhTQQkxMQBFKu4hwpNnvMlL2gpZYhIthIcrHIDnMuQJOdubYP9DXs5G1xRAuCbGjXYGiN3Q8coYVegSLPSaU/LnYkDAsjQHR/rGAusGb8QCV5IAAi2bSZ4DL8HULAxSLjBGr53DfU0i4KaA8pDAA8wEoDitvpTjZJyACSmAqbFC29QutTwAzgXE1ejQ4KKikOaQrBIYEG5EEV1Tzn4tlLgUQVrW116tTvGCft5KFXfXFY/DdXaKjOgWFL9UYjbW2EKDZzbn1RIFWxrQA6ShWCEFvb1EsDFGRLHIepYFucCvbf4lRV2TSb0IlHwXng3JW7zGtGKVjcjI1ZUUI6Pb82YKhJjTOQDybNrAx2xTgBQt6tgO9YhDMlYtde0CT5BJ0zYK4v7/xX1VpC+yA1gscXH8sDc1h6u6gzlmXfQCG0/YHDaQpPYOcgExKtcSxDMEyGAlQMywEzE7ZLzmgD6qrngORGHgGH1inGzMSlbZKI7WiWrhr+eCLiY9sUqc59i8VX7VwAOopIguXCdImqb41NziVF2J3NhM1k2w86a0M7Z+6gszhCHt1j3/lVKNZx35LaqEwR8gAy+4xbSt2lCJw6pxF51QbtYGlaomU25lSruxgglhAwTEUdRizAoncQ/uBWOAhSuuJw+N6F6kmy+rqQ5ACEZX40tz4gnUsV3CiAgY3JaWMQpMCy6gopyyFKmSlWpw7vr+jwFNVjh7hszQSwXnFzb8/9aZLKqUEqSF9icEywfqzuHq1sSV2uV7ECQTzDRWGYE3UPJ7KAqTpo+K1ghT/MHSLJfU7cBfTFtONQBvWE4tgMgAJNNH0wO8BVMRGS8EzDItqO6TBBDCZNhbb5kJOgsxaoK97jS7EBMVEyX8wAIg+VdmzxUzTs05IBUt/PIBIOtIW201HMDCMpU3EPA+sM1A6K8N4VccU5yG+GoAa6ngKp2OAet38dKHTkPRafUwcw/HTNEc/c/5CklwSyNc+g9M7FcIL9LAMsRlyGMKowYVtOzrKLHmfBjJMK4XSCzadffmbG1d0Aowcul4b0F5s2x6T9l5o7d7eyB9x45906x+f/+ZMUphqyExDqzsC+QmfntJ42bbgGtsGIyuD9RHg8O3fWrYFL5uMczEJn9xhiaBNFu4nkHqMoQHiONAhA+Z9RR4BlrsiaThTAwDh6gtJq3AgE+TeZnHOVAChjcBi5wa0pI4at8DjofW23mEDRDbOPB4gIusTg+5h+/m3S3DTEAHjLdAjxO4ie+BgYstYSD0P7xxA7S4AR11ld+Agkv4C9x4g/cAe8MAlVeb1Jo5kreAaQ8AkT/ZkW+4CMi5Q4zHLKpT+qBqH5cP/JClTzEBROYGq2oNV9bhaxTG9yLbP9cALMTrIE6UQFEblre3ljdkpADo0pkFMX25/e6IEKHGLxX/xlaSkjTShticOj20bzVjp5+InKGwQwO/hwcXkT2QBVpUCS90bytVA3UX0jmwxwbDuY+HKKOIMKLDQrTNgmh1QrJ1L/uawaEX+gUvO1fiTUGBl60v8B/suRa+hKEwBnnyREulFqFrqDddE0XFyHrswBL1y6KTKIIIh7s5aVJkcV/I8XJguh3kiJ8GL1areEUSSUWysUFUhxe7C5nW5kHZMWvK0Z+KNwqIQ/Lkr9QJ10gJsn/GNLS7JDDAtA1NVMMp8iS/BZ2w+TMG/GxRdCvEOxiB/C2s1Jxvo+/AiIms+8k7srxjBrYYBb0H8rJcjMWGO3K9BGw4AIXoDDsQB6eP/9J75heFeJTOWwa9N3rB7rgnILM0KTN+iApv4nJG/ifUF/wu8AbDcvO5CU6jFFBhwOiwvNWMB3OW37ByNI9ff9eZl4gJnMbF6PrTecJLGPOaxOdSpXA2WP2WtHw+V/23BT5Bp0x0UHMjqLs9i+df3fgsFMoBCL2F+o3RG6O4Q4JRUIhEb3bMWcYx6DxY55e+aAd2sdzTpQX61LtMC37swgeL75ZygL2/o/gMQM0Gy4vUIosugLlvzSEKMAZ3FQZVJwZWhPxEAaUIUPxFquYCpBqTGhRXYPUJXJJiJNs5CNzI2+Sv4nRXxD4Nr3zZkf1spRYbFj+4jT9w1nTHX4G6u//+WNsACEAC4jhAIxSDARTLAaTAwS4DMAjAzvex7gMGeYQErzByCQwCGEEgWOCgChbhlhMoGr9lAfBcWqGCG4KpeCGny9GA4MPB2UxE2NBYAxLGYfwPGCg4SFhoeHgoFIdEhcBWNQMFs4NiAuAgYDmwAEXgyMPAqcWAoADlsFZKZnezE0bAwGBqkGqaiZgoaAMg4vgW2SRD08MoYMRoipB1e0l2oBfz9atU9ntn1YqrreijV8C0BAZlwHIgiew21yy5PPknjL1HBfc9Lg5lZvsAcKb1Ej2jHBVucaAUJIOQoDZDMgJdWQgxV8SJFCta9HMxo8aNghRyBPTro8iOI0v/mlxo8CSihoAeqlz5MqbMHh5n2vxY82TImxtz8vw5MSXQoRd9Ej1ayCjSpYGUMn3KwynUp0KnWn13NWtBrVyjduUq9SvPqjsSIkQEraLLjGvTohSbNWcWuD/DHrGLFsqXrz4V9Nm211W2mTv5GYCQkWwMrDv43F2E1+Fgiw9TuN1G12pNBiwFrc1cdOHlQd5yKpgMUt3QnAcUROz8OU5hQ7H/zHbBwIcdKLvWdcodhKBCIY4FjYZYm2LbyDRBQ62JgjZq569F2z0eZ0FgQbPrCjr8entyHt0vdlfgDgADAwu4YLqBCfH7g1vr7/lb6xQSU+1bgIOhhSRB2OLEDeDg/xEDgQAYYMYIB4gyWWUFrNEAg+soANwgzFEnUk3gJFBPE/JIYo4kFiKQTg4kUMFAA7ZYwmFND5DRgCqZ5GcMGG+MIQAsB+IIYwL2YDJKicagCAUfcxjwTApNhHgAA2FIERogKAJ3ohvkjLLgOFwEKOJDWSC4A5LGKPEPTQpWpmCIA6yABnAPwBhJHyiyEJ84iAVnX3ON4aeDA+og8UURAPwDgRRl4MACTVhI8ZkB+yy6woIN2rHPDiXGY5kAFUqDIQCnJcXhUjXpgSiVjbnmUpbK0IJDqKcN4FqpXgEiwJ6XDBqoEQi0R4ACvhgQy2ml7foOqLmNqqkADISUwJJNtv+SKhIZVvnHNzy4ugICoaQnaQyP6thAf3P2ENIuD15LKaQ3UFpDNt1+q6lqM2bDCQNE4vOOcIzd9xiTj91nJhQofjEMTV8gwQoDQiYJ0DCuFmAKAVz0ICESC2T6MMSEbGirRqfqULAbosRjKT/pNIZQAiuiZ2tNKxiznjtrgCOJS8UNACIQN6cX1RcdG9PaKtBKq0fJCMzYm0WnNpoyispI6zAZRsjA8BVGhkMeHFKX9UlZC48gYUBf7xCSwDOoZo6d4cSHyV80+WtfcS0Eyuufh6YHTxBfPICNOctejbAVRqjIgwNy6xgNobvQeu3HIRM18g5pqowY4GBkaqiKIUH/LhvU1Bn1gqCPKY5xKyvEwqC1dyNbkLLb7tMLrWiz4EKTPFzOAwphU1TTla4cvvKCBwguKuEAaH5FuRf7YPuhj7L7N6eFS9/1DmqfCwp77i0a33oi8omRnyPqRfKLejgWIgt9z+2FjjYaoPww6Oy2xPOCNa5DuUbsCzRcTW41gfDGge5BDmA0KUBTS5wz2hEzQISCRTZCRfpWsZZXFMsLF2SG2HYAwDGNoFxHQoMahNC+YiwuKN/Z0/3SdoD5XW0chcKC1XpAQhBxgnddgFXZ7AchGO4AZj3AX2/yJIIF/O4HBzELyHDRma48cYDAoyJQpmhFiLCmVqbaTkRwUxQs//bEi2DJ4k3EaEYopnEmfVnhFcmojTPoqiKKWWNJ0GhHyeXxJXjcY1P8eJI6AlJkg7xjIQ15SJwkEic+6cd0FilASBJSkpP8AwFoMMe8DCI5UYyINTCpSKR0kiFwHCVHBMmDB6imgH2ESysX+UpYBsIBByAAHOMQG7fAZjqm1MYvaGnLUGbrieXB1S0/Jp53TUgHxaSjTxzwyG7EUoqUTEw1rQkIEFmsELn0CSePiYtfaFN/2DxKLzVUysA0E3isWQWRMGQmDB3IHHprAv2gtDwaje6aTuNnPwmxnyhwAU3Hc8Zd+POlL+zLhvlLkIAIGjUtxYkNPQokKxlFBVsgJv9YEDPS4eBwBQIYwEa+sgVswCHSKPiCCl9akzIZRoYnjC1yKPEmFmSVDRRBQA/0BBgzUhWDTIJmmoUkalELQSgwGEFdC5DSZJJqqBR0i1zmMkG7sLcubo30WyiQxiqFCRlGIQBFN4gWGEyAgucJzhrCuoSv2mM6gBABDub4AoPSugc4XDVjzJyDY+wWFJuezxgNCMOTgNBTx8hAaTNLAE3FYlRARlaySAUCH85GtqdalnDF0RpC3Dc2zJ7hUjBM2DqxFdaQyMAarWhC0QzGWu0hhAaT2OXrdJQwbWEts/yTww5ccDZ2bvKmGUqAazjTpNwwrBTK29sfeOhKf1ZRuiz/BOhmsbcJKWVqYIpVAbHWMwDnKWx58cJBUztXPCbhNa6IHKZvARLbXoSrdiBtBeoSh1bb6qF5nkKWDJj3UmZyMVj5BefHBOubZ3CCCVGahTgW4Be5tm+CXHLOZPd4YQxXVm8QLZHNrpsCWUTBQsuYYfwg+kJpjUgBXz3lRVXr1XtQahwrc4mNRogG/QJBTCztYQ17m0NerLbFK8mwHY28RiQnmbrVich4uBISBRj4wEzWYpXfcmXMZBkmTo5mVn4l1Nco2YxjzmKZzbxlLqc5KWemYpsH+GY4r5khc2ZzE82SEexYuM565DNJAgEBMhGDG+csyWeAK5OwFBqSihkO/xHI4OWLutnPf6Z0JAEBnrCOVzKAIURsTtuTlUy5I3tZNGTphhFDIYGcG560pf/16vL5oDWA0CU4n6ycyXBmie1Nyqib8mu6NPpfhtrbgVoqoIl1cB8P4tdCDxaQ8zkBpUxQ4iNq1LcZQYHVpIq1rL29mGxmKp4MCCiCZPDODBlJwVFIj7kTGtD+LKOwtvgLs1RSk8Qqj0hSGNOXaJCAY3cM2hqMNzkL7iR3NBt8LEqAJQjwAJLKQUXppvK3w63USIQtXFdV9iXQqh2Ik2ek8nvfqsBAVxnctb/RgvYwclVdcJdF5ubDJdB0uuqPRwN092YcVpt6F/dYdZmFSkBX5/96t08kINKVjIO+d07yE1Q1BnRa0KRK7d1iDQCqcludLLa+KIxtl+dgR4DvUPerBqxAdj3HFarNZ9godUx5DPO42i5JsR41oLMDcDkLNmGPh+x3ALkdad8a+9g+yzzOk6vJJSkRdz1UKgVDk9tDRDuwyS/zTwnb39mWHpN8g7gAdtsaaNUzd7lSvg88W5/cdtazRVRs7y3T0QOMgLMmQKv2Gnr7rTLerMEBhHnEQ8AaSnAClijO6xYKk+EzF4/Br1ev0+4BdLtNc8aHrCYJ4NhxDztEwoEOl5l6HNB/C4QId+pPR/f8CIbI9HJCZqzq9+4nxBu0SAgf5lBnHdj1NnL//ocdyxcqPPAg2uFW6DIH42dnFycExcYPtkA/PnY3DIQj+3AHDSBiS8BQkHANjDN41/YIxCIKBahGNIdx2RcItNYCC3ZYjQAQANQDHgZRdwGD6wcw83Z577droecZUVB/99BvN7RYEmgED0Nwv+F6PoBwuOQlCaY9c3BjDQRCBtV7d5YQiRBs3BR/V4SCKbh4LRQTeoYIoNZ04IZK4aERuGZOX6h9EQRogmYSZGgIiOaDKJiGfvaGMfKFYOhtezg6gLhneNiHgjhUbohgU4EdpvZPKuiGj4iHichpJhFFbuESjGgbRAZraFiIkKgRa2CG2yeJT2GJrbWFMReGnpiK/x8RijEjWP4mJbzBOFmwBQ4lItrWX+TRY/YkN+jGGwa3bmASQ7tVbjsEA7iodnCAjH9EiKrIibUWIOcGcNxyBcFgJkqiPQfgIqcgisMlXnPiOoKBV2YFL0EVB+OoV1UHdZ/AdT5Xjn+1VDewLvznW/TIjI7YjPgIGUJHddpDWrACin4lLdHTeDZlevm0C1rTKLp1PYhngAt5en5jN0t4idcDXCMgWoj3Cw55aauoj8/oXowiV9SIfu9lVsbzMgE0VDaFfziUWdMXMaJzOTDZSVIVdRSZKe9DYJYzPbtzAIVxfTOXjx/5h5IWhBnnOXMAirVSKbkzct3oGQx1JjfEY/9akFABQWEmKII1WSi/eF0e9j4isBcElZXPAgslmHh+GGuGeIhDKU03OJYDQYUUwgkuY0I/aYWlkodW1Ipq5pF/WZTQyGd7OUBgBlYgSZRrKWlzRpiM6YyICZl/yJbC9piBmZiv1mhONJlt6JaRqZiR2Ce/V2zQphF9WQjF5BJseI+AaZmsiZm+J5TAR5pZgZpdWGmuiZmV+ZqhGZujSXlzAHHvRgf/Rj8clSPTgDNgQG0qNZy2OIxJ0jEFlTMdiGzjw5uf2ZnYuXiwiXGGpRdSIzU5VwLfaFUPl1/JeCj7sAYEkHJ2FV5TV46zYVw+x19cQI5YIDo155nauZ+WNmz/9uGbNXR7t7UCB9kQl/iTnvB+63kDg2egDbmAJ0OfhAeRMdmR/emfuumf3PmAbrMw3nNbftGScvUQ9IVdOiB4O/ae+nN4rqFT5LU54thfpmNyF5ebGkppm3lq19mhZdIQLIZ+MFhiJAppvrUpKNqgKkpR9cMCOfSBHlaVtVij+tmauJmjiIiFZyEIoRCXh4BrlRIXOHql2bmbFvEAXESHRDAdWYCAYUqmN3qZGyqmg9mJb5qjOsoXc0qndqqHwqGZaYan1KSnjgmaDkgEHkoZtikdLWGKdDSohBqnd8qjh+qjpxgT46GafomhYxqpfTqpw1OpJxmc0cgFtFidBUJR/yC1nNbmb865btEZjF3ZI7khjIq3qXr4qIDKoY+GEAUAnkkwow6AjuJiXuQCc9bQnpZCnsRaKbExnxXpdaNSjhqSq4BarVn2n6mGqFcwoJLHJBW6W6xgWvV1W55FBqc3DC4BeOFQkbBnodTKp7gar3WWrXCHqN/QH3ogojOqV9VjrO5BrtLXH/mXrvvwosyTk1kHXu96m7e6p506mLsKqiqzF0BagVqwUlZJgQ/xMAYQsEo6pH0DpeMgEMEgq7DAsKvpsPR6rVeWmU40CFxakqQmCPclqBD7sFbqqWaKpj4xSmHQVnk6ryw7tGvWmEbbsi6btEx2tNZatEj7tFv2sv94BmWa2GsrC6k6G7GfCjBgELSkxIWHEJCDYJrYp7U5i7W6yrWO4QBa6WsjUbaNeLZEi7OMKbH3YVzAkW6EYk9eMnAaFItRoCOBqyqMwgkYMrbRqSMi9QvLOF11m7VpK7V3+zB7QnZIMBkcJw3fZSzOoqbhiC7f1Tp91QPP2la/YI+PO7eRW6WSubbo0R+VpwdVAzEy4K5McwMPgbsKODxju64os5FM4FiOGrVSu7TUVa+/5xiboAwmyFOeq36IwXzZ4Dtr4TvZ8yu68wYHC7yqEZSa2rrhC6fbubashwcAlDRGOCL4AwsqpCPuq4vcOLYfqK5nySLEC7lQm7+Tm6X/ZMAUcTsSgVpGxytdAqwVTbsUANwhBFzADMxPCIytDvzAElxNEKy0xRvBGFxlU5uFE5Gmg7i/xqvBTEu5s2UcPmPAWhbCGbzCG0y5bhSSH9yWLbzBFExJyRubgPUGOcCergA4NBQg8vaEbWAMVKAy9/scNnzDSsxoJfxAsPKrxofCRbesixJwY8USL5rEI8y0TAxLL8y7gtGtKMx5nwVfc5AChZWXTJHCV9HGbuzFiYTDGKfDgwKiruN6IzpkYjOfyDUVb/zHdUrDyOvE7KAaFititHBdIRtjjeOCKkk5cSzHklxUfgqzhSCzR8XFyEvJg2TBgnCmk7zJDTzKDwzI/1s8yJxcytf0yV28yqzcyZJlyVT7RZGBid7xyhUcy340x8RhwpImw5vmpqlMysRsyuVbh2TcaQe8y7zczHnUyzxQxzwMnD/MQQgVAwAHUTemUCyyw8FQbUTCbDd0teI7vpKLrYWse1CMkcCKfkXXjz+nL2isAji1dndjVyk3g54bwM8Mzf6cZGCcPWJ8DMrcXSrzCSOgNpTXMiERgmvwWu/Xz7m8xBTdxMg80P6Rr567hA1hfvpSYAzo0Ep6M7Qj0Qts0YwG0GkUzSzzQIc8B4nc0WNpjCeQY91syDObonRw0odpzhma0nI8yx1MCJnsySvN0khtZn0Uyod0ylQhyP+rq7ZB7dRRjc4u+9RsrNRoRtWV3L8Q3EnrFMyitNVWlNWmgqWG6gpFikvK9Bhi/cZnTdZlLWeFSqXdWdDc9kHQY7VjzZnGPMFd7cl3W2wvYKqME2IKYEG+hWLJKXHfbA7hDAXj7DF8RNd1DdgVTNhGYA7DWhkQMCpjy1ShkKQJmHb3nFQeGwn7nJYuJthH/dq8TNjOUHiIDWElub0SPQILqgO5l6A6XdoRzWsTndm6HNsYttm9w6+I3Rr0QLof/Ti9EsYP3dsmPdwoXdwVnd0XrdbAhzY9JiGyoAAiwNg1XSKmEIFGo5QkzUw0dt0+zZ9XXcN2HRV/KsLbrdLHDc3/cv3XUu20+C3Ul719Vv3TOwvgVS3gcJh9Q62lYSsSc6HV+v3PEh7QXLuNWhBAmZo6+yNBpqbhcivf833gXt3dCpApPNPWuJCp0eHg+JbgCu7f6cy1Fhu/nlKV0nhPxrhuVZmLXXIm/yFt60aNFMciF66ODVvg8jrig23hD2Mx7UdVXHAuPyWP59UK/EVGqAIDiVK6rNIKWsV2b8JF4BvfSU635NvdXd55uGXGi6XbrCAYa/4YjCWhrUJaftUyKUnm5xziqrzgMz4J0QLlzTOwe/3RImesWQ4El8O9MYqUxcOATykRSw7blC7bXIuLp0sjPN5cHTadFPU8BhR4JKtA/ynmQOywxrZq5mfe5wXM4P573zHOwrLuwi/Oh7a+T/Td6v7E3/2968dM4UmN6yCM5vBDyxds6c4c7GQ22/zipW7tasmuYcu+1Fyraj2uhWY97MT+66yc3HsTUsWZjdlcnDzjDNfluEIr7RO+7hXe3YZiDnbQVicpMMzwQyAWZgPc7ktG7Wbd7GHSCvQOIHtx73rDkepO6yKe8IRs7ZanOrjzDwf6LoixXBHmk9HV79qe8XD27RzeD2kw8PuDhE8AYY6Flhi/78Ke8tUeHJc8690OyxtfkNueGb0eyTIPlSuv8TgP42ho817I8z2/6kb76q3MFoqaaDRf80rvSt8+m/8DY0lIz+Ei4dexufB+fvW87vS3PBEfbh1WFvR6yfQ7+u4eSm4BiTj7I4woMlDOAlFaQyW2s7dtsADinN7HuSXyZA8nqPM7n/XAftcPmBCBgXPMBCsbXo6GgjqjfQX0Ytg4ldr6jHbtMS8nBPZ9H+1/7+0NX6lqfA6ky4RuDURRDDZiQgCBNlixB4K9PVswVPVqyedD/9/F/nv2Gqrfp71f9UONQg5zcOgNQmLOy94JONBMArp7DtRhn+t/XvaVqgQMNrah/6519Vs1rTPnh77DP4UwlMgqrPkxj/kz3/LHrvAwb9zhn/Pfr93oL/Rr+fO4zP7tH/tlGv+3rvzc7rr/40/UZWi1IACII1kWQpmqK9u6IvrKM13bNx3jO9/7+S8oHOJ0xCMyKTDCVDqCYABACAqpE2BAIGFv3aSIIN0xweazrYxes1fqNpz9jtPBy5T6aRAgqNaVVtAXmBjPXB3i0GEio89iI2Ra5OTPXUneCEECAYEf1ZICA1bgyKjBXmiCQ9gDgsLSAwCWgRTDAkTBnsABAIGur8ACQtaSQcPJ60LDwdJuESU0WfS0JLW1y+P1tCUJZljCyUDVCBUuCqmIKYLtwQlCA5/DasNCgWmWAcACL8RC7xYzK7ToNQDwwMEJK5p6jXmm7eEliBJHZJsIqaJFRtwoOsmUAICDJQUa/0BZ0u7cllIoRRjgJebBx5ZhTgKwVUDBgU/NEBTqIoZZMwNdEnwsJC2jNoxIESldGqep0zYbm+DxOEVkAgU1d41KmW4lAJkHFtQDOa/KUAMLGOjjlUmKzwEEVYog2ivW0ajRoOpdw7evmb+AlZTx1usjgARoFwjYQxOdLLAyw6Z0BSuyCCpjchVjiNmzuCXgYtgF6rba4EiCUx9ZzVqI69eVCjerHVt2R9yJbuvO2/vp7zpTg/slDtw4HN7IXyhf3mK4cyTNo+emHtj6deyEtSvhLt37d/CKxCua7t08d/TpycNmHwS6e9Txfc93WN/+/TTqse+33t9/fvgFOAN8mf8005AgZZQkgALDjLUEAQUZ5Awl/0Vn4YUDyqchc4ssdIKECaawkC0DMCAABDU5wIstnLBgG4wxytiMDBguZ+ONHAKhY40eIrZPaMYAsIsB4OgygGUCfDTAKQwyoEs+ViGgzIkIAjAWFcNUV0mNPHbpJXNgYiPmcz5eKYAEyhi0igCr6NOQAx9N2QCT6+wzSBjN4HRlSQmwRUAsRlXVXphkumHoi4huqSgMHjZzAFCdjZPlCLqYREpLeB4mgjhsicCAAq3UFuWg733JKEeodqNqqqwW+M0Ic1H0xwJwIsZpSpkK4KlVWdwSYU0KDDCAVjXdsmgP2eBo3LLMskqVq2b/jhCakkP+UQBjUSTJB6YHgNoYCQu2hEBIS6xCywiqIGvIqao2S9y7v8Xb26t9Kafss0Pmq++z8+pWr173touqv//mW7BsAEclcKGu7ovwaxCzprBTDI/Z78MHH6zeODQIyiWhFzusMcb9emglgX/M8LEj4zXsbsYlR2uHyjKwnKzLIsNM8sgzt1AIgyZRUdAJDISmQEFVqHsXSKCwVW4UkdUsIM4vExxzz+6ePKQUTG4aJzwFbWKtO/AgQCxbwtbpWUIth/wcz1lfbbILQFtxQD7YZol3OvmM89JHijVDFGI3s/t2ojLLzajEqdVr95VRnrJF2CBtMc5YZaE9rQEM/zwJV8eGzDj6jAMzjvXOPrMAOd9n/nF00n8Y4BXU3iaDbttINT7Y7rzHTXDv9v4+9+KKUqxj8AGjTrzWwxu//Ol0K8586tUD7zyiySs/PePaV4x99uCTeTyH3i9l/vnii0m+huhn5P776oPJ/oDwT2T//fJ7SX+A+EPk///0x6MlBKCABjwgAhOowAUysIEOfCAEIyjBCVKwgha8IAYzqMENcrCDHvwgCEMowhGSsIQSJKAJU6jCFbKwhS58IQxjKMMZ0rCGH0ShDXOowx3ysIc+/CEQgyjECOJwiEY8IhKTqMQlMrGJIiyiE6MoxSlSsYpWvGIHoYjFLXKxi178Iv8YZci//AAwKdB7nvSKFz4BIm9jbCzfGdeoOutFj3tonCP16qhGQ5XxGmO8Tx+tEUhBvrF9g9xGIduXyP4dci+L7N8jAdlIaEyyQnHkoxvtKMc9ji+TxStd/ZwgIxpARlMGw8Mod2DKhIkyRoZ0QUiiFBq28GQJtRJBSFIEDwVAAEYNyOVWdiW8Uq3qK51LjFfQEDpHErNVveBDnhDQFS5wbGq7WZcOToAYbbZglSyATACbCS0ANOAVDDrNNbz5nkWUSwq68JxaChISKQBzl58KxgiAeSJhbi8ipTpBkZApFWtOwjDFzFMsPqGlLCRTnckiqHCwqRJhKuZWKnBoCsD/+RCDOjNUnLKoNTCaLHYGgxZk2RUzEEOFfNSTQff0By5RFExefU+c/IpMQMaGrWCgs5zmGgtbiDUkXQhOK8hoTAMExy1QJI2ooCCnOd3UHZsagRNreQAUpLkSzmyEASURxjiK1hjRPPWoxlDq2Zg6VLK61KdtytlBD3oCMdhCAR/Z6T5kYakpmHNJYtjF4HSSgCRZ1Ku29ENkTuRUl5o1RFXzJ2QBoIBk6tUkY+GUVoKUNLwZySQkeFAUxnYXgAajXLFgEmNCAaVnCoAAohjrAkx7pWyh7BIkDc0DGMOAB0RNBLptabFOBNOm2Yam6aOqSnhSpC3cEqjTKhZLeCGT/6glwAB9QIsA5MkmK1RubNS1rh+EqkyJeoQAY2GGVhn6ps98hVd2sct3r2uP7JrFWuSkr3elUF35ipcIHIXWCfA2gE18pLlruSUW4jQFZTCpZswwWkoUPCeVuDdwH4mvH0BkFp0sdEPjdGZSIVSQvPaDHW2Zy0GG5CYSD5dpmeFDlto2uzPhA54D6AKTPCcsGQMEBYAiEEkhEJIpobRaV2GpTO25leHqcwnG1R15I/MOCFFqSAsl1zkZCoEojYMU2OWU3+4WpVzY18sFwPKe7BDlwzADIXzoCqXwxFsEg3UYXU7Jl/Fh39aR+c4wOHNI0mwq5H4FAXsgyWChaWVozv+iNgcgxQHMya1cOZoEc4ZLncuM5/mCedCRdSYJsqKTJZyNAFs+U1DsO2pFy+IVwALcZ3oCFk0MBTEDjgtmbtJax4oSljL17a6epKZ5EkMKKX1pPmW6zyfHj9BSTkxr1zuAtWQ0H3Udg5/JFgO7DkmX9HXA5axgZs5l59PjXEg93DHNW4pDBWbrhQLclO08czvJ3w63eu3bacR9GMCT3hS7D9w1FCh4WrmKRS/PVqyCr+DdBIj3n/NNb5DSp983laxbxpZXcjRGCrKKeFtaoOBcqAnX05zSSYLauc+Z3AgMd0OQR6DbKXy1IUqVqnCTnaJlD9PcN3XHVbaAV3RSyy3/ufXUvOcLimEILq0Mip3EC1D0csfVmQsp9DSB8gpqikYEvfxD0k+wdGgv9ema/vPU+X3xVgEdVkNH9da3VWpOFYMP9FCS3Cdq5K9H3MxiZ1CHD+dzI/B27FyNUgKoTYyud+zw4SqGhCb7lTCAbvFv/VY+SuLalrNWSGVyHiiDYDgT4C8PqQSDRq/gPdO7EiKpJ31rWgmjSNjkBa+3QyULWodeMhv2+YvElFLkApEyRTbBfwHxd2SRB0C3BbffjiYxGcn65F411b/I9Kmf/fj8UfvRJyVlnQDRiEXj+SCn5A/Mr295Xb8R7dfIDfKs/jyvQf3+XV1t/cvpfD9n/7pP/8P+zZ//oYH9wcb7XdP3dVMMCKCzrMDoHQGOhR8ejB8CesECSuAlUCDvHGDxRV+KPZe1QAmToAJNbQungRY9OU2kfAQKElcoWFoz0InQ7dUIOolbSRXViECktANj5BUwtNYeCINh4dMIfCBmhWAx1OALkoOknSBtERaqVUsLlssSVlwR4qBQVYEINkkV8lUzOOESpKCTrOBshaEL0lThZVcgcNU5cCED3KDobJ97zEE/CJQDSIH8WZeJ5dOmYcGPYVbaNMSD/WEWvKCwdIPwqdcCxII6sEN/PdaIjIGBeVWPCcSN8RMJ1OHY3KG2gZmdoBO4/Zkf4gVIyIma6OCuEP/i5hyi4KWAJm4BJ+bhJ5JAKHaiKhqiIKYiKa4igvyaIjJiG37iI5IBB0ZU9J0IBADKWMROBEYXCUzGl+lahCiVkkTaTkhjiA0OCTCJkkBYnElGTgQaOsUf/l2FlvCBrFHehNzSCCCjMqqJ/OUKOkEjp2GjpeyCNZIaNlIjxdXAHLjjAyxjJ+bbZDhjJ+5jbSRAPr6Zq2Vj13FON2rBNxJkOGYZMcohexyCA+wDPcAUdgWVPNLiWQxgnGwOSyAcq5VkF6YAkDDXwFEkubViCfxhwHlV5XmGCLxbPnEkWYiiMHWLSN4XSaqCRRkASi6USvaeh9EiT3rkfIGkQeLSSA7/QlJWylHmUwKY5Aq0pLSBY0wWQTHSQVgeByBQG7dZC+YBZaygwpeVhJDUTpCgI+QRF4UYi9MEAlDsAUWmnRWiIlf0oEvcpBj8HUhNW9ogRhWkZUiuZdBwmls2gNzFZS0hFV2O41JOi1kiZgEoZlSSE1s65lzCZd1N5ls+SjtmSyjgZd3tpWleZALOT3R4DdXlUXDIJvRx0vogR2iUxWzq0W/spgaOFEaSx1iSJR0ZT3FKxXAS53KCR/fNR3LKAQsknw8UIB0UoPe8Aq/RjNtwSC/hICo153lM59bYAMsEwgNiBilY5w1g5wywZw1op5JpZ/qlhOEsUw42Qnq+hToG/8F3Nk2K/OeLRGdxRJ9D7acKnCcGAsKCEoF7UsJ80ld1Nuj69aVEIGgPAJOAwpx4rscKNBZi4c0OqkQyFATsjCiueMZYKUlZ8cHgoGdfeaFIcAFgMpQ4kOGDqkAaymBl3YESvmFUkQBjaNUWQIGQZVe2oMgrtNMlmBMvKFVgLoiSFAKUQB0kjgiEvFaJlgAVepVW9MMyaCM3Mog5pQjQOCnZ4eOjFALsDAmaTku1QMF8IU2bUAsvkamThOdr7g95aleIZp6VtI0mdFeRWgl64qF+gdeXrWeRCl08FMsyTWKDfdau5CgeJGIgLKJ66iGQNF+yHUDigZU/hEQDROh8tf8Y1/hKqGnFww0DKXyMUVZoftYYqFyiQlgUL0rWRjpYpSqqfhVqqtpmYrDqGIgBoQYrqdyXdQXDgEUBPKyChkYbFKDMc3If+ODYsooZTtJFYijkmAFqCRzq2XUio3pGltAjx53j3F2JpK2r1WzjHviJRDIaOKIZOvVSdVVUtZBqhDZAznWDFbjDtHWGUbyqiSjVhQWnzpSAXWTBaNSFRfHjVeDFQq6rn7FOPgwsuBjFT3zrniWrZEXBAmzCHkwZtMrUf/IWtRLoeBnotl2YS2QeKU5et1ZOKBJiikKO351DsYhrlsiDUApp16wFphylpW7lo7kkMcDkvsnckKrFOPD/K7iErL8S4awYxLKmyAOAayFS3oNJVsJ2Z7XZWK1tYxfG2zjEasKNm7hiTtZirYsZ6719bLgGg0IyBuW8VUjww1uprJ7iJmx+qJ64Kijkg2lwq1206eHmLB6KWx+iwN1lJbBmSQPswR7UzNut52ge7WneZY+NFWt6VqiBi2JECakSFwRo579SRDEoRDFwbeSKQZIEFH6S4+pkadnS4pquwrTRyeZumnphbOcZrkmwqVq5bQl8Qk6Y4bOSU2qlbG91A8uewfT2pm7oJPXugLCKpcImhycd5ybhxt/lX+zVAHBqRPcqZxqBr/Tt6QB9L22Gb/y2b/O4bxsNAXXygKFF/68hpC/cOCD5NkJokIH/Ekgd5G8b7G8Ac6j9wpHgXtQbIPC2Ot8WYBV7+SPYFfChALCshiuwJii2aTAJnIgInx9c9QC6yMA09d8qNWMPWDBYdqh2QEULYwgn9q8Jy2S4LPBM5h+GygA8PFR4xAF11vAQ3HD8Va+auSw+kCCU6EQoYEHlIkmMtuNXgUYzFGmMasEOokCSOAAUa2kwOKQfiBbOKl8kalsQyhYXPwqUdrHrthZbBE1d5okcE9XjyfGQcFaVdjDIQPAaXwYZ7sHAmR2R3Mo0/SAwCAMSNkYYi6DQ1eiP0ihPRUrg9YgM8wd54sMn4kk5gIhQlOKChUjRvP8FPKQIejrq3KVjLZLAJ/9N2FpLllTZZarofAlEjwWvlWQFTlZBjtUqssKrjl1iuK7cIb7VM8ZC7f6x6uEyjY3A18qt2FwOeCZyJYZF43oyijSjpHIqOk3iD/8t+3bSA3dLF5DEo5yApoZFpRUhszJE6/jsv6VjQaKzSZRtx/zNAMCEhdoN54mrrxBsCDfsgNFtutjaw4YaQtsXAyCsH4ut76VjxcKzx+JnIgtmNseAPXPFBVbZv4XFaXg0T/AwAwMun5azPJYyL5/ISWALPfVjrKCjXMxtIWSJuCaYV6w0R0Nst0UcyW2nAXNwnqUjeiaUTG2ti/nyyqEL8nIO2TL/wS8z9d0IU72V8P9CsDrOwlVKs+XI6kXHWkazhU6nnCIOLYR1Zk2Gs21lMoCgdHRh3k45hhSPbN59RdcVguDMWE3Pc+V9cVzvdLeSHWJJFoVedRoPdeWp5i64JfECVhy7lkEbiBxriubNsRXMbizf3wOzzTmMJhYb8tR8Na4l5isIBWM4Bmdm7mKmQ42qtfSyNXVoz8uxQe1ZKDn/ADumhxJPlUnDQUk0CB0w35X6Jg4oBnCfx24P8Tjf9nLPT3KXb2+/bwO/0nSH0nK6Nvm9h1X3Z8U8t2ZH9/2CsHiPtyZr9w6Tdw8HjHefMHG3d934MEnTC2wo7Ohhd4Wst9rJ/697q6iT7iCUeoaoaVYDOiDuVgGRzOUynallubFp4nWDCPhG4benNXfginfUeA3L8LIYjA2KgecpqcAv7xj/hoUy1wzQdA3XpguxcriaGKEfSTgzzy/9pjfyFmy2ZB5ZOMioDHgKEHRCN7Q2JnjjRg5OaiyOM3KkTG1SwDhE7/eMn3eNG7XWyux+fRyPF/NTo+JhVqjw/lg5wC2gVPkpSkS1ziFsx3Y5Iq9pMDaAGwO1wHR2E/hkxwBmc/mQ882av26b++5DLvmZOweTN/kd1S94K9Kf58j6ynhuHjpyBHocVjckMfqVd4+kw8slMff1QDoZXfqi45GTd3qhW7enD/+6ooN6qe+Po9u2qZ+6dI+6fr86rGM6pWs6IHF6hWtNGOW6ru86r/e6rweAFv26sA87sRe7scNQsB+7si87sze7sydQsj+7tE87tVc7FkW7tWe7tm87t+sQtnc7uIe7uI87B5V5Rla6pdM69aX6rMr6p996pod6pKs7dMLvu580vVtrot97q8v7pu87qfN7v7M68rC77fr7vyP8uqO7vNg6vhM6hQ88wTuwqz95wAs8xUP8xBt6vps5wOt36CW89LaeDJTSG8CnH8mebfCABIOf+6l8bbjfdisTSemJOBSLY1CLk02mfUOZswGUWBf2fBOSsz2TlmTVCtNsRgk9mUf/GTdFBpxfcMkzPf914OCRgFsJWmDMPPXG3Ai8wrBEmzjMLH0mY6M7fWMEDtU7AtfzdtWdmwAYNauZPINODNpTlJFttsu/59orN6iNk0c5rF+0Pe75WiJGBlkw8tgLqZLEt+/8vGPrVI3GSlQ5VxYullEFzVntRJuuaFFBlblYr0FZ1W4h/Vbt1TZmMUP4ArrYwuFrlhnHQpeKJdrT1QJw29uxoYz61Y0GVmBVMZxCyOqfQi0cS/Abg+VrxeybztoBPmVxFaTAlFAJ+CFDvys3YULsArU9IhS2/i1Y/zr5WjPgheCMgc5rRZL3fU1dfaH5gsYZm+J1baVIFy9gGHZp/5d9Hav9S52nggAgjmRpnqNwqiYrEglxLIeAFOpAAMsA4KSGoADQAQgKBOBgWDZHjUUD8HAgbFfEQMEAKHyosHgscpHMqRGOOYgleL4Zo/dTOd4I6cBAHNUYRgB3AHlTIkJERkhKTE5BUlQOAAYHkwdbXV9kZSudUAkCAgRTNAAQC3OVNFFTVQACkjyVpyQOO68FOGCUlrV4Uo2NpbSbZKFjDgIQJVcLIwMCDyYNDwZDxdjZ2tucLZ51CEKiWWVKIgjJCpU6EE/XgUNARU3XjT/0ibdD6ALq3MVoupUwA6OGAxw3chAgJ0+EPUVg5hTw5ydUqCYEBjx4A8rim3//Av+++obQWgMY5F4xVGHN4qVbBxRY1HKrZahKDp9AFCGRokOLApqwa9Ix1Edj386gSJAEqI2hS4DiI+TUXC9cDaGSsCngQM8DV4BaBflKZC1lJRgIcCYCmjSeMkTIHEu2rt0wIvOqsQEA1A46A1CZ2ANgjiZcRfTlYqHgDVohU2whhtdn3l0Uer2NgMFjccLEcIqYgSxoR8ZnCthCgaTGACRMl7dlHriX5pE3gFEBtnMU9CRpEJ4qEDFomoDIpsEUSV2CFQnDPmBnm610BMUYskhcMeDDeYo+pUw4kISoIfQSxVGzDR/7mJhkFocXXvvMKYMHBEIpWBa7f/ukaYiAEFX/OxSwwFo4teWSCA8INpliOOinREda6DfFO4pBc5N/1dGm2QtHIQSEETX0g0ZHCiQ3glrK1WeUXLcIsiCHYlAXIDibvWEgglGZSIhModgmWlA2RCFAAggAydcIKKrIkwAtKvgiFQ7C1xVAAApERXxKFNDSEwk4qOGRiN1zURDWyLQYCQ12oZ2SSrAo4JeXuUfjnXjWlZdTFsV22hgN5XnXnnyaRaOBboohkaBYtlCooYz+g+gmf4a0wqORalOpGJPeaWemoIY6kqjBJRpGoKJqA2mq1r01xgPyseqhrIIq4KoYpZK1Kq2b5EqGrXl+yuuwdu1K7LFIIauspcs2i42x/846K2y01M5a7bU3YqsttNoOy223tE4LbrPfjptqueaKim66Y8Szbofs/pNfjHWump8595IViLxRorCpoO/GGyyjqOZZcKQBY/Nvpn8ujFXCoxoMcRj7cqrCKV1cU+8Y+UkTFl3aVLyNwyaQTOPEAvuHMqArb3Iwoy2HYXKeMz+sJ8Ex60tve/YSgAp+fMHHRVj9MICDTKxRZVSSL5ZIpg7QmOP0JRc1wEB+CM4IcMrLGtoAkA7IsdwrLaE4z4Fc0Ik1AUYTuQB80swQSotITLk2A3SGaugDFjXAXWELQLCHfkAuY2JXU+9YCgEtMb4WAleHolodMhkwxZcXMgHUAf+nYW7z33Pw1+gJX4cStmBbkG2UfmcXrXYobONgzduhxH0glGz2bYSXfe6RZttE11BZsfbGMEMNWnDhhXJXQIADEZw9c8sghVQECB8lnOZcFTgkWnN/OXOtK8Wx9sIL7gkYgMAVBezBAN4DyOM+A188P8kONRxx62YFPmXA+/UL3yYMhZacOGIP60PfDnAXmCOAgQ5yIAD+rsGd7pkAB5GJhQgMIA1YvAAMm+KgzYLxhGeRbyuVOJ8P0pfA9v0PfvJ7YQCJYIAJ6m8FojPCAqQxIvWlYkSKKVEJQ1I8gyCkKEc6iUvkkYDeBIIrB4jJTETmwB6diW90+N5/xHcsQ/H/wx9awVAZ2ncLGDDxI22Qx2mAMBFRGOKDVEFAE9uSgJdtDQWDS8D7FjCRdSgGNNdAyGlSYoM1suA0WGxRDBlQFMf0oWEDYKRHbPYVVYXhi35sxxh9M4RAmJEFcyxCHQ/pAzbKZBQkyCMgFsIXIG7wAK4s06CK1xmESKcvw1ELLEHpRPmk5zemeMrObuidIBRyfwPjIrF2RZjzPGiMRsjDLrswvwqSsg6+IMEg/fc+a5oqU7sqxRbYQhlAEqEaNwxNYK5WymseYknY9EIC/iDPMhHgLRmhZ2NstpzJjY5iTXCmGHERTRpYsJrxu2agfjkCGugwOgp5ZSw1NkuOhSho/0s8kDV2KYJQHuJASIKThqwhJBKUiGpGiRCZToowZS6TYjNq0yYpMyZJ0C8oR4Bd2+AIBKxZTps+IMfdbjrElp5gDvrpgpw4mY+yBIUIJ1VcJQz5QZX2RqVJYFpQHPmTrmREqwZwpDyWOh2YbohKbhpoJy1i08rlVBQ7rWJPq7ai23GBRBeJqCUmOjw9CdClZQVsuLLxPSoKFjPY6FSN+hobO95FsSZUWL8GM8xMEeZcfz1ssjSrLmz4SgyG5Sy8xgAsYzD2Mo61S2ktWYzPUqyyedIQH1klLtEm07bgxK3edJtb3sIss77NVnBPNtw7Fpe4xz3ZrtrxxpCVT7TAHf/utzSEAGtMNrlaGkN1oaQh7CKWQ1rUpigidNpq1XYrouNGeFMW3eBySy3nhO1A+kBRbPANJ077W196M9hi4Gc+5U3lLUKrKJxukK1KSAmvWgbJbGBseWQIBIHFMJeOxqcPvBjgqmJSF03itr2+5ZYQiHPd+YJkDhI0YBHo4NEFY8MB3THWhCOcGgxXAgGMY4CC+3uXBmMjELMdw4wBtYDDhBIUl0tQu1aVgLfIbi1wmwfhQsEftUwBGpwFMW+9GB+88YkfRZPRWorCvqOt5coW2dkMyGGPsbWYxyYoShT5VMeWVIJ3UPKIIoCEByX1lTuhzDAPILBjWUEKPs7w3OH/5nyTfKKufE5DEp/Ux+cfmU7Ppqm0mHFHggSEDUxHcYA0BL1kjuHEfjWMyjwSuMIYYQ/LmtWybnfVPDVGR3lfQOB3xmg/GAhhGSK7ZxXbDIQ3G5oMTJErC4bhDDq0ZcCm6R865FPf7k1K0F+FJ5xLoOsSiJCBGAGhD3hBauuVk3pSkMyz151iWy5ACZsK3aI8aoRy48Vep1aoXgc6iQArU9YfDoMSb2LrvgClib3RmLs6Ok+d0ItoOG1z6oxNW4rdLtzYhLgN4ClhFWUhw/VFYgoTFLhCV3wpR5Hki+qB8SpqxQ8i/SMUBd3xKmYhlJtyGpk8KuqrGIPJTtY3U31j/2XRZNm7KgtDsnVZ8Ft2+xX8Wfh+SaPutsgndA8pBcXPhYLmUQHj8mBPaKzO7qDaYDwAQERd+ZM6XuC4CSbnOh7V95NMcLURwq6iM0cgwuAI6Rq/rHrqQLNNLbxQvy8IOiM/Agol2BszG5ZPwfnqGw/D+rAAt62hdrTRgm96qpIz+MbXtF/Rp5rvyvF0fnGCRH8bt2QXATsL8NyEHUHJSAnYSRb8RqTKzGAEV+C96boAcfnCTAxYezeQwoqYYDQaDDJNZV7/TgStYgFsuNe9DW4aFOYdB/VFUYAhuFLqMRggvSMrsUszD11kMTRd7CedtuEvqPXSCG9KVi4ZmPuPwf8HHOlbRCtYkwRcE397MTcFmCeupTew81sAGIAPeDMROCgTWCwV6FcXOD4ZyCwbyA0GiHkd6IEB8Sgf2C0lCFirsk9cY38ceAL81zWuJ3dhoIIcklrjMi2z0QDNxSYxoiHK838hGFgowGHF0lf1RTPqVydicH52ITJDhhcxWAxeAXtrEYURcwJEqCeMZYOWZXw/9yEd8jUKYISi8E5TsFrtF4RCeAJMKD4s6IFhkIUweBkzYAUnACv/ZAJteCgnKD26MoIAEhM+4RuD94QJqIaRdQJX4CYZwTha1WcWUQD5U3rusgbugjRTgGdoMFINgB03JDRdYCU+0BVhJVVHUGn/csNpmxVnQbcGnDgkZfg3WQARjLNnUyKKbxKJz9MVPnghQFIJfBMKOzgPDrCD7/ddiigAbhKMx7EHaBOKSSVmzrAPXYYqnOiJwgaKroAaYjY01TgEV6I0R6JVyHRvYChcP6EcNWcZQIiIq1gCXrIZBIhuDaBuQzCJc+QuYFCJt8EDPDQakFAFWTCLuDYAunYaHhQaEUQex5F3iVgy+dYdAVmMYiSLwnSKSqAI0hYY8NYi9rgYMTYF2MFA04h+caYxNUB3A3QqJVRA89BNBlmQT0dRtQaQrWAFWCAcmTAAtIAdMAYbh0EVzqOK6yYI5BFkX2gtwiWISiZh8mGI7OWO/3lIAvEIR5OwOSAnibzET/zURCthUlLhQBshekaBc6NYfUtSSPsIS6c0jMgIkQLCAjpHCQ43CWZnG3+ifXL0ESGEE1JnD/EYSP5zJN9EjDt4We9IlSWkSp7URAfXYkMwcF0RKHMplhxxcGoBAfc0A514cJLJUdxWEzgRFxp2jgIhhowVCKSBhkcnlYkJfMpolYHHkJ6RJGLlAlI3R7vxCM3lJa/xgy8JP2WSG+wUTFZxjFnCJEH3UW9EdabxBlGzE4R3lwhVC7QpD86JGOjUUEpWh1aRJErQIFMJm9/kUDsgTU6nkriwdJNpk4r5m6biAKuwAM5wS+wJmqnkS7QJEP+A+CE6eClBMiTAmYauWSNLyB9/Yn3hYA3WAD1rsU9S15VvIESbOEleECNW4hVI8zcaY4pYgzs+5ZbJ6RCS5wJjcplB0T8mgpdgoJfch3hplyYR2otOxQdIFWZ+8E0MAB/Ys5JhwIQ3eldsRRwLknxYoVHtyW0WmiIjkKErZndESnBIip+rMY5AUo6Q5yiFgoh9+G9iIIemdRmIiQKLYhdvqJTeZpKvdRn4BxJH+HomAKZFKShlei3nVaDZhadoWgI0GKb6Ijmuh4c9loSvOQIvGGFeqGFl6KZWqIQUxl++ISiCii13iqddykWXiql6ihebmqWdapqfmqniI6pR+an/AzGCmKKGpCowq3pBMvZcuyUqZyqASfgubxoqDrlM/WktgbGoJhCUWAOpKGiqe8oxgBopXFhF3HY7C5F2QCF2LcgwhJoqJFMztkp6eHKrdcokFjom/SCifwiqLlAD+XeALfo/eaCmXkqs6HhUYVICkyoxrVVU0HCU/yMEwyEE/gSHsjqt/eovtRoSjXonYyleELUDbiEaGsQz4modSfgnPaesscau7ZqfIoQeTvRu0qRNlfaIiRE1rdEnkcY+daBU38d3SwIKB4CvlGOBiihCsJIoZvZTnLiLSoaLmIONt+KhOjBEi2aXcWRmr2ERY3IAciaxbwmP4IhSP7VwHgs6/4GDZ0o2s5dDV5d4ZiJADOdgYFdZIdKQsCqzqx2yFg0oRJshbiBCoOwKKRsVp0FBF7ASlC/AkPX4Cw2wB31FB5SpjHPkUT06H6rhFuIQjRKoiG+jnnWQQdtzEES5akjLQQOpbRCECoswENGRaHfZawmgdlbJJMNhraeCO4trM/RIGITBbFT5fWjHdx20GNDzEVdAAsGhQckgOECxsAy7py4wWxtbMmAQsbO6LRSbp9ymABebSkU1CbD6J6S4OSLzlVIUJAaiYH/btRa2st/6OC47hC4Zl21BCVJRMGapcmSSEQW7teagli1ABCWRubzUZsraqzgFuiggD5W5cFD0Ff8aZxWL1EgSurXawbUk5RbQAKsVpbtN+gtqmpfoGjhqS6zGwkjOAJ5UAq+1mD0+4He/REW72Xd8gQQaVHT1Ya8MwLIFvL0mkAcOgLjy0BjFVDAIpU864ho7SJwLcw3oxBlRc0ace0Nel8MBW78sUEyky1/pIxjQ6r3yJMP/awr+lB8HKxrSkB/CioEIfA5X6qpn8lZVvK4Uy7ZOURg8OjzuIwRK9qFBFXNu6yMjxRfBURkelkrMqgQs6wVkooEp/DcOAJxYlZEeUTA3tQDcAVYfwaTweCCL0y8WgT0RMhdnBIsNcFI+1XKcKsQuQiZOCydUAQa0l7oSQshNfL7cOiX/CYtU5WrFZ5CqQdiq7AJiwQta9PLKeJxYArSt0zGwSUcryWoCthwurEx/w+vK/poN6cqNx6YNu5wN8aoquAw+vJLM2oSltPXL5kLNNzi8xNup1gwulVqg22yC2HyFEIzNOKjKIfjNwkvOP5aoJ5CrrSmm9ALNddLM4XrFlwQUw7x+6iwq8kxZc0oGspy0sMwNvWxhUbwdg3scfDIAtTsfsQkBQLIfInAg1BQNweEU4FrJ8Jy6FnMy9OymYtuunHOX3oXOlJoq/RyaXbPO/yDKYGka9FEDb6AWkyMThtDQaqGMRwNA10DRUvwk+/qQTRjPkJLS7fLRRNSwwAcKB7G1/6aTXCZtp/ecVKUDC2KTOkRyJKzjjK5zJnfzZLQTDVYkaUaxOy2hHJFDH6cxJpnWNLczrYZSN0+zAxa5Pn5W1bGgtSYgyDxwIBCgsoBLAjZNpMuQ05KEX2Ti02BL024ah1v5s5HWOlwABB6LsvOrU4LtkQ9AjnVgiQVAP7jrKSEtECmJAlGQz168tmTQPP5nPpWAPurDPgi1SPSTUDRkQ+YGbWOXut4zAL9GeNLmzu0iM3Rbb3e5x9D0XLHrL12RZ0cM1IJ9slZiETdlCCyr2GId2NEKlgz3CtExRH8w27xBCElD23LrCpyRbkcJkmUA0agN0kp9DkzNWAENzF8scP8fChbpkEnu0FQEVUaj1N2iNHkqEL0XmRhxl0gO9BAeZwNthEqFqqy8SNd3mZWYBMB4RLbVdSC3wNjWId1oYdiAHRW4EZuLTR/bXRHdzXJLoMa3AQRQtBcC3gay61D7kWijiZ8PCio4mJwjXQTSEAVIzar7fAL3+QwBVWT76N+ddJ4GZeKHl1A8xRLAIRzr5mzyh2O+rboNfpxdPFpAZZyKAJ1nt5/fm7XrESURQhQIqN1yAeKFHQptwwU35aBEMOIezq8ngBC22XxN4MG2IU1AcIwHFeUlQJ9a8DZG6azY2hWG7ID2rHO4g2fSrHlFfkFTWrQM4iBq1T5DSlRvFTv/QtfG4QBSu/PWB1i+K3QRXR6iPtrORAsajVwkDLpWZzWWUVCY1lUH15DQhjDYMhLnDx3R/IFjsQ7dKb4ZD3p3QjF9NZVxmswTbnU36LEDumRpYt0QQ0A/AyraWsonXHrp6Yeo1YKcrNXO+SwEILMoD/De4BzMUW1e4u5gsSlk7CyrEkKBAOsyx549lZ7aEBzv1CLw0ULwBT/voWrw5ILwocrwm1rOW4paCi/QDf9jdmLUIBjMoXss2+Xu8ZStox0xUEwVW7h5Ez+iD48N8MXR3IDxAdzM8lNZ4cUtNzywLg+V5F64rnos/wUSLp+UYC7yJEWySrvxgnXyyCJiaJDS/z9fF02fzcOF8xSvxMMCY2Tx9OZozzAgQSR7N3kzJ33C2b4TZq8o7xovMzpVNjLuNz4AijbbZa8DV9IooL54E2GhlSv+i9i+whehA8FXsjPfdd/XPRmR1tPooHL/szI+OP1QOKfYNJNEi9zREgrg+FL7+ONooclOOUGBZp0PyUdb16nY9oQrIIjMaPBkinjWBqIJBJENNfMnGyHvAp8EDS4EQFJ+6O206EKOQKkwumZ/33OH+6iCQa9WkLoQwEP5vbjfbaQxkt89RvjoGNFfdTHfj4OQbQE69dj/BhlhQdAkQ6MY/Ysf2wp0BHSb2xi5alfQatlBC+124LOstIo7kf897LlAmwUOCZQtAgLLABwLQ4yACoik2aoJoRpHIaykwAxGkQODwpUABzQeV4QEwFEsJJiAQeIGRAgQAGtNRTgMZoDaoVg0DNPqNXuIbMPj8jm9HnwDoyqqNXdbPMSYCVQZNRCY2RjpTUVJkaBtoQn8HERSlsUwUUKOHaz0hW0tYGmhwOH5kWYBnD4ItFAyUgFwWvrhiNb+iJ7WHhwomCH0puhyhmENIpyW6tqppIIa9ZSZ1UTuLZyNjZQWCBM0JAw+lkYzp6ic17IDyNAokggXEYtBE6VKIy0BKBf0YMDAwIAbDIC0GIDDgQMADSjpqtFgQQN8FuVIu6hxI0c2Gaf/GBBIsM+0AgkVHFTRJ4ECAAwEKDoYcOCAHlocCqjoYIatSwVuIECgYFMlNDunyRRjwIAYXx7VLG2q7iEWgCFp7uo0bYoYZDNOQchiIFBYe62MdeU1Y8EnJd6yDGhp8WOfoRMrqnj4w58ACAAeoOmn8GaTBHFTIhwxwIRTFQlfqOsxSt5YAGWfzdUnhJ8Ucj8QCSAgUFg2HQKE+aMXKOInhUUedeT4MTbt2vhmgxZNUiWOiUycFJE3SoABmAxItyoiOjmsKUUUVOwZ7TOsoVlvCS3i4DhxXWX2NlYz+7uXgmaIMl8ufesxtcwFKD4D9yva6VwlcWuWZSKh22luPKeF/2v9DXjIGWgAKAwzZ+iUiCqwfBKeSRAOBx8CxSnAlhWuFWeWRkXcMcggtpFY4mYmophiG7OpeNFDeLV4R4xwhDdjHSzamOOHOOrYox08+hhkHEAKmUZx9/RIZIs1Filek0/+qCSUU0o55ZNVWtkkllkGuSWXSXr5ZY5hijkjmWXGeCaaKaq5pokguilmm3HaNiedtdl5Z0d5csmkbHzq+WGgVtJlxG5r+DkoKopCCSgQh1q0mHJaPGQGW0AkuiOjV26q5X+OdnpiqF2iCCk0CjU0UUgPtfTQApiqgyeooy5Ka5JGnmFFCUXE+koRh8T3awHFwWdNf6HOausaHzVAj/8DJcjUEnGvPQfSNigRG5hyDNxQ3ALABbIrfDl0KMgBrG5xGqzOndbACUW86mtOc8CprI3J2uvGp7y1EsgdfpWn1wow5FAGYozim6+MQ8RF7iddjJuAAUFBdNVI1FylgHk/MKVDv0G89OoeAjxQ6XMHn/XiOwQYRATAdNSrsIoJy0zEvuluEQ6MIBFywgC3rMOKCsEMg2zNLX6EgBMKtEYABD7dt4suS6wkBR9GnGIFOKHtXO47MLHqKmHlAT3sX7AoVlwCKHtE89Fu11zoQbs5ANvAB6AgsGPqVFaW0UezyYZkDCygsX3tiYKAhjuAJJJ55eG8Qt05oOrQAquqq5D/XG6pfFReQrPQ1pBwy0y6wh9x5wMOoBkAI+Enn1LghPBxCDrCgAfOsIN/mXB4WgM2lHp63GI9ghWs7zzFNqFRqi4AwsAW+3MNANjz8ijRa3q+2tvLffe4o6hkpnsgiXvM4OOJfoneK8s+rUSGxXYQmJnv/qj2/61+nfrvzz9t5/tPUAHc0wBjg79OHXBTACwgNBJ4OwZuxIGKUpJrBoUZU91IgoPSYKA42EEICrANL9nLECCFwRldsE0LBCG9WDgXF74Qhj+Kw0MYlcIIevBOOaTTDnkowxmmITcDec0KEtCQfulqeY/LDslAgqGDMfFZ51lZPN7VnGEFh12hwQVp/xoArSlsbkU9dNMY11RGM/7wRmmYicYOBRSqHM9fOGOI5ayCAMKJrgnl0wED4OGJljnmExCgiFdwoZOGdKELo0sjzBjZQkdiBJJDSsMsChEEFDyACVrTGRfa8gXWOGwFRKuHH7vwChEoIxGRuCFIuPK07EmyVrFc1ixXVEtaMsxijwNCCRbwA7pZko56AaXk7tE3uCDoUp9TnOg6h6S6MIFwhsPIGctUTTndEpfZFNUQhGiqjuEMeVZg4mqUksco1i4oGFocEbFInK+d5plmUMBNHtA7am5TX/lc2D6T0M8cXDNF49tMQLlU0CwdFKH/BCgM4wezhFJpoTaTaDQoWv8Li65wmxBtlEUvStGNXgmknvpoR0VapELVMqPZNKmQWNpSjN6MDiecQ1XooAv6QY4TMxWPS33U01vBlKQl3NJOUYRTN5AwSkGV6E+BytR9NYAgTGRCGBRiLCZki5wqAM6rhFgLehzgH5l4xybAih/4nCcZ8zIICsgRHByIK1Y8XepCm6oju97rU1H9weQU14AeJNVgfRCmL22yh4yNYFyS2cVY9aBYNBDspl/5DRNOodPVyREVeDUTXevaWVwAggaDAIMYRpmFPijyC4wg6x7QAzRMLMK1EwOdZEdxDsv+EgdbE4dmP7vPzXJWqEK4gUlGMLkVRIQsp2WcMCt2k5n/EOQ6PgGKUGTLgsjIJSLgtKxfgNlb4XrWt/lEqW+YOJ+RTeuOpNEqc7q6LenaBxGFs+7sBsAfw5SWE2eBZyaQ992ngje8AP6SyuQEXKSJd7wJLtKR0KTSWx54ZiVdMIQjnLsBY/ifFg7fht9EYQh/eJYPTmmIRVzirKRxxCYOsIZPDEkVx7LD65swi1fQLO1khatajCqD1AdjScqYREEWcoIbRgQ7fi6pNMgs4H78Yhc/ucbrWNonZPEIoLnErccCn5MdOeT0QZmROJKMc5M8NMZZB31dFnOY2SxlLVaZOs0pED0MYLe3ffl/bU7xnmW4Zj6/WaN9huGff5hnA9I4/8P9LLSfB01oR7OQ0Y8O9EohDUJJu/DQBLQ0BDX9J04z0NOyAXUBMR1pUpca1QE09aVVvWpX84/VnYZ1rGntYwEEINe63jWve+3rXwM72MIeNrGLbexjIzvZyl42s5vt7GdDO9rSnja1q23ta2M728Yugra77e1vgzvc4h43uctt7nOjO93U5ra62+3ud8M73vKeN73rbe9t4/re+t43v/vt738DPODYZrfAC27wgyM84Qpf+LQJzvCHQzziEp84xdEt61Db2scZ57KoQyhgRf8Wox2/yMhjSGkSf7Tk/jk5ykE+XpU3cONclnmTYQ5ElyuY5TG2uRp1HmOa4xnocf9L9Mc1zPNG+hzIQi/d0R+Jc0En3ctNj2TUvbz00019klV389Mr7FsRjYjrAAX7xa+k5JiHiOxWTzvYpc6GURqGBWZQR1hExB8zyLHu6lgQLBAgL3h9aR/c7NZB/Bi+s5+Umwy1MT2Yho+i1gnxPfcn5c/2GvnFYaA2Oqo+Kz/RvDQ+jzLloH7btgaFLCcYKhBG8lzSHMcwrjh4AU4kBrIAv0DgiGE5YuAV//luMcHwb5I8qfi5+NX7ixbQgDyeiO/04x9/kJSiJz40j03jf/55yb+zHJgfeBZ5LQesB9nr5S6S3hGucH3RwZ13b03fV5Q334HHhJQJeu18sWHTIkT/tW7QRS0Tw/TUArG4Vas4C5FhX/ytHpLkn7QQYP+dBnHw2Dt507R8SxGEixLlgLyMgzk1AeBFIEwAQba4C2iITAJ6FOUNUlJFF+FAQA88Bz34BQHQQwIYiw1sw6UQALHsYN9Z0QnyxcncmABshwkOx6W4U03sURoInvEpAAP2jv49oLr4nwRmy/B0CyyAiwvwSg5o2SdwYFwNzwc2R+kty2yEjBCMHxCkIezBC16gSuW8glxZBhG+HwoiAVDsIDy0wBftQRglUpWNgMRQzE/MCx1xgsrAQ8RMTFUY2YzhYQ6Mg3JURCDWwiA2IiXcwCGFAmIR1xjMQH8xWTS8TCmB/8HEEEHaDMFYAFLnQV/2xQXadMIt2AQWDOJXpEpO+EIfMkYocsLFYB5fvODmtCIvEk5kzACxiJ7nKSD0TSLXeEI0MmIhbmITOEAnjsbGgKLHEMAoeqG0vEw3IhdiGdZ0WENphMgadIiviMwa5kAbml9xtAWxwAsPbNkKuN/1MWMKvtGkCA3oKM1pNM0rZUV7dCJ8SUJBpkVAOl7/7GNGsIQrQY1BYkzVtFYfZI1u6QzlqE0fmdNqIaQK9NEUnRIdNmP2oWRe3B7hgEPT+M5+/YJ+3EQWZCTklKQkggZMMCQYog07ZAFtLaErpmQK5kFLhAFBFtIudKJFNgJGGo9GQv8jci0PGsDg2uzWOFiNIwCU843d6YWGQLyeO64APG4D8ZBCt2wVfNge7umeHerjKyogUHzNWijGPXGkSxROCiSlJhqBdayfMymkfRwWAj6k+LUFPEiTXrqHUvZlIciELjll5GwV97GFZJjEKRLGepzZQaQZTozNUDZhIxzERPBChpDPS4IFTfrLY/hM5DgFVRRRS7yE6CyWZ7JmZAUl/BFl9jUkYublSzLm6jlm49BEZHpX0PgFYOSA/dUNdNUEKgqm6Z0ePTLB8ozLO5ZfWZ6NAjiBv4QFGvAdKahAPvZeJPKGFmDBDNRfHg1IW9hTSuylIQYIPAVguwSm1OwOmBX/5grIC/XxDnwuJl8GiPBUIOQcT4+J5PUwwIWchg6CYFHkABPZWfVw326eZFzSw3W+RH0EZk6OgDXgIIXU5FlQ6IPIY3uW6HpWiBJq3X6qQH/W0z3FZ/XQE4Fui3GuDoJ6wYG8zmlYUeuMoRGa4VzVGNld3EB5X/EdgZGyAZI21T4wqRqYRDC6RfsQlNohikk+yk+V3QCZjkOtQZL6FEeAqZQ+KUcogDdekpZOEJkyTphyadbJUtG12NYZmpzakp0a2tVtD54+BctZXw4EKgJ1hJjyy48k1aB6nEYoKuTQBoOyqabo6aRlKR0o6pDmSKMSyfhAHl8eqhzglqDGCueN/xocFNVAFYOjVqrgzMADpIWlRmo0+Kk20akQNGqjtimNxKr39YGhHpmoUk5uRlAcnGqsAitMxoYDGKsaDFSXvlqgAUexRCFKCKlZ0SARpRL2RGtiFUC2yo+3ViFFHGGEhMHE1GArtMQgAcsY6CgTUlIi3KA7fYI7vcEgSeIOUEK2hOvOwOBpyOB+ccK2rkAqJQB7DesQeOsVAoe2zp34xYoDPEAY3OC13uMP7teAfMW5SuwwBCy8gGsEUsQNEmnXtdz8oOIpBGIrKlZXqSdA9sVimAK3Duz6pQEWQMAn9oMx0qAW9JW4cqcvIesYqClcBkFE7qIgvUoL7MZLeNHEDP9AQ3hqunwGbNRixNCH1JzsqIoBYXEl1amBzYYC9miMYTXGAzREzv7V1bZCyxJGK+bN+vUC26Yq1n4m2HJCPzTrrDrJmzFC7DhNJNzkZaUDXyCAgQRH33Kr4YpgECiucESBTw4uuzoIFvgLCowkEdEqEEgKBb7FMrDCoWgM0xgRt/ZqbAUranIr4p5uNLbCMqKdEDTuSpSD6uJjZSqAvc6tTG6gLKIA0KSqM6itldlYTjpuZRmrs/qP3rprLjkOXk7TMnGCcspkRM6mc+4C9Yqg58SAbMKERbKmLxzXCnDn3f4MmlGVXe6jMP5FYKxmHiUEHixGdYorX86N6SLXq6b/asU0L3LJRXN1bYsWLffGBBghhvUuJyksRkP0QuW+xWd65tvqxNUCL0yW2TsIsEWK4xny6fcMAXdcTgq8Z7oQ0TV8RgNPiDxyR3co5TbIIwsk1Ql3r+mqqC+YFzMoMEWggIT+Bpt+BOugAYi60w8/Bx4IjHLuQuow5Wl2KLd6cHTZ2DYUrGps2nCxsHEgR7QeQBPL1VHM5n2AqO7yBhGdglt1jEzO7d3CCwwXr2m4bj5ssJWCqpZiqggpkhBAgLCqCOEEo/IKpZ6EL5i8sa0oSZkewf+O3RYpUCBX33x2CR/rZs5NaqaJnCLfD9HVKVM5MgpCMsnKAanqiK8+X6Hi/wgoU0kmpy/UdUqootiFaYQn2+qyrsjZHQqu7u1tyDIeSIiXMEAbu2oRhd3/mDLRbjKyGDKicYQrr2mJzDIsA7AorwsuQMMJOHE+3ANIygol508Q7Kvktk5N3UJcTZVp3KMXHlE3alUWXmATtRXHGqIwiCvGlqqt8qC3CIgAwrO8nsUewmsi4DN/8h4YsQuQdiyv7KvIHqwQmC3lGGWPDTR8FHR+jpMUx9UQ/nNeOMA0Rw08+UCdBPNQDjMuTC25PIA3s6/kMIFfidKbbmnhZgHXfmLH9JfMMubUPoRfIHMzC6ovcox9zYsMCIwoXIq97uw3wmRQA6G9woOy3sVfQP8tQIgnCuCs8RqzHb9KUtuXuCY0RDy1NuKtXFkB12YwQH8tImd0EQHhnnT0hYbcUGnC5RICSecM19AjTJiWA5dHJrHuF+AowO5F1EaB7+Kx1yazU5YNNpBPKtWDL2xuYHRu0YhkX3RjCXjRIEwCFEgBVJsuLS+vELzEHT+AZBvLOwkviWa2V+NAatmAzuwk41601mqzoyBvrb1Z1RjM82xChJRG3fzxMWkBwQzNAgCt/+41d01H1QCm3rzuYBePMwGm/e2Xza7vx4TOEDgAW0zEqyz1kTknBg/tzQlBdZ8LcFvOzuhvcWY2k311LpJQ+NamS+wgHT4DdFDRNUfyqbH/NVnpMLsogLZIYA2n00SwDTidc/GE0yDWg18H3xnMwE1nLrBGpmvIdwGq5xX6gg+zcRBrbu+k2YAQRQpfjCawcTwLwWJwptVMESV4+C7pAYhuhVYhT3u+o+suAxnKN31z8s/pSMT6yOQoQDFvtrIMRBvrWUcEuf7EtpFj84yAhn8uKrIoB4LhEFmrWVpb6FrXd6ulXJInspY/ECZzea62AQYxOMz4uFMlMzQ8APY02SRf+ayZakaMeXSKh4/HuYg/cx0oDnoOgmuzgeLsRWiXuUPGCCmfXmAD85dvELHCuaHfSKCPSRAxc9H6izusrhq4xp+j40vZCKETCpV7es3O/xPxdJEWqWcO4rZy0DNjunMlMnSinutV3QfF2s0Ml+vKvbJ+lyDgcSC5AEwq/TPBqugd/HnDJt5QjTqHRIclVAGxDEA4yzo3DxclwASyk3o3EG4x7GA4i6Gk3rjSrYHdHtJP06ULnIBOWztfhvQKVIYZEkAuwojBxG26jI3OMrl3w4oisoxK0+wRfOZE8LkxCjsvzYumR3u4YzXUHhHB9OwhsO0J3cAILLXZiru1T/BQL3xY4xCif9AQxC7GADbkjihuVY1bo0eV/kJd/67LzmTk2vqaFvbZJERHApQDN0bi/KMDY+oc59V9VwNlZ4U7zDXemDBKiTNxADbFn5cvBP/9VWZ8m2PcEGCvcNjFIY47iYc86cZWbftloo5AWfB2ys97Xbamya0pYC7T3fD6HgQCaSr03igP2+jXs5B7sUe7cGa3YCp89Ax9Smhv5Nw9YApG0qfAH5t003d7lFHxtCjCfEr4uO5XZCJ4frN7w6YT2D+IDkZ6H1cphFPPefSomseAv7gTk91XsCPXFLmGc4/pUM0nh6NYfdWwTAoP0G4FevUHGbdsBJoFDWco3wEpt9fqR5eJZkPio4qn+cQUidxxHdT5+ny606sI8RMmbaQ5lb5P8k9J8wvZ8x8+4ge/RnH/96Oy+Hsd9HtpG9xq5pP5SPXII4J5lmg/9hs++Zf/LKSvcpOqP7PKtM7fNwgA4kiW5ikK6Mq2JTGMsEvX9g2oODkQZg+YBWM74G5V0B1ZAuXyCY1KUc6p9YptVVHCWxcrKKTEtmR2tD2fuhCD+k2FGtfE53xqPjfh/P4x7RcoiMbi0CQQE4ZwqMCQlHQgcGCQQKDQlACAcCmQGYlJArFA0iDAAJNwuMh5AFCwILDQahCziGDQ5JYFGMSZuQnaMyCAYBgLMCxg0JB0udDwKQnAINAwqMbbHNuwKDa5iAlDQEsQfTCTrGAtwAoQnXnXwOnQ7e5mGWwA22gG3Dm155rAQbwGGrzCa4ABBENykNEkAEISIgIciCDgI0mxX89G/0RiMIIatIUDLM4IkyKGQgALYhxYwIAWRAR59KwgYLFUAwccGygUo5AhgAYdHzh4FCTTFwMPD0bJhpJAgnqTkPnoxRCIEBg6AVTKoVKXiI93BigYQfVezmoKGcQcYIanpmep/v0p6DTvErx6+9rglSBTwzANCBw6UBNlQ1u4Dh/gRIyEArMHEjiIcZIMym+Rc9yqRazmrpsUJx2SZCSwx9NMdahe2tQvDqgiAqe1epGIViIwqrpys9nNY1V3irE7cFsI6qtSzTRu0uopX9nU41S//ndF27cOE5ylhliJ4hm25I4w8AAAhM4iBizItKDjSQhj7LFUCVMqstCmsJFWT/+Mee1dFZQIRFkjQh6vpSeCSNjdQJtXmUgzDjJnNYQbAQxyVQ0ADvgQHADoAYjAHSOsROE9MaxXog8IyBKXYFYE9GCN1tmIIwm8MOCMTGG8oowkiZFBHjH+EJMMLkIZiNIDusxQ121AyuJKE5cgwKMyNnFxSC2QtShDE6Mk04mCnkCnnlg5rhChaum4QVQnQgDxyTkqWbmON24kieRV7R22Hzv3dBloRVVq8qUUNK6J43SM6uXoo3nx8gUclUpKCKYtfGHiG4tqWl2koF4j6qgE/deHWabquCodPPjJx6etTjqrbKXWCsetuG65q1Oy9koqsL4KOyyxA+lqrHTJCoT/7LJ7wZGEYn11ipCzpwpyCyLE/mqtf936Eam0LMwwGW44iHYDtXegC0Wz32Z3BrsPwPoGtX1w+261+eYKxwKx3cBuFOu6WwLB+zKhBruX+WFvrAYffCPEYKwgTxMWoWSMtuygiUouQBTQ2ADvIGMALo00JpaDIywAgT/wZPQcySbHlAtAEvNqQhK4LGBMei7LzA7NWo6limECEOBIGNK015gCnNA3ZSsvNUGmjIHge/OzWet7gqpoFOAeQyeFNRhQPrRkAlkLMQDjFpPdcgBRHvYExALpmREU2+FxvbWiSKBkgA+RzD2XT2u3bQI6Brg12UQlBLVIDF+h/dIpDJpL/+rDfeewuc0oGKdAK2GoVrZ9mVlli0dfGmHA3iUYlUAbJYl42gE9pI73Va0HrHXn7f6d26HPLSfC7ltAKdgACbBrBEq3dxbaJQT4RO/Vmvd9/dZ8oQj24tyFeHrddYzIIuvhgUTKAm44gLaAuKE9jLnGo++377+jkMcMMb5a/PkvhOUWWjDvKs47G37oxxOvZc5+92PgH7QDqDBkSRmJ0FPpPgYLRPAJTCI6QJbUdB8SIYo4gsuFCsz3Qc85cAcR0p8KjsTB1qVQBrxpAtIGWB8MxqIVRltGnKwGruxlTYg3Q1ZMopOjldxrhQ9k4myIKDEoQuxWh6jedZLhL3A5cf82W4SQFA/2xX2FUYxdhFcZXYC1M2ZKjQhjoxbc2EY4niCNbBzjuyK0hBchETsa4pscWbWXfxFEkAehoxrt+C08HiEBlyNBARgSDXHFigxsIyQL/zjHJ0jSBJuckSXVwwkF0Iclp2mksjBZMFSmEn/NWgT9xuI0SILwag95ABA1qUpA/uGT97JkMxiHEliABBcIUhQiu3VMa9HGH+mZGiIqZijV8UABBHhINOqQgnaAjGM9WMg8PGSlpDmjAXWJjChmlMs1nsAYo0BZnoJgw6RBAmPhJAE+/vGzfEKmANC0yAhSEZ1IwMcUMYHJjJLpLIQuizYOyIm/+tieCz1ORgD/RUEkigkWZIyCSue0BEM+dKJGAKBxUZnQQxaBznRyDgUFKsGIwrAdklIEbCItlwwyEqCeyOVFOyEgTU9wCQSV4iwZ3AZCFJospBqLNq27CGKkxw1DhI4HVjNLNefYFJRo5DTEEEJTa3Oa5bnGpGjRnFK3tQLSTaOcJiWd8oZUTrsEjzG1G94koqMIqe6xou74hzBxscdTpvOswmLoWh4iICXCMm2x9JDUDPo1ADiJJXsUAkgjSj8z5WCU6hmFCnOZkIUQDSQKMOl2BCgemr6ShjNxn2sPeyI1/TJLYhBmEhawJMGCVqUrPUE/OJGeHvoEUGVdbYKyIqbAHoIpv6mZ/xD8YZGMuU41UZLsLXu325uIyR+UcAg8j5a0yErXnqBBAAxh2ACTwZS4I4BAKEcpTMmy46C8JSywvsjIQPqhkikdbH3t2ysA7+qLetylHyD6WVUKGFeGPOOCa/VgCNf3vxNWaYRndeFVZdhUDS7jhkf1YRBXWA2XggLv7tDJXIVYUyvGVItdPOIzlPgJJ/bB6UqQB97t5cWP4jGjfPzjGGdhxkuosY7+pWPdKljIS7ZwIcLZz0CpIwftuOeZQHEkMRijEeAIGrrIZOMKdvlkufhtE9KjkJn9Bcg5YnOjeNvb7HatpgNQYFe+oi33BAGnS/qIAy4EUzqXVSJOKIXZSv8ngkUQOkEqaOhQ/JU3KtWgw110s40sfWkm/zOsoDuAb0DmXY0UCQHDaQLcxhDXBBTmMKLxzW4csmro5FgFXy2H+das6T9iuka7xk5CRPq4ZXQIpE1S0UzIF6DDmoV+3pmGkAo97DB35zvPBklclK27wDKh19fhdqjg7G3qFES6ZGpFOtZR5sUgyYQISG+QtMxqWAAWXXWhZtmABNgPmlkAaM42rp0M8IDLWVG8REEpcgsqSm8x3LYCd64NXAZCtUrhTmS4Xyx+8YfDkeJMxDikHC5wBXucViFvsn8tPPJinbzkmEx5IV1uEJgfC+QrB63MmaXxjee8jjcPFstbvvP/Q/b8WjUfuMltHnQH09zoqGxCAJ4O9ahLfepUr7rVr471rGt961zvute/Dvawi33sZC+72c+O9rSrfe1sb7vb3851p8N97nSvu93vjve8633vfO+73/+edrkDfvCEL7zhD4/4xCt+8YzfuuAbD/nIS37ylK+85S/P9sdjfvOc77znPw/60J9d86IvvelPj/rUq57vHF/h0AXxetgn3cOx1+LPdT37Std+ibeX4+5jReHeu/H3wBc+z3O/8KUfXeTIr7jymx78okO/+R2PPtOBTn3XW3/50zf+Ibff/etjX/otJ76nsq997zvY/N4qGFcPEQgiZ5qT78dawwQGq4Al/9mRQkxD/Q15f/xTHcpDXjTgf/83aQVXHxCGF4bAWRlzGXYxDA5QCqcBAWTCDhjFYJnESSOgMyDxFVbwBb5xEazBVdjkc6ukgl5ROwFIBbw0MAVTALnTAuiSYpPGgSoYLVRzKK/GAjHIAg2ggVViQ1HAXKz1VRGjTupkNOwgNhW0f97FWgnXgBFBAg+gLYvgWZcAAUPFA/y2H/4UYDmoSzqTCSE4BSOoJvrBfx/XgW9YG1VlRWgEg/mXBlHIaKMBh2UYGXp2InP4A4BocE4jSC/CWTsAagWYhGS4hClgT5nANth0gzLIYFV4iFhYQ12oJV54ImA4DKYkYXu4RvNUAP9fETVDMA4KYSVPw4LcRAIkmBQ4BmD+R4ZqhRvbJAmLYA1JIDTLUE4lkgvWAGb8dwnL4BA0KA6UkG3aYIw/sjEdYUa6xIcMYRQ9KG2SQAkyYQsKsQ/hlWZBw1hTRQrsEQSNMQ6xgFxF6BVEkDExsIii6Ih7qB88dW8nBAOSMFZU5oobszRhAl6P0I8xZ4lXqC195QCYOBRcxQAYKIZjCI+9JWrKGEKV41EkY17agoZecRZqaE9VlIckt4LqFFe2czat0FGZ4D4vJQYHIlkUWED8Zw2O5owZogAMEYLGE5MXM4MlBSGMGI9EiAneeI3+pI1I4j2oZZF6Y1EFSTsoiBH/fSUGtFAK9AEE1AASBTID7xiSPymNTThVmYE3zDU4EpJRejY2JMMD3iNTfZFGDkiQdRAfSpKQErUfDzAMdDlgPgmRxFCBBJA6njEnPoUb7uFc2ASLbOiBs6iXTmCLz3MaNIFbxMAAbOVdkdQ6ugCE3IOMRHCTrqOZ+RiNjbiXDBETD7CZUliUHNQc9tg/4RhYR1SA+SMymOkDs0OWDaGV0iiaTsCGw3AKUMiafRWHodZVFWQf/5Q8YnVxAzkCCAlWR8MkdPmJ8HRdE7eYiWmT0Ak/+aEbgvk89DFZHCkDQISHxbeVcdaYJelSgdNXpDUh9MGSTBKTdigCpXWMrDkn/27wCq5jnzNJlu5hXA9Ji4xGmkj5auMBD30yF3tzayMgDwrQFAlQC2jDWrLZFSAlSkwTQO6obbrJlUyYPNx5n+aiEZtAVuFpnLB4WnCxYG15Gg11CP4ULdFRgYdwgWDINgEZiuepBBoBERkBC1QSmDlkY7lgbKvRJYj5kSrnoejZgjBTM1A5QspwhqZWNa1ob4lpJQwxkz6YLQrQNls6omS5MGh0nYwWo0KJaNFyJWRiETTYQaQwhKYRTRWqA1CSC9PjWdPQI+54Gme6gk3YVGAZnPC0AP2ZbqcDi991Qy3KfjiDBgjofPRXfxDDNgEqoJIqLDzxAKDYk5T6fgv3qP96SH7jdzBGU5P1M1ijOjHqp3Suqnvox0Cs2qql6nu02l/ily4dCkZPIUiTWIDWiXKyaj94gYXR4aagxBOpigLUIBbOND3vp4Al4Kzn0QpddgiWFAOnUE8G6KsF6J/jgk0u2G02wgAd+hyCeGRjIRxq0gTWMJb/Zqs6twJs85Ro+RkQgRdmkUXUQB8M4ADIqq4/CKZksIgNM5lZiDTc4a3t8qvTKn9BViOnIBMkkJtMQAZVAYvKIByl0noOhKsJVgIvkTpKxBPu9SHMegK0oBrUgIKYgxbAZRXDkFssKxgHa0UIkAB2A1Qvq4SOFKQ81E06UmXAObP4OJxWRpOgcAL/P/ONjRBJ9cCLQdIJViICW8YAUfaQI4C12vAMUatVpnCOR7Mz6bgM3HoMJbATFUs7TsgDuFVgkWUfG+seIuOxIauquhoEwUU2RIGsvMpojmBQ5xCUA2ICjkYU3RMbvPgKw7RHnbIIsxRRoUkClJMfKpsSGlWPJOMN+YgTCUk9e1YlCHe1dHM4SKQf1DUhkrMQ3bBsI1VneHmemAW7SIGYqXuGSlFCUTkALGkUvMgCiwArPNKQkuU0KKgYGuuutoMId0usvsML2Lonh1CdJzCSJMAjDNIptUaSJnC9ONu0O2tK3oGpejkTKYAAlxK26Wu0RjCWr1Ear/aXLvWkrckj/4LxCqnzkt3BaXplvq2ICZp1vwkSmU94KENgmfJFoaTgAGz7hyZgALKrGKqysR7UGE/0vJ3zaw3CMorFUpA1DSwTUQUwPXzanYeLbdQqwhYSpw/crKngJdX7sytzQOorBig6okZQovY5A+UjbamzwITjwjJkUxehAP60v4FmXB4smrT7kYHBI9hkCf7kQrkRn+O4JBSLTSTMOCg4Lw48Uj4wwBXcV84Lq8mHAmxrGUx8uIa5p7oIgS5MAswEs+7wxtUwPHXcNWUcpWaKP0GLITqSqO3rJ4ZxqEpBKPLLlyA8pQraQRgoBuuhGYfmXeTGXk3Ktaw2VpAMIEQSA7JZKP9ixbQNom3+gDRpmbUBCU2nHEnDEB24gMFnPKlWcKlRJCl2KQXkykVXoMuFhbdPkcEavC+GCKlQQMxT9MsNpLf0Oq/Dl8y4JMuzvMzHF83pV80gC36myn008FzEsLEdEq8LtQLOpFwFl64JyK63WSWL4xUDK3vDes2zegTdTGruWjLCqUwr8ADmtqcLyAIXyyYZ6wZqZYbt3HDw3Mx1pB1wK2nBMxN02xLhnFQucE6bZqV4Qr9uKwNnIQoYlbwDLSOkmJEgiXTxXKws8ADH+z+J5s3LOwzxk8/BawCH6F13ZkXEWwJHnEXrah8E3VUSmXEIPc3f98+yKwSlcK7LKzT/yBSEDR1Znya5dbwIoDjBZ+HT7aaObJnNuNd7X+zFopUA7aojUvOxkhJaQ7hZoOsh+bewRVyfhhAb9jbAV82C7nw1W+17D9cWpbBHaDtlrbw0sBzTK1s7JBAl5zbHnHDKMmAR7oFRqwyCp+GjwnvQqxrM2PN82tx0z4xd26zZn61rnN1ECa3QJg29on1Jpg29l609qL3LpE3UsE17rD1Emc3Vlq3am+Parz3U60fbRWTbeS3Uni3cuY3Zwx1+xF3cvT3bxq09wc3MNrd6003d1W3d143dAUB62c3d3e3d3w3eerfd4U3e5W3e543eUzfe6c3e7e3e7y166w3f803f//Vt34Qn3/et3/vN3/1tdmV90s793AJeRLtNuaB928wdqwRuy7/d4Lgt25UG3cOH19Gt3Bae3Jvt4FM04aUN4QqOxgzO4ciN4Bie4SXuzBveqypORiSe4BdO4SIORgaOgzK+4hEuqn6RJXbta3OkqdYsyJVaA0AozqDKVTTWcwco5B3HnHUpAsJUgemxHv5UahKqCUaDDjYqYgKamOw80rkyrTjH5WEiFIZBE4V6wHoQ5ubZpD1qF0kgw+Upx2syoCsITeJoI3J+Fy3gln/CIFB+CA0w5fvBymcRVOpRm1qecIBa0F/uKWtOdG3ekT5janOu5xAC6ec35kQY2XFeKv+9rNWbPlLaK8N+cemxvAJ97uSklMomM+hyWbmdUAc7zmGMjo+lCKQ7RArzUDksTLX1ViXFSE7EgdG/brVa236SflMwMS/8cYsxExJGE5liMLWNAezMOOwXnYE5YO3H/k25upuJCQNsY5+niIsv5AtH+w5dNhXpHu3bFbbOiglWi+0iG2fqlKUe2Bie5lmqkiTrMAnLs++vmEHKwxymGSQ8c2Yk040ow6hJszM9Y8c8uG18boV+/uSmUAo8cTQVQQ39TDQeuaPKPrrjMDkuAcIKFKdNhZGt64w5WdMdgmese5E/xXs8+ojlIAvOLj5pXiXMlrsZFdY1nwQwjxI2LfT/Lm/ztUrykMCy+mG5kXgoO/UMP/GKpmAEVF9MwDucqtHyRD9s9KAKnf2hXJntJcxRMEElsuC7F+NPaW9Pl2MLtoAU7Dk4K5oHMcWiUVlCeztpTT6drL7xQmMRSoKFaTsUTgKsEovzBNqXf8kenWYVbUCkY5D3wGFBv+FdzfNI/qvpjX8RCRAJR8HzfhkZ6IKFaJO/kZHEO8k0lakLoNb6kg/uZT+axCQVkI87tFa/7rA6ulPYzRkLn1zAm+9Tl2/vdV4C3oGtfUL5CYwSzb8kBQBVQ2BLB1zFRrCaw4kMytkQZkD9R4PWgmzxnJUELqI+CWkR62Eow7CwsXAK0XEl/yMf7gRa1yEEoD/gBuQ+UyAADAQACEUhlEpiQkAjNIBDniJpFqVo8D8wKByqgkXgEUBoLVACRAoHWAxESV4MoVQ4SreR17lqCV6xWU0nVZcGviEcfvUKjykEeDmtDhYMqhVNCw8YgMEDAMTTgEKJw+BQ1laXWuFJFABL3ObPnEndj8JBSQLJwigPgoBBVcPCDM/NFOrQI0CBwettEUFVFBjCaQpDDwMDK2bv7o9tnIAn8/NzV98zgVYMpYMApZt0ywPBs8ILp/k5ejqdEWjJHYAqScGCwOnPgDTqg1/Y2qW0Ai0JnuEZN+NLjhP4ntFSZ84TxB963D35ReLAuCQpnv8NUrSjUkIn4wQSXKjg4A5LBRYKaOgQSTuYFLWU0DOv3iiMAhSoQMCzZI6FBp64EpDApzSauziW8NhP5cadSl/GitnpxwOAWnA9e5OAnxWmsriuktgVloIcyXypYNmFAU8f4gQQYLB22VwDsORAo+r3L+DAVY1IK9zXobJNmAQzllPHsLTGQgrFWSxZMETIzy5zXlP58MvMmjur+/MxDmXSSECrbu2ayOsgiogpZh374e1Nwcp9zq3Otu+/uzlZxhwc8INGnFK/3nz8uWvg0Kc7lE79+jnr2LfD5u49tPbv38OL506+/Pbz6KmrXw/dufv4V+XT/xRHExDm18Xl8Oz/t7gzueF3T3/YITBUFemANiAhBWLHX4OBAUhEe/XdVqGFzcVxgHL5ORhHYqRBAFYbH6Jzw4TdCRFiYBxOZuIQLHIWTmgbdkggOjJeNiJtJfqFInDwZYgehkOqdpgBvOF4jo6SMaffiTukaBUQTVKV5Is5JkiaA1sqGAeWQUAZo5ecPQnjQ1IGWaSRnbHZ5mV9qUJbVs804MZQChAzV10mHDBUPjsxBM9PLRxAjwADHPqMlzedosqgbeSyk10ntCTUDIDqNRBDguoSoBA6teToKAQAamo9CDAw1wI/zFlCnTLgSakS1lSagqgY/TQKUkYBEGsDiyb6A6miToXbEK/+/yrNnQbkuaetfgLa6a6EMiWsoog2Ss+j+RAyqZ4p4IqpIWdx2pKnez0GZ3lvsstYX7jEwpsbqp7ihjEKVMFNTQkO64Yg8LxCACI1FQwEIIcy8KQBxiAzrCszPEBJCYeoIa4SkKgYRGIJ+0HARTc83CMP8npBrwH2HoAvXAOkkGBi//pgSzAx8EawEB6vWmZ2cJjswrcqs6yvCZTEzMfMLdSMs8E5V6Ewww67DLEuE/9gMZA7TEThu+N17V28b/Rg1MI5GHBAAoMMQMZHMe/wZ7n5FMATAQ3MTddeqtC0iIOFLIGJqKswcC7bywCQ9iZ9KaO3Fwgoc1dWgJQstjcJlP9dMdpqJ7CY2wDAPe2lQ1l+d92pPNG4lYn7TLnolxuSeRuFK+Hv2z6AfgDpdtOd9+km4NF3Dn8XEXjDhF9cBOJ8fW3e8unBoSwP95q9csPH7Nt2wTfA3QwQ3HO/hwh+nCkw7kVEzANGxGhShuHJOxZjwYD0sbPhIUpSAvQlSI85yw/zwLT2kpYzWnxPfh/jGbKEkL9ZFOJs/bte09SwPY3xwHsaM6DrIhSM8pXgfCVIXybI8AJMuG9dzbuOu05YIzhg6Q/jcN3ZakUXYshCJxipnbUIkpcG7JBY3BrFk6TRhcWw5Cg/MUALOIURUlCQHUOwIalmV7+pMeVqL3AhpRr/WCpbLcaGAcyhDBClpx6W7IdSrA6YrihGGG5xhmzwIg579YQdktEdZgziNAwXFqP0ComH6xQTnZFCFf6GkNM5jIsMSZpBPvFGhkSkIxUJL0ZKUnWV9M2CmnjJv1BSCAwiZCY3Ocn3aKaUpiwMdjopSpmsUkOtjM4ro6NKUBkHhbFszSxjmctW7nKVQsJkY3pJy1tyxjoLAUzqllQfxSFQHVPiGF06Y5FiEnORoJnLM8jCKLCoAi3NXEct2VNNN6GDATdI5iaUIYshpGZMziMTVTDxzB/wiA2NmWaEACOdefaGNOO70DU1FsPooYIRS/mmfcJ5yHFS8xwx6Jdf0Okj/wsxM55F4OdE18kYfEpmn+rBKLt+yTGBNoRGhthSMt8kzPcxNJjPA8gxIIM7QJVqBGLbIw+vl4KhLGAbAkCEG+ihpzwUyhHS8FKvgOosWvlUT5yEAwGKOgJ8IKCpDIAUpTSVAp586oPfwGphCrKKg/wJElYjREBgOs0/rYQEUWWKHE+zMSBgVU+akohNe2Uobd0VZEAQ16XOQoOjqgKHebApUeH6E41y8prSIAHoEBADu5AopS61ZUsvGwdVQOAus0hEq6I6lRicRp1O2IEBQlYM6+VBHotYgBZY5IAuuGIlKfvDypxKtB9BlbayMkBKdLslzsrznJpMn0pgULUu8P+Lnq0qBQ2GWwaLcEgLrd1FVZXDWCdudrpzEG3AlnYwzjnoZcqVWJdSNrvCes4HRLWuW12b3X5gJqBXc4m+SmhZeKUys5oNAg/lxosqgHWOZYLb/3Q64GX4LQGHhccTkseigRJgZdM7l694C08/FQLDCQgwQ4obSPQt9nf9IJ49S2BOCBDsUA0A8ajaQo9yPFhvA90uKwGMTQ5WKUG3y90zAVcYJA6iF+yF24OlsLgn3FiujU0nSfOTC7nuV6Hv8S9/h5CARpiTx0yzR4KBQNow/wOi09xgjRdRPVYww7dt5Z9TA1NRRZhYBHE+HJdjTAwSChQRdLaEGbqaYkecwhX/z80zBxlxQyUT+AmzhQGO5yOELQOgy8PosSM0+YhL/+qmhvPgatncEiW4160JSnNV3TxKEAk0rJUuC0W6wlI59xfLtB7CTYbCYyj2lWcsyakO7vILITIawqo6IlJ/AtTpDTZSVFHcUT3j01HRQ9dwWQWf79EVvpGiJN8YdPjU14Jcx1gKGLGwFPXWgKEMxcncDQK5D3DtmyZGjo47y7wz4RIifuPaq+DDOEp9RlSvexWRrs5KJX1rcdpanyo8hktyk/A23W/Wt/kDybTEmIrrc+LgXPhCG/7U5T025CIvWbQtaSGJ1oZRwfR4QkF+5ZM/m+Yatnkhcf4bmKu01jo//9HPcx70BA49cTz/78yLrvLJWAOhB4fDMS8zj2O5EjAHShTMI2TQC1GHaV8TKdezzHClDxMI5tQaBI1AZYS+2t2dcLs53LlIwdBoQnJ3UvDYjvTgmIbkPD8l4EeDWbJb/AcPPSMR1r6Jw8sB7pwwJ9VxKZgu6VGZrikEBDx9pOs8QJNGAjvhBxN6Kl2NI6Zt9rAE1ZJcmWWGgIJEA37yiKSQS/WjANYK9N5Rn5nxrRn2KiBFdZRvE6LkLUFiUg83va3WYwYsyYE51bV5qNqqDwjYIHSV8IC4Njtc6WpKq76edVCOfq7EWrBCYCtFmSFeUvmaWn5udIPzWe1frWLfD/8cDMwh6Myv7wizZSCXg9iMFDTXo9VW9p0NxizBmFEGcMVGXwxNFSQH0eiN3jiAdq2EcC3gIKiC35Uf6YFgvKBfAUgYBMGNjCTP2hRHVe3EKGjPkB0PHrQOKeje3uFP7xiYseHVMnAI7TkIgoGBLFAY2iwf8iRAEPbHA1ZdEKjgIBhAh/RC571OGHhYtkHYB4JgjmlhzP0VCT6QBMnFwbif9aQIwLAPqKnBA9wUmO1W2DlNuC3ZVDyOCljMnznSGdCADXzEASqED8wDj6VNHqbBq0nf3LHTmk2gqSQILuhCH2pgj1zhiGQhF34cF44gRJ2Av4kaDtlQ69VFcbDEKHD/ilj5ijQAFxY5FeTtnxBEkRzy4LAZnGTRg8ZwSmqxQfJdnQIIwxH+0U7kQOa94YpUX8PEACqkRQex2w1MWyAOwhSKXyWKXiWqB8Q9x9PdXUNRx/c0BstZWWk0gZj1zib0HTRGYxdqIXmUnDU63tQFR9bNRUCYSSRNH1UkB8q5nDl4XdeAXnMEnj9GxuBNozlaIjoOJD/CktiZnEAaJEOa40FKXkIm3UI6ZENG40OeiwJ8xEB9EKBkZPhMQ8ad480p5CUOpEiW3/ip0EUOwkBkCi0oAio4GEwSCsVIo8MFZElW5EROI2i4jwMgwkb+ZPcczGRt4ciN3U4mZUE6ZE9C/wIYbGSFAQGb4eCx9BxOLiVFZqVFNmUFASUBUZBQdpAAZJxVImVOaqVSiiBX/pEWbKQiJIiDnRtNvttNmiVWWqROXmJPAgQsgM5H0kVKIIoDhGRZkuRdpiVKGuTRRaQ15uVZIuboPSQ9ylxjoiVkhl5KnpBkHqI3HkdmNs9ngqZjqqVE1qVhiqBJhubXKWZpHuVpmtLPiQZkBJ1sGkZsPobg4dxmkhNjemYI2kFhVFhhbNmWJAAlKEIQMEDEdd8M5JohHonj2SRBxhw2nQDozA8OetOk4eNcUBA6oRhXgFk2KpzoRQVdBA5x8oBxNgU0HIhaVJu68FPg7IBP9cl4Sv8ndRaGNiUKN8lA7p0DSxCYsuUGNu5mMf3jP/oceYLT/7XXPbzBH7zAXCTnIjqXFmgCINjjhUTndEbE/0QZQbVBI2wEzySAXnzLVS2AknRjwAACp8XJb6KcUiCYpKiYisqQEFxbDmTojcjnTeGL9vGmUVIniOpPQY0oPrKTR/LAbDzagShJaxSoau5jjM4E+tzU2XlO+FWe4TnAVKpCFfRCURaH7d0CTc2OqfRKF1jVrOjJuUQefnpoTRTpr5gNSpVJlnYlRAEfteFEKz6BOSXIjd5nh8rolf5Alh4KynlS2pDAmCZBX0UL+kTbGhLD1sEoXX7c1lAhD5jUVLZfyWz/w1FIWSZowxgGFVO9EGCtDLOQxQvuClZ5nhdM6bvIqaSZZwGgJw0gQog8Uzw4AgYGRHFNhf191iSCFyHamfoMQL3gFrhlqkgmATZBVlhN1jz0iIykgLac0aZ2zNOQCA8oQMEsxIwJ6YImFK7qqlD26neRAHQN66Kulhv+AEY0QK8swDxSZrS2XjRFlrVWVon+numgCKAswKkmIiMsq3mNmZGClgkgjX9wjWUWqpVyJBCMCONQRCR46akpByM8KhKoSYE5jo/Rgodp0bMOqa1u6kbmnn6VyeHRWViyyCv6DhAoTDg+p77KaYPSKPhlLJcWWN2MZeVd4dokXpuZa5xK/wSdZsLaaEyTFICoHgvHSc5ELYEVDo/YjOwXSelo8qw4+qz+IGO8ImqFEoL6URqPhmynfVaY6SFa9QjK4l/ZUeyc3peUgePb/oA9zAa+DMf/xA8fgKv10BXZEuq+VqyDIszhcmn+7egE9ijRgmEF5QSJ4AOH1hy0SmvTBpXiQZ1HEsAOKMJeEAC4AsO93BkmMKzbnph75Wsn0GpIVSl2TSrxZQUt7BiiLic8Nid8rga2mams1ZvsoR66USEp1m3i3i0PRNariU1UeFp4okJ33myImdGD9ohODCZnnitwzuhwwsqo1YS3NOF7jhWixoUM2WcbPAOYsdtydubKtlpSPP/vPcKaehpGSkQbpJxEfhCb8fKbnZCFD3xRUciqCcgunNQmKq3H0zFhLJQSbeLmbOocAwMkemAjLilwm3Dwb2QuRE4sai6PBh+JBw/JCWdICqvwaKLkCi9TCyemCLtwDGNmatYw4RnoBEMdolwDpEmDeGLO/c4Qq9hgBxWVeHic3fUwNhRGEHPqHiVK7I1DQ6TiVJTwub6GjtxbPSTItLnRoUZwZMSK5eQHPTjIA0NrKhSxUT0WyfhsdeZqDxuiG1av5T2P3gpL/P7IC9NHBPKLKxTjTkDalgqx4mroAaBJqCBCHnrNcQAIPtDWAghyI8RAIUMxwITruHqeuN4x0eX/howcgyMOyza8wDZ4ic+OL2hhQzxO6nKm8ZCqWC6gASmzzynTK71BwopVmgM0BIm6H+BOFGpkE6wA0SXLWR/LR18MBU0MxAHEAJI60kY2aHLAKeiII6L6pyP/aVw4n2Ad3+YAygDo1RYwxV01b+84MzTvgjTTQiavgCJX2kbGavIpb00UFTlPlaO5b1joBfO9Aut5VQeWRSnXipKk8kvqbRDMa/56207o7HQKNA7ODPuIw0HnMg8EKoh4ccGECD0PqNpd7DF3XAub05biwwPEAExJJS3g6uAI1R6DyBgyD67552zRH3NRgtXSzMDIV3GYdPGldGHcmSFHMQxwSukA/8FAAA+wKld0Ko5vNQBPN0tKqNd5/YoDcCCoZsWW0AMDfPGB3VRh8AFXlUk9WAPb5mH2mV+nDov+jCVY3yy9lVwic0RIJgZea0whHKBCx4JcPWmcJHN8LHM6twQ0W/KxTDM2TyrJXPOxwAUCn6bG9gCK3QDQ3o4cAggzd9szP3SqsPS3aFm+fg/KKkFMV5S0FMbxug/xZJuMYMRAUzQEiKpcd8JyuoKSgOMGvd3i/kwISjSEyTZt4zLT5mgnY9qu7ulEEWFId9AT11cMR7JyUbIVtLOhOkKC4Ow5AKID+0wRsEAaysJOQ22jQQHRapskUzc+WHeNhmtMFsgBUAIX3P+DcjyiPUuRzOp1UFg1qLn2TIsyLVdBKcdUQyA0IZRxbTGD0gzqyUAaGihyXwD4YAl4GRA4cX9oyZROy3DMqTVMMNtZU7OuX0sKRD/ZDLcBE0OacvAE/WaTOHpD8KKDhyWxd4/EHsnOTSSKvclhvt1Diq9zJgjsdd5UrLTyEds4FtBiPRfe//BviVEGq9x4tnniGruvF7OPIqgfn2JdSy9WmSx5ty2CQdw3PLDxYL1AloPvUW1NC+bR+cmaDFHQAYP5jceNs0H3idtwTecwVBmxfwm2e+jwbZ44SNkaahcdoDtwohMJDvN5nufwordLo5NdpNM4U046ot/wo1N6pW//82VOSzxjWdj46Q5vJaYPHZLE9Mn1hYuetwWz5qYrHZIg+aAnp1szuG7COl5uOlzUZK6zk/vS7a+beqxn+nKE+p9zQiO/+qUXO6r7TF1seKknS+MOO0+e+rQbrqTWehBsb0jSXKeDTbjT9K47e7aj47i/U7mv+2PqJbZz+2U6OrGz+2G2e72TprnDu72P8LzHO6VrOr3je8DLcL4ze7/vO8EPfGTqur/LOsA3PKKnu4IifMJTPGZK/FXyu8Lr+VYGgMd/PMiHvMiPPMmXvMmfPMqnvMqvPMu3vMu/PMzHvMzPPM3XvM3fPM7nvM7vPM/3vM+v/DP8vNAPPdEXvdEf/z3SJ73SLz3TN73T53zQP73UTz3VV73VXz3WZ73Wbz3QCwDXfz3Yh73Yjz3Zl73Z+3zUn73arz3bt73bvz3c43zaxz3d173d3z3e533TC7rBQ7yxbzykv3vf+/25Czzh6/u9Vzy6C761H/7gL37BN77Fy/u1R77NYXzGK77hT/6/M/7lMzznO7zngzvoJ/7Cj/6ql77Gh77oAz6no77IYb5drj7kBzxsPn4C5+axn58zTRyEoBFh6H6UBMfvC6MYV7BugoYiPMMLcLHkIIoUP4OfccPyF0YDQIDsRRxXVVA9qI8MqLQ1QCkE0u5OEcNaRwcI++bmmgVNiIN5+weZfv/EdhUHi75EPa2QyuKg/uKYRoEAMQBkaZ5oikILo75wXAopjdrlIOwOIhc42awgLBqPpJ3QIYAwDIsGgDkCKATSxg4LEThIDMECvDCQBomTdncgMb1WrFYBQFyJyPwpOKuVgAZpCQR6egJ4hYkyfEl+JQQCD3U7PmeEf3yHMEAnIooyA5eGjnsnoYuIAJ6fMKesSIwAsUEPBlIIBKkqnLC6r78mSjJMEAcCaZNmcVkCBgIKXV8AYWMAWgsPbSgPz89uzQIHVw1zJF2iwDGzpEDGBYMABQti2iQNV14HLQADdODHO+gAuWIrwRYEOp5J+WfQ2z0e6UrdIKWKQIsHkBD/cDpVwJkwEg0FIND0RsCAgWIaGGNDAF8aOzvS6Nsx4CGcP/MWHBjJZtTEnzlEkdwyolu4leFaxqzjEsBMkzalkYAZiWe4EkjThNJhzNmCN5KeVoGxDiiABRBOyKOnqqlHA1tFblHg4s2CkMZAphFBwABVmfNMRlTxEQYxbmPnuRhnzYtBSNKolQgp2ISzBpenNClzuVxjOoPJUuxDAgiuQIQWjNDn4gxoEgbaxJY1IoHfkQWASHHwRZMWKfAE20aAu19oiciDmSAwSJ8xjTROqY6XCc+hAQt8iABChLmqKgQImXbwMgoBSa5TTGftymdy0kGHYNdedMQAM6vCU0dA/76OefT8vGYCb9YsUEB7JxjDwH1EcAeAAYTkdZ4RZSUn0gnrtaCfabwwaMJIENxXiSxE5AVAAnsp4EN/CPx3HGGxoECMMciMpAxjWjjwBETTiJEgN9WQgNQOkjDRQEJyeANANC8SNlojpYm0BgEjVXLhVEwo0EYoECijiSuHdGiGJgco0xGJ/FxyCH/P1DNYhco9koAxDnAYHZUX8jJEEu8gs50NKH5HgidVesRGAVcQ0ACbWpZQZRIIoQPLk7KYIlSfgxZVIn7gjVDoFuEgKoCijLo5myoHIOgUPiK5wosnnIiq6CKUBqHTh1eKRKhIHV7SACRsBLqniYGuYmioif9K0WQSMZ7gDAJPRKFZFTjC0cVNki3pwC1lLCfYNZpJgQ853sDky7JwwmfaiaOeZd8+ppjBwAIKVPGlmrnZoEAaTTS2GyH38pmDMqGlC+WgaRhoZ5ru8pNJWiTex8ATJwG6F3q78ofMCf2dQXDD2C0o6REGV2pCe9cZMDFcaJapCsaeitQxxxvfN+AXWhwoqQGSdBFplJlSN+DGL5RMiwFE4CLPuwxkDIQLriRARxip+jVDWqbZsVcVMw+9LLOt7HBrHcBOdxZROX4TmY911LIDlSVc09oVBxjZWJJbzPr1ewfHud8k4uXkJpLaPABvwCQCEZAPDSEU0EJEgHngFm7/RmT0chsvfMpKV5zQ+CEM4AMXL4GudEDGVOm6gy2Em7DWraqSXKulQ4S+uqZOmWE66qzisvqRlH+IjySqJvSsqzbASgOwttBqFnwgbZGARoILWqXtcF2yljNtlM2u6vRuPVXvzCuLbrN7p7/3LKCCCswqm6CvvhDst1/Yi09UPn8i9dtvRP77C6DfgmG/+wnwgPSTHwIX6B71daE18WMghSQ4g7dRMA8KhIUFL7g+DnoQgxn8oAhNNsISOsmEKHxeCk0YwhUy0IAuFGELY3jAGdJQgDa84fxyqMP0wbCHEuQhENHlQfiNUBOUItm5hsg/JkJiZDiUX0luwg0kfo9n/y6AAD7ogKRqzKtdTCRhGINYxLEccYlC3FMifCcGroGKABCEjRnV2Ik5Wu4FBrFPu2y0hh30kSjE6JEA4ki7H9CABS6wohGM+IkfliCQllkKABBDtgYMxAcD6NlNHEaJMKZxjHfkICM/qMgBGmKJQojWbgQTSCp8YpTpaJYxCAGJMdCoR0FaxjfSEoZBAiN2R4BlIRy5SxN0QQEL2AcTztMag1SOSSS4whUABMRPghIYzbIKXbgTDoYExBr4kApTiJQmHYzIE8aTApIIUUUspOA+zqALJxWwkDINwiN9EYMP3gK5E6bgdd0LxceG8oy6EKVpYjPBLZOhmbRAAmKwEf9MQuiZuG5EASn6+wX6upXMJjgTlyZgTEMFGcd2Hkk8huKHAeLJANNQjqBj4Kcs8HEAjL6CmJohyrRciZm5wMR85riJFmzRDE9ek4wxABEQ7FWb21xHQI/EmYE8tJyaSOsB2+rXKfr1AhHN6wC/ORHApKEfdzzIjDxDUxIbxpqWjIhP/VjMAObznadtozJnY8AU7SiCsAYnX90R34vQBwlj6MA2XmRbNN2ZU1DFkasMw4bQvKqTjeBLRChIq0Q5hU0pQtYq3wQDRkzChGfehDKQ7aE1j8qKZv2KcnpC3JqyZCptECBVIxPBkGKjjFPc5xiEtARsamqmMeFBeZliQEj/+IVGFTxKFriw4yEogyI/jQBIZlyojRrKBKJlymXxMC7pBHsc9OlgHgiAAhiztVhlBbKXcfxtAkT2KMsO174kEtY0ltsyzmrUsxDVgTScUQAHVMGZl+SHJqUxD3WCsZqsXWCzpNajA8Q2cvga2M0aozMU9FVa9nCnA9BxK7MJ90FgFTHAjjuCVw1AQVZgrj9RMJ2QjfKpEJQYxeJ2pWlAYZUjIMaOKtdXFVdULy9rEvoUZ4aGVIG9uhwpfNWDW5Dd6b5XjpjVnOLLffU3yf+NASQfxFVuJGAAdqmCFr/ZRR2A5otvveFqI9zEXcyDexdmWMSC56jh6bmqnDzGFeEY/xi6NABeJ57NRPspKBdTJRBqVSFO2HJjIpTkALZrRsUk6aiyuTEtXcgOoBd95BPJpCcFi4EzWrwDIvxRWSJ97w4g+MWCbm51WY4NfjVRtkfL2GWmu+mc6dxAYqtv2OnrGgkeYMcAIjsFAIyIiSn47HTYLIY4NXaqtb1DFwJLRSWsdgUf/AuDgJuD4v5EQgxEw2xzO5bvPna85T3vr6W73nu4N76ht+839VvJ/y5vwAum734XfN8Hj7SgaoDKF+mpzgOHtwyEub/04vWC7o647DSOzRd5QpHCLOXeHj7MX5Ccfg1vtxAoPj+MdGIL0mDjqYo6jW51luMdx/lN7Z2KkP+nPDQnx6DJcyhyCE+82QE0cCfKkxYFyFMHC+lXV2KZ8HpXfd6EfVtLD3EVjwUEHw7FXUnMmDpLB8SgPgpHIDrSE7xMcguLagrbMy6aXXhkAFQh3koL+hZulul3gQaWXDb1nb7klC5iwbhhdJrOQP9KoH/53lXEEvmTPQ4p50zDb7QAQQdIYlSEUIDhb67z1pbe9CrQcb2WGi/iCIeWmsKsEUcMV3nWC7NJYHAbWGACCkOWRVGYTtAnpQITE+jQB/LLV3nBess8IGd7wk3u2oJJ24eCmtTuqtU+LAWsQn9Q4Aa++Sg8ITeUx3x+hf3L28jl3vMLO126dphPr4irx3v/wshAw8klx7CPY2rhw8Un1KVfaAJarRIYZiBfO/JSPjB8G4cCz4Vig1JlKMZ8NqBc0gNeAiN9LrMK1CUrQCVheGRdu6WBC3csqYKA8ZAsKIgVxQWACBM6ksB5j/R5B5BH8ids9Fd/OwhxKKBjo8MI/HcK/geEZnR8ODYwI4JEYzMJaVELJqATXVNjq9Usxocz13EJuuZLvABj+/J9sgAxV2F4qxBXMpIGtCeCqacyFHNo6GdFqzAzIDJJH0MeyhZi/wKDqlAesvF07hQOh7YgH9Na9vduhchtWTcqW/eDGUaEmmI7ZWBGPXUHjdU9CYVEc4cfq6MyhcYAqYMAnFOF/y+wFiaRd3oWG9jDC77meI0zUf5VieVzFj9HRCoAiSyDJFoBd6vwicyjic0QdwdheQqhh95BHQUgc9rQdSpFdT1Ycs0odM8IjUwEAVC0P4eobXQXjX2jjc7DjUVwjcYGjsSWjdoojnRmjufojd+ojgnEjt3ojjMGj2slj+jIWuQYjfV4VPmoOLPIQhHBcp/ggEUgkM6YQvwYbvl4TQkJSvlYL4VggWqobpcAkHkAkYpAckX3gCpQRXiQEE8oGIGhaeowi57gkMAUAwRJiPJYNCsZjwLEbnqQkj70Cq5AkUhgkYmAkf3IkjDgEfm3Om83AoqhChfHCjAZkwd3j8+4kP9j1Cx+NxdbdwXSMnc0UHk58DgNMVA+GVrAAkd9V5V+Bk8FNVij6BEB1RcsMy+4qBSCdniC+HU7kBZuVwJfKZVSAFBnNQnEwSr5YpchEWcauQLPkExQAw4JQElDOS+5FBVoMnYz1RMikJUccXdZoVIs9RaDxZRG1ZKSFiVk1wQO4h2SxQnix2PAsWJ70FSul3wTs3o2QJpSlXzQ0oT+Vny7NwZuNX0uU5Pi0SrWJyIjURvoQGGYECWBxVYtwDJV4gCgESa8JmM8+AJU4Eo60A+jApK+lFc5ICDXIWofZx+cFTDTJiSDRFkWlpSayUTpOUROaQOvdSgWU1800IJC8oL/pSRb/6d/rzmftkWBp7JtENg+0UUGiLIlExkzCEBdQ0gI2AGUxSk0pvZcIqGcE5qM+YJkGTlBztU+XGQSioOdLjAvH1Mq+WVdX+Z/aRKB4nAQrrCF58OZnbmS7QkSUxMqFmNlU+BdeDgFqBkMGAZXbBiELgCbHNaiGaVRL0Cb8NMP1WAc1uObOdaIePKEH2NX4wUyGpKL/IGFF2pqYdhIXXUTBFadbweiRNlsNpMyK4M7HYg70jEWaeUzRmpXmQmjfMOZMxoPd2ajSLYSzjBOnXSVw3ifP4omXdmazcAJpmikZGl3QAk/YVAFh3YMGVOJC0qUzfAxqXijeKk4V4AA/z1FYFfaOD7oLGV2DGRKZkK5Bf95BsEDOqLDpuH5o6Q4V7j2MyiGPXVqp/wGo9WWgwj3kIi2QloAmEjKQNHGnutpdLwqRoqwbjsZYUKkANhXQh+KdDuHQHnTlMuqWs26jXbarTokrnJGrir3reZ6rs2ari6klM3IriskP14WkKKGiIYUGgmhkKO4rBaHrc4GrykEsCiEPuIwKDA3GTolC8ogoid2AlL5SGKwGHjzNhBFIdEqjfuKBAAZBhdrX/nhr7T4T1lWNF2KAr3yCS53AmFAMCGhAHjQqqS3rt/qrM4CMd7RIlR6l9MRl1y2sD0WYqj2Bl8wDuVgLr0AcChpQ/8AqQWsYJP2lrFGMHwyWQRKZwrIhAfCYhBSALPzJ7Po+gIj0RreEVZosZ2yoB+iRzAOaQLcIE3fwD1EqyTn4DoW5WAK8ZcC56hKAA8S+AbyRJ6HUj10GRNuZ1JUUSd3glEigFCK1UG7cGX5NCpe4QOH8BbatIDZo6dsIZZ/WxqCg3mWgQbIoF+eJ4FvIrD++LV29whiEzOI4DImgRZwwbJzdBmZQQyckSSg4RnGuYfpp3C1qR6sJlbDZYZrGzTICUEk53sQlYaTpX51lZ3d9rj9FyGawDLOeQJKZQNv6hQtYJ5RuBoaMkdPIw8uoF+nwLU6qLpe+08EwxwySAJlmx7/4YCDtKtQ7VMkWIAk5AIa0AQ0pgZeZ5Kh2RqgDUgDfBsb1AVoEjoiHaKCCvifHtspbzeeIWuykDu8gpK91iB452kJDcyoU5ErA9p7oNIGpCsJ6quS7Mur2ZSdN3srtqGzRQFW36u2ZgQJIwAudjMuRUuJD4oiYUV7qRW8NKZHyygPqdK5y4EeNYZoitovUFgCUigKHgszPAaqBHysItt/Gux/dkVhVGNX3RsyIiy/TGNE8wIxxpG1F7LCjYS64Taz6GMANosMDhIS9lIP1xYGIyI3i1U37rQG5JI3IXilpEaqAIoCoVgH8XQrl4a/oSK4ANyLtUYXh2tfu7NpgnaS/6HUxY4Iof6XinuKaQTBEdVzxpp7K0akD46CBS2rLMfCjC0crjBQsDRZjfr4bi7ruOsqx0dExzEwrxdZr9gozOgKzDKEzLXsq3SszKTEzO3rws8szbZsBAnRr/T3bJ78Ck5rjcOso9/YcyDbJN8MQtbszEXAsZOkyz4qMEjADdqAFCzjpUj1C92cAt98zvSmArh8SoDWVe4sMFOLvASXznhqBEw7BeUMvEcwL/oxffwwHQSordY20B7W0AbtQXVcsUf7CP6azw69chptCNDM0Qg9wmd3LJTgt2h3FwfhnHYZeAmSHReigW0szs72ApGbT6JGausUXpApUHiBUXNXOf+O2Xj8yxd+0RSFC3dWuY4b2hoUihB7J08yZRQBxUnNo9LHgJcIywZgyWnT4D1s+RJ+5paMqQ4njW4pjSsQ4GIBIle4p1bOGVhakBaqMiGeoIGcUNE1xNPWSwRwkX7QJx23SX29RwercCu8p4Tf4YaTlFWIkJulSaNfan7+EYLqUJZ0iaDgS5ef9y6RfVXi5AoZ8lgNQgOXTR0QtCEyE5vGO1dQRRZtrXjNHDceLNcDSDRIxMEoAl4IAlq6QzA5nX0qgFzfIcC8BcICWoYquCugMiLColug0twgHVGU06BFFcEnHJiuQzBVbaQYuBSaYBrWzaonQwgN/M6cQJ/Lxn7/GXMqt0VdJMrWb02PeFSjHywoZugxSyiGXSrERma2NVcMvSXDOg3Oyf3FNaFiQ5wabrIrVApmtDkwayrZIVbZXLMxczjF8ls3C97ZU40wDoOrseGFMgaF3PdOoPHEj4U1rD3ixZoxSHggTOwxPFo0t43c06wWpSzXlYipY/A5Ay4Iq4MO9XwiDkDP2kAZFytx+uzg8wQcAYFSjwoem8hloYKZJWCLerQUS10FvLiJl+yJvQPelgExntoqWrgTosMvq9MdYd6W9jAPCQDWYZ0Xn4gJS8E75GSpwXOUN9Dj90zNFHSHcpbf/8xx1Gjb+Q2P9fhtxqquiP4CxFyOhv5C/5Eu6Z3Oju7ag5sekT+uzr/86eo46qQOSghS0NHZxerDz0Ug0nGM6t6o6had3AcbPTSRBAtrc8bU63ezYI0VCVE7shBKRzkH6zxNwYpgRCTn6g1bXriOQ7Z+6zzNdHRIw7IgdTQ3IA7aRw3AJIGkAxhdSACs7FyMwTHwsa8EstL+Z9R+7eU4szQrJ/5yFgHmD2g7el+eTFeQFkP1DOTOVUDs6zHxTfZFlSZMCaT26hhMEItCJrHxUoFLaU3x5WYtd3eCJM2QeO+0rUwdeWIB8otQ7Tud2wmt6+wnffVJG7ILrAImYI1BHtf5BZA0ZrRxIk51od2rk/nOt6VKt7vRA/8Uv3CNLb5N05sOLL2wDR0qtdqDUq0mcNi0FH7nV35gRiEoz+ClbuoeNl/UKr/7Lgs3aBLAeiwtkCMLiPMGz1gCIzmWJZ97QHjhBabUq1Ic6F+VCl19H9/T4TRZxnzJkgLCDb0oCIIg+I1dP71fv/L6zIc8z+2AeMN0qwxUkDbX4vZ6TW5oIvdXRoV7IPAFPvQP6mVjiB8Y48RpjKAoUOMIil90qtnOm++0F4fiPDOKXgON38+X/vh72Lt6nAR8XIfGviS/eBNM4PYJ+86gzzCN3PCOM4wQrxY+NU+6wwamg5d//6HiUyX4hT2xSOjfI3oLV+a/GIvtqPIyau+9P5P/oPTo2vr+vvz79g/24Ur/T8v+7Q8CgDiSpXmiqbqyrfsKrzzTtS0L8b3zvV/qfsIhMRUsIpO/o7LphD2jUlVuar0CmNgtUsv9Cr23AaFYEIOBN0EBMKj2CgtEugav43foPH+17wOe/M2QzRAMrJy5lVEVKJ48Fi6tFTCwtTyqSAZSDXIGen72hYrykbZsuhwmnmaWuIZRNoTCnljSlZrc5eae8n75/nKhERjkFAvMueUoNCwfAxQYCxwAHBYn5FAfaB9I51SPKBYiCyArs00bIGgrMKgXyiVXDxgYu7ugNSjkODwbOEuXI8EJB8ze5VjHT4C/EgoQCROxKyIoiqKC/1mcQqwMtzYGBsxyloDArDaFFlSDsMCaAlwiEiiwBhElAJUkxpUhwPHSxyyOmLCDEKnMAkQHFjCoh4ABzRZoBsQU0WCBswf+2NQSAZUBgIePHDA6kQBixIkZ82A86ySt2ibEED06dMCACGlztRJgp00AglVuFiSUCUCvNpc4BcdFhFVHAwLdhrLDxVeSgXAs0CAwqOAAN210F6PIpi3Bo8opxlo02xYM29VFWrsm8jaajkMhAYC9DRZAUxGrggJ4QJfAAxG9b8YgB7e24p9cYQKw5E0A15OIBiClbNkPi3pTnY0AzZusG3x1qeMOC6CniIepYceeFD8N/Pk9Zid+1v8MgGgFZb4JMBxEjgVIV2feqIPcIogx5xMD/BggjzEHPBhgPIDRpF0+KbwBzjMCEATaVFyRYBA4FSrUz3oQ3fKefay9CEyMMs6IRX3BkTeGesKoVuNaPl5xI5BQDCmFkD7I4VJZRxZJRZNRMPkkClFKqUaVSvR4pQ9UaplFl0lwqWWYV2b55RpmyoZmmi4gYEyOaoYH5xJjVkmnlHbe+cIDO0YX4AiiCaBAG+ttNyOeTZYpJ5GK6sHofS848CZUCwyaAEH8CeCMaUAeWmSijnIHqg2depqCPCh1xhcJH1n60qW4Fbepj6RySuusoo6Ka64oFAXAUQz4JQ51cjz3aiH/stZoa7LKGqorDcw2e0JkEvWVI6DU8PeqA7EWGiO0L37qrJXibkjuoib0ih2w5DEFgVYxtYopHchGa+5l39qH73z67msqhtUE6+tKIrDTAKD7rbdXsvY6xW9sDrsGccQMX0axHxK3hbFaGm9ssZMeT8lxRiKnBrIRJguCsi4kU8RyWSrrAjMJLvNI8y8284JzzjLHyXMWOpcC9EU+S0S00J+Ea+/RnCzNtNFGNw1I1KMQ7aXPU5uCNVpPc82z1ngkbe7XdYxNdtcyh01u2TCeDfPawAgQgNxz01233Xfjnbfee/Pdt99/Ax644IMTXrjhhyOeuOKLM964449DHrnk/3/nMLnll2Oeueabc96555+DHrrojVc+uumno5666quz3rrrr1MeN+yz01677bfjnrvukZe+u++/Ax+88MMTz3jvxSOfvPLLM9986GmL+/YwVUu/RfU2Xh9k225vjzL0zmZvRfjid2/y97qObyT15YN8Pq7pQ7n+1VCz7zH88c9/9f0/5t8/2vT7j3v1s9j+3FJALA2QgAlkmPtEdUAwyc9rAJRgAAVIQa89sAuC2IvCwLdBDjZwY4NyygdBeKVUhAoIIAyhpwZxgIWgxkTMwE0yuMKPfXDQATJsCARyAJFZRIUEluDgAGRoDhIxxRwkANQBeshB8DwrZTE7jwGew/8nMI2QalMcFwBwGKhuySArhGAECluwikv45Fw94+IDRkMiGwRsVINC4wsOs6BycXGNXVzIZnYgRhlIooxr+cMbCMCVF9LQXSMwkT9uKII2kgWSiwxMFwOVAkcmkoYQ6ZCqrCEARPSFK5YY2Jm2ODNhGYAgIzFSFk0hRS4qoDhueFUN/vgCQT5rjq38WB6LJgKV0GEfSqJBHO2wSxoE8opTeuUpRxBLrdCSBrZ0AS6h9AdjDNMgihSBQSaESUk+8pMiYMoC+OEuIF4yU9wUgLsco0h+8KM47KBLCUbJAy/gU1gdWeWptuNFB/yqPFmYRn9oAyGDFaZD+wnQQGb4TwT/mlKP/iFBQKEy0IZa8gwHTRCBDHkGYyzARMVJVQIIM5b/TIMsNhnBLNYFKHYsBIy9tNq4VJLFnrSrHsxYSDthmCpv/Msa0zjHvBKC0Bywow0mImVXyLOtM5i0Hvd44zIj6sv2qKeiMWEoiGao0QA1gKPHYMBHkyFSX40mqij14SBVYM8SGLE42lyAPdQZHHGGc5MMeYM/0IkCTBrxh2D1Uw8bIsRk3JOZa4QqNohiFKSMwKIjMI1pxJmAdST1DM7QYRpvs0rLYpYNknWLYq/aRdGQhFCqBS0CMqtOHUaiig8awBk8shOKUieZ4zGBJRowFwQUUTBoFGc9KmZVmpYn/xlGMRBdlMIORKySAH3NlF969SudoNUj5DFAcYZbAKWYwCrWIAhV7KgUpshUj+o17VFTS9lqsNa1m3VAbBkw29qu57Yj4EZSyOhYI12TL21ErDZLlClOggecd4XINHKAFL+eALDsNMilrsXOWdDzsEy1Q2lpCtVZmGNaWXBJZr64CAjQ8xKSEE9xL3GXaHzGJIxgQ4n7CMHjigE6ZECxRGTc49g+Il4DIE2DFPHChPpXxA6BygESECnh6tJXGT4Zjk8wFQgwpQB9XLGP/UKN33SSL6tIDAMAFSJdxqsEKjkAVGxiXkbQq8rH5U9MdpxiH/sEyDoQMpF9sxxfLWQySf/u5BMSVUj7EpidBnbGQhKM1wXThp4GAYkl/2pXbSKkGoBxRiE9CUpD9mnDUZQzbeiQjf+qywTFZYp70sjlRyggROd8bRlUPOMRFvfGMz2CjVfJaojY+sc6iPUZqiPbj+RHEdytyWSiYp0TYIe8VBGuIl085aruOrIJ4MpUTKKAgXF5QavoYV9kmS6kjJk5/O2KrHsMXnTNATv+GIez4Zxe064Xub0uw697fEfxEBs99bAvsoscg2WTW7LPtmZ3GkwQI8bEIM4AsaMhskODyLKHAHmiQy6t6B4WpdJJNHU3xonYRpEaqoNRYj9JwMlwPACyrr71GZhB8skwIyB4Fm3/yXXdTDa2AxcxJ1Gw8xx0FHnyiMlOTkL4MhUQXYitLL2EcPyMKb5Y27jZrkugWYTXcJNDG0YBR8vT7WcELCSVV09q0je8G+nQpouAOakI4rx1oNv8kTIv+mJsjvSOktXg/3D63KP+aDBl8DUl5KAQimmCabpyZStkgeNfIT18rvAPxKL8myYmeROuoPIKAlfi12SFHlIVBZDf2g9Qz4LVl+wHz+S8t4TgelZ4q/RD0H0sFqi0Cf6vgirjvXww6Hux7SBg1SyVEJbPqUDAHo6d1wPxt3R8l+eEPMunY+2br8wUiH5Kx2SbWIirxHmCOAfpF3uBh5h61Y8p/Hao/qOE//8C5X+f+T9wvgnkf7MUcENOIBY3EMRbtYfHuYv7YUL8Td8a0F9i2V+kmVUOFIdyfIh6PNQlyJBixNRdqZ/L5VwWdKCBBUpSzAECoARhuENZhRQF4gD4DRVI0YFCcZo2rBW2XEMqdcNPAYg/LcRVKJXYiaCHDJhdaUUIBoqHcFgK0BVvAAYEZEM1GGBXIGCfoMeflByAHBwitAsTscRADMYP0lAJjuHhbckDotwFPR5P3JZylMQdvcvMfJcynNF1fMY2TZ1I1Joduhw+uMcDKECrEQw74ZcB6Bce9d9OaJdnkUSw0YRNEEBLLFFMVFdKMNVo+QR20EEdusEdmgAjZv8BHy4hCjgGN7zBZQ3MFEoYB70fne3WODTXlEEHdkHVbryLDQ0AePnfDLAQo6BhKUGC4CnHi6VCjcFXAcTLGbXBXejUtu0XPUlDGr3YS+zFpRhAVDTGYwieGpGA2cnEi9kFPZEBYSCVX2BHYIDZXpCYZhxjMjaHlHUiiLwROMYYPI4itCUDXxgAYDCCKlahAkYWYATItChClm2ZQArIyrWJZVyLpVzKLuLAL+6KGlqe1R2GbdAatMXYwL3DO04jb1iGbtTaMk7ZVpDAnvQEdEjH0r0gKf6ZTIikSIJkN4KSolUdcRjHvbXYdx2bR05Zb8hk1t3jGvqJaHgdU0lYAub/wBsBR9Wly57tIwM0ZUJGhi2WxxtxJHuEgUQO5fCZijBm39VNVGSVHBtUiIVIYxUJpHkcYaDonD1OEjgM3CwAFUNNh0WeAn40CA2K5Q0mZNLZA1pRA4CUZFlWQtr5ZBKRIVm6ZVpOJAq4CW1cwvqBR1JaIVURSGB2Bj8M4oAkBFXyBdqpiAxRCD/QVQOOCleOGkVawTvcW8u4hmvSB/BZUPAFCTT0y8bgJvmhjWry4vWpDXCCj2+2JGt6ZQTaD3Fyo/fwQoe0iRmyHpBApKqphxiRCiC2YsQoJyLW5gkM2KB0iLtIkkCi5Q9YQhvsyespC60kUVgYBGTdECcxxDCh/4AFCkYYJUd1igEpcB8NoCB9ZkV/ppHUbCcJIWfCgEhb0sV4oodjoKYMzAI3PWjc2cgVcBIuMBIVNsAbFIdKVNH9DciE1qd+YtsTJIAsVWQ+jB9rFKjW2eYJ9NC3QdYbGMOJihNgiNICMNVXTVvLkaA7NFhhmAg+LFWCiENQSdViQiAkTMMBtElxYKcXlgNRdVw8rZM3HZgAyJKCNVWJPAAZ/FQkgmE3xmAyIMBhaGGJlkAGBiFbJSG2FCEUrYciHYUPqUNtUYMGOhgT7RlB5KBoJmihtWgKvagJTNqkLQNUmMONXiGOCksbEAB5PRZW+iFt7WWlvlstWFd2rAN6Wf8fr1jiYITUOkyiNSjiipAAhmHYOnmoMWyolh4higaHP0Qqb2xoWJpqqXXjqRbcgvSKdXJIEGUiHSoGHyqaLuACTp7HeQAbT7qEi/UpS9CBAxAECsop4gkn+qQAOVrSG1gqWzkqU0xZkJVUmLlEQ+ZHQ6YZLIiYoNXda3LnCHArHXCDIp2jn3hjwFiYu0gcgnFoXpHAmrXZStgnmClJvlrqIhDkfm4rO/qEOzpmM1JVJ2mZOTTAI2QCG6SZNEarXwQpvN7HoPJSoYJgQxjDd4nTgCGCozro6LXKuVHqG+WHSWoFqdJG6sGshtTfCRwHCjpAaIlnQubHCGzaMpSBxFH/YZZ2KF3hbLyFlLjJksHSJIUewmE8pZpqZCb2pGMS7XYYAB7iBpFxRcY6a3i4C1ShnZ9aXDT1CrYeKMWggTEoUhuNBV5FJnnSC7lGQ1CR4GA2SBkCjIMh3ZHOwx3Z3Wo+njq0CSI4gDtkptD+7TJExcghLcXJpwO839thSyEciNSOAMIexmYybH0a5ln2hLUpJlvyR9QaFYqQbdutnWOUk9oSTKAhwIhgichSmXEy59uigGy+wH9uwZcaULa+TwSR7L0o0Qxgp6HoLtb2ru/+nv4YrwMhb3cO3/N2mPmUAv+9xoru7lciH/xBW/5FlvnSXs5o75y1DyVEHzKhL14E/yMvgi/0pugXvG+Fki91jl4JeK8KOJ5f7KIAi2hEVi+owEb+AlL8ykb9bm//etD++m/8/i/4dd50Wp3b8m77psBS6YfOqQM3uAqwOBgJqGDgmWYN7qYEtiCskgMMxZ1OBQpPIShADGhxJq42oGq71Okn1QNguMMJ4ymbGRXbMWNdrWAMkJT/IuFcRJPPVeQS/3AJGtlowOHKHUQZXocNyoQRV0Y3nFEHMlGYbnFjvinIzsz6zhT31qfNgqJ4iHC2FNu2EuIlROobpkIhtmFO/AdfwGJrWZZ6LJuAumgJ/KoSM5c1oGhWkkVQnAEifMesenEnLgVKuMK6SYU6fZZhFf+a+O5XbvXkJefWFQWFJsKkoinHJBNwKHZiqRLwG4siDKjxzyWvqzxjXcTYI8Rxq7RR20oFgfitqxAjiTKIuNXkmeanv5FBmVkxIROqCatKQVJKH1UsSUjCHQPzXQpmQkyydhiZ7d4yjN1wJ5PvkSHVNfeZObsrS2WzOw5zF2fdKmfdvf6lXEBjPX5kwxywozyFG2fkYoxtaMba1J1rTKxkn8qksOClMSukHdnaug20M4+sIW/xu7gd3aFgkxl0MMudnOJgc9mbsnUooQWlA/fe/CKcu2a0SDMbcKmHSlIDI8vkGQHMcEStT06lIvtZScNlPsxyvrExKZYwX5olhHj/0uzWXKDWBWBMiN72BzGbnQVGhkPLGKCqnUSHbwmIrsl5Jlhx0rwxNUd/CEEoFEi/6zg0nZIQtUkX3xoOHnBpw7wxHUO59E2EdWkmBHQlRFiWtWAegDLC4+P69SqsdU/rs/SOL2LvbStWcL18AfBy0xMHzU/j23Eq9uzxr5l8CxcnnSQuyT774vVadm+CtqJQdmVHL2krdvSYUQHjJ1brAVt/qgoosBktbxE09pJGRG3vQJuAbRqXtpx4AmDL3oPCnn3C9u6p5xXzgEpk5+cWMIsx8GzvdmsMhQts3gYFN5wMt2u/AKXgngx4mWzvrCcPAf9h8HWrj0Xw9rLSgI2t/8x2q8kebKBPPBSClV2ZzoFopIgLH8JeZFhvkcACQACYdsMZkzOT6nAhxCmg0upYsaBIEQYRm/Fc7IVliFdkbRVhJqnqahD4QTgbYIsI9DDjHoST+cYDACpZ/3eJKSmqTnUMAMgArPgivMEJw8N/ICkSk0iGx/dqR7BGbmJzjNYbGsekYldHoKoG9hWl1EMb1MJDLORUMDQr5xpp8cqfFcKxpkdkyZZXsCFaLcgbN0Qc2cQqPRmLdepxfLhG2heY54iyXmVTfRhfUKuobmiEzLkgwrgfx4Av37m1Pjk0C4UOPNuvnFdT/HXIyDeaoAHE0hg7TmO7VgvVvuOmEACbMf9CLVhFAqBYcCE3SSZ4CSzsgkisrPAZS3LuPQ9oHFkCBBDHUeiceh/uSZtAqmtBNR8VGB7CAxDEx0pCQ67KMUMVoQE7I2Qj2Rl6Xpirzi66dgO5trYxwb1jzRr5bqkLwqYRZ5WEJMxxqjahA6RLTsiSUGI5z1Z0KqCEVTKyqpcBT+s0XKHEVAwMQBsuGgOjqoUyGlArzZK4jioVLQWSh/sGWfv5bkU29r3ERk9HdaBadtjbI3EycEf78f6uaZ4uynoIfgeVtl8CoFZgPxr1gCMCuS3IgZg7RJ3AVi/zWkqlGAKeu7flQg3KgbgcfF5KUVtIxJ/7CcS8FmTmZvWcIdb/LpLF5YifRxIi8976EKCus4RQA4pEXYbwPHyrUKNrtminNrlk949vsP1ofVCTi28bwWmbfdhzsPFVvPVi/ZeY/dmvfQ/kdtAAA3nTPfXGPT9/gffOvf5aj0kn92yqwHe2pXgyal5DX5j0omm3PTVN984Mg90PjQoQlIJCGstC55AsvnDXzwZq1RBiSw/CWNMvRMgzPU2kaTykFAiC1Rm4S6wJMUO1sKw+5is02A4TeIdzxZDu/lAjIaSOlRZvewnLKwxHYk1QhZTqN33+ZgrEqI5WB0PZ6MqiBzmlqhh2CEAcRRzy/hBnv5xOcRC3Q+B14lTNSeOLCYcQq2pVFh8+/+JKAHqTf9d//coCFIfVvkkki5dKWCUIAIgAFUIBGARwCMALx/IMuzSwPIDJGj0wMCAYi8NAwQAoBkHEqyFoABKrU5DBWA4WTsIAYBXOHAnRQqpwLFCwhAJAWLVQhu/tLrPdHIIB/zvQpyBA0IcjkHSYCPT2dAbw4EB0gGOEpDRg8tXwGBlzxVAHM1Li0jSJl5qnp9rq+gobK9vKOmt7i5urWhuTUAYHSADhA4ZyICSQnDzi9GJACWdEwPwiQM0zMG0906JMnIAI0FCYfMADvMMrqy6yzUNUoECZ7XwAruz7+7Pjc+L7MiDfCy/F/s0woEwApRE6gCxI5oPgOYK42P+1S/gmUCZlXx4mIULsBQI+8rpBBCLMx71kCc6ZFBAS5cAE45SZM7UiBTRdyXT5/Al0lsWgRIv6tAhKFJEl1Yz5KBJjgR0ADhyIs7JCqkMigHDimAqDkxQYw+JMecNA4cQv5yre0RoIoIIFAHM+O7KoyZMoVKsUSMrEABZRYZrFICMjzQlSkCKytUHxFlIBVlNYMfQgWcdwhcDCCCI2xghReGGcCz2DHoIibgCkvSlT58+eRmvb5nk7t25YFrNAtPNgQaITPwoghLnjYR8EgwTooFfgIdRuCGVG1/wJn4kGoVo+RAgbXVvJd6jbSGuHnmw+5eAkoxtIgAIpxMkRwNL/nDAKcnRHNbdGgFVb1ASTY+kM5Nk6dyAEwQuZJaCRM4YoB9NOANkEBD4vJCDcC+yppUd8AuiTYTJWXQceNnZZWNFQu72om4swzmiUjKFAE1luQdDoVio7JrfIbTfyaIuMRM6iHpG0HclkUUY2CeUrQymTEwTh3BbfGlFKeUeWbCjQ0G1UbunKk2TikSSPS57JJpdtvkkLnHKmYuacW9ZpJ5Rr5mknnnwe6eefSgqaZ6CEwrjnoWwaqmiMjcrJ6KO2RVqXpJWmltMulFpK1KacAuXpp7OJeuc6BZyT5isqGpVjl5kemOodiZKqJq162norroDaguqrssQ6I7DA0jCr/667hWpsLMgmyxuzNFrkyWdvnHBcHQYgdIl/JrpHCAMmjMASFfU00FxlIjX3nBfbIAhGc5SYVEYQDyGxKi3LOrsLvojquy+/jt4AAV3iOvDFCagKgQoMDmQKyhL1iqvTETRUJc4aQbABA0GG/PhCCwwAtupxLMZQrL9B3WvyDCinnAfLk96RFgQEPHDAIwbboN4zMei84S8BPbziSPJZyDMB0sygsVMs/IeAegS05JW9Lte28tRVWz11jXiocQAn/d2cRM4WLvyZYKFsxAhAPkS3E8dUWQXFX76iQ9wxKehgZdMrrAbbsCpfzTLgKQs+eNZOotmhAr+c4FsdK4pWLv+39/HAyYgIYFuEiBYyl0y6SBesdHwINa3MiVFraninqZ+8OuutH/X6UYT7Ozu/tdseO265t7h7j70L9Tt5wSs4vLK343u8s8krX7yyzfO2fLLRGzs99c+7GXyreJR8fcvd5/s9+OHLeke95cuoPSzj2ZL+51JWjyv8tso///jbq+L3C+sbtb9t7RNLP1IFUFQDJKD9yHeDb+FDKQtokISQY58gacxdLFDOF9iDhGyICDki4YsJQgERKYhoBRNsz0oo8b+/HfAGBeRUC124QmKdLzZ2s5tpcGY2pmSsYICISJhKowUDoGB/T6MKiQzwACg0iB4a62Ev3pDCVcRQZVP/9F4Va3BFLCYwavCQRwzOYZCAxCBpxRkEARqwkhGpZ3/RYQYDVpIAGzIRdD/YwkmiSLIXSkqPj+JjH7NYjRlKTC79uWHYzCaKHRZjHx6CULZi88GDqIAF4VAcFKRANjIegzEPMFCZ/KgoUB5KlKMEJBhmWLkyoEcGjZOcBOloN3IYAJM2UU8rYzAHEeSnDPeYpCYjAhFPSg2QpBRUMY1pSjxFJ0iCQgzVjsknaBbKlKckZizAdChyKMAwTpJmn5JJTW/OSZyQIieczPkmdKYTnMRU56LYac146qZ/tOLe+Nx5JnzmE565oacA9VkqeWYRoFGqnT8JSNBcDTSc/JQB/7m2JZ/2GEeixwnCF5jBA4g9wwQIWQB7wmTMhDZJpEwiaUkb+olGVAMQdIFKwL4CA1Fg1AUavQkd5CBOe4bPpINCaQwtIjQvEkeBCaGGMy5qjYyuaC0HGiVPayXQKz71WfjrBwo6WYmoTKWIgUAANtZWBKYe9JxTnVFZ+xXVKU6mPd4YYrWSoxkTRNSrLricfMIKmceE8qwv4uuxGJpWWWHsdzr9nl//FdgVmok4wyts9w6bG8hG1qeKlezLEqtYyh7QsdezLNUAu9B2atZ+nv0sZklb2sOdlrSjvWdqVbfae7Z2p691XWhja9hk1hZUs91pbx8rgAAId7jELa5xj/+L3OQqd7nMba5znwvd6Ep3utStrnWvi93sane73O2ud78L3vCK97nJGK95z4ve9Kp3vextr3vfC9/4yre75Z2vfe+L3/zqd7/87a9//0ve4AJ4wAQusIEPjOAEKzi89V2wgx8M4QhLeMIU5m6DK4zhDGt4wxzucHw5S80Qi3jEhN0tiU+M4hRLUcUsbrGL9QXiF8t4xjRelIlrjOMcxy7GOu6xj3+cCx4DechELrIKjYzkJCsZgEtuspOLLOTE8KU2gQBplPgwFp9guTbdSFDutmwnKJgLSc7RRVoK+eSRysiOhHACFBoxiCzDIjNezs4DzuwKj9QGy1Yacwzi3Ar/MP+EzjiICZrKTIM3O8gQouIzZVqhaCVM2TZiTrR88IdoD5EgFnjOBaARJ4AcGGFEF3JApDOjAwolcsb2DATcFiCYSH/aKFWOhZ6NImhd5BooaVGpjzLt0EvratepiPSLKj0DY3cJ2Hxw4Cs6nRs+NMQPI+jPICBw6jLruTM0tufoNqQQCkFgEOz5AgPYYwAInLkQeenDukMthW48JNV0ObcyIPChaXzozrJsUGbUQDPloDkGBEIElsX87kdg2d7JgICI0k2VSb/bWo9+eIPIjR2NUIgBx9gWA8jRh4QwvM3ijlBmsGMlBQwCCR/nyA1OjhnK5ACXx3lDzbaVcjPG/+cLK294xBtQ6YIToXSHaPiWYf6FzBDgIVZpOXZe8G6OHwduj6aQVcRNoGlQMtSZFpHNleNnoYe6EI/AOLabM42E05I7H3L2aJBGAij4INupDgcRBt5i7kG7yrK+GV2aPZq0KKPdA8Czq+WeIXpHPEF/UETE1W0A4cAcHFzAQ+SzfHDKGP7RWG68DAKxAkFvvgzfvtAKBnGqUGdoAIpWNDgO8KDPAHvxkdZIrQsBASuRsA+xX7YOcA/zML05EYqusu7dc4C3x3k1f49CpS9/kBNEGsu3JwGhH9KA3sdA8MlwvUKQLaECRDryHB8R4mutsE0XH9jQd43qXS3phpPfBP9IeD/no+D5GPSZG5QhNBQSom1Xcmsv5m3r8np9xx2qRyHJAG2yV3iq12f7V2sL0FJXAgTHEYBJoGfXRmhTQHTJJmyaBnSaB4H3VzmLIDPK8AaiZ386EGcpmAxvEGebx3qXtkHO0QDHcQboFwTKkETCphHNBgnOsX90loPvIWfp52/O0YGy90NllnL712x4BmgekXmmFoJDeG/Th3+bhmqEFmdHCG8w0Gk3+INWAXNxd2n/p4ISyGybVmspFxYhiGf7B2iKJnh1aIIDOArIETk4AGvbQHeOBxLd5iLwxwmxxkEzqHp8sBMNeCEPSBd9Rn+JB4iLtxfwEYBOMIXk14T/rvEQpONsKfAIIohwJWgVncdohyB+l8aCmuiCUfAQrSiDUUCDrZeFMPAggVAGUACLiLd61Zd7j9aEsbcAviaMn3gV2bJ+DyCFJECFUcBRP/d8pQh6jweM1FdmwGcIs6Z9naZsYnaNzQaMkWcYlYh+mkYJzbgzpaiHVvFp8ycf7/hz+TdGpLZ/HkgIe9EIqOZ43MZqa6YcWhdxJMCI9fYhwqF6n+duqKiFg6B4I4dvMVhm8cFvMbiEm6AMWkEAhiZ0V0iPC9d28bFyP0eGLShpDUCSl3aQqxdpHacZ+TYEzcFwEFmQDhdzofYFRdgHMqkJMnByWqGMPRCDFcQSAPCM/+qmeoPwHWsXdCDnG8e4aewxkVIQlEnXjV2YDATpfoUEk32AcEx5bTdZcGhIkSBVOV93lAQHlQ75aQ/VZiFpi20HlAkBDXIFDYOoaiOTdzcmA1qhYm4zI7OWZoXJQn5pGh2iYjNzJIRpmI9ZA4gJmZNJmbJTmZeJmT/lJ3h0Q65ARsQyWLXBma2QPz6mOLTma+zCE6FJa1GWC6MZI6ypG6U5RmBRmnzTV2tWOggAm2OlSIylmsBJA7SpCrDpI3MjJbK5JbT5mf10OuWhUuRAIuiAB0MnH83QKsYpWOxDRzAjnMnZFLOQI8T5CqP5nbsxR8Vpm8jZC1YmJi7SSVLAm/8F0JtP0pzUeZ6fwJ6woJ2ukizkuUgwQpsQd4EMsBqjCJvYhJSG1p+gGWTKuRdFAqGeWWc/YZ4TSmX76T6foaEjwEzvmQoNJAME0BxlwDmkdqIOQDmrpo8KQTcYYxItQEHwAi6kFlMh1C7tQaJH6QU1Eza+Bi8XiC1hMyZ9GIMMAJemFjnE8SEFQ0FGOo+4ZEEp6kpgcAwtITJQmgAnamVesBJJKqXYgUFvVBkzc6Lxoi4tUKMJwEBudyUO0BCREaPXARUzMCTuJ2c7SmpBenOGMKYnKpx0Og/XEqU79KX8sTMsIVPWEARDWpALsBIjsB9b6S0R9QgnRJ2V0pFb2VH/dDUIs2QZMCFCHIEhDjJmEhNRLjpRLuoFHXmmMlAt9EFBeoqm6CAiaIQhtGodWQoDBxCdJapLnSOkUTqmwyQr3AQHK/AtiLEaDUA2+hMFQnQDrXGfFLExMeExfoNEYMBScEB14/AFOsMzMpCtCFMEcRMbMkAKg5Q2NfAXlddEF0gDjJExYfKsBZoFBVMZLoVm6kExnDBYZMSuY/RDl+Aw1gAFI2GiOyit9VJDMWEcigQHJEIRWuGjMgAOryKtGfOtvYoIjCkXSbAEzyqcFiscp1Cn7DJUFtiZKYBUTWOuRiAG4VkMDbMR+0Ei1LqeyUpJdLARmDRmSISuqkkWAhN6/zwkr/wKB9tkRGaQhM6gAxtDFwFyFSpJQjXImtT6rfSgtJ+hD2axrK/2FzELRBWaRyHKIgTBDBioEONqAjP3ecphIMJprUrjq8qgN6wER4v0LdZ6AASRDcNArkwjNnL0KgWXfCSRuENTEL/wS2xZqvpjRjm4E2FUBsRRo8vAofUwEBZCRkFlIfFACLiqIV7wAKRnl2vERWvgRaYREnBKtOhgVOsiA86UAgFrBwpxt8sgumeURmwKDcA5u3krG7/JBpkBmNB6VO1AvM9gEDTrDz4DNT3jEHe0sxKRVwfzRvhgQ7HrfjITcPThFJkLIHbAto+4tyvLm7l7ND0aE2zmSf8KkQ3kaxhixC5riyNHoxO/a6wvJ63zqbbWYLt9cUPRARacNLcB2xB14wPbmjcDS0kie7lXZSB5QxBL4RkOzKgrckkE3AZo4aJqUzY1i0iwFBOt8RoTkwD3ChgBmrIp5SFUh7tgMIqC2Uil0asUiAIDrLrtyggD56FqY6AiWq8vABeKyQKVkQZQN2nokDcabBhkgMNvcxWDdcQf8zi/OYoJ27JctcH1oBfV4EBhMBhoMwVb6oXCJBPYiyDnoDgeowQ0AZwgexjnSoHhaTcvTBED7LESvEhYRRAPfLVDi8BO/MUv3KvR+bL/ihVg/Ej9O634sL7MC6gIkKKUA6n3WCD/L4pL5cDAJTI6qaQtMHG5EDGp2EERwcFMovPFsnEPCvAqKCK/tYQhjJMfJvxF3xHCAxFCVBpBAbqqMZFKXDqiX3APmqPJoPoh0DBJwboMPSzKqwSrziad5FoOgkpwzcG0CzqiLsfKvImjy3yEqJfLoTYPWcwu9xCkLStXg9C8KPQe+iiprgRGZSBLapyeayFX13miBhAvytAA3WAhW+DHi2Q3wUydlTzK/gwGpswtG3O1JRIF9/zQwcAPJ9GHiRDAlowusaEzywzJtDPDNNCgRnGn9rNM3JCaQVHSK+SbizLSL5IA7jkpnkW3XmYlH6omWxlDCjoDp1kUEKxiL51P/zG9G7h5LJKZmUvN1EfW1E8N1a3jmidj1CWFobtDx1Gt1WZFKSjytOoZoN6rCqtx1cpS1i17C073yGxinUwLD1sN17mZC0K50uApsa4QH2dt165A1HfAm2XMJwp6unFN2CCKBy9ho3uRBPTUg/LRHA1CRk0qGgBoaDRLAxwVah8FV1ABqDt8pBpkDSoIQshRrB6bENMJAzo0AzDXAK/apquKQtkgBMDaCwDIl3f6UoWt250SKefwLcMpBCNgzBFdGJm61zNgAjdFSTDloyT7FwYbGINFCqgC3b9S12KsMAurkj6wI0pLopyo3bGQsX242+U9Gy6C2CQCBYvNDupBHP/pGb2xS76VHdbInVfpMLw84w+nrR6IC0an3ckAjrFr/QkIkQCjXQ5dlHwAOMmh2h5tYNt78AsjYN4Vzju4QNdVrJ/hCd9jC9hmDQPJ21RsfMWM/Nx5kRMoDCI/qtOpwBzqnZ9FwMds2iF6bAd87AoHoMSVkdsW7uPQkwtena6X8t7EXQBRyaKYdpScECRi5QLYPM5MWks5IcsH0EogneMJwd2v0tYGyjTtYAcITREK7Qpwuc2D/eNpHtKepte28QBmqygK0OZH8tZqbueyotRVlNV3zueR2ed/Dugnk+eBTuiaWeiHjuhrnuiLjuhTzeiPvtuODumTDteSTumX/tT/lo7pm46Zms7pnw6Zng7qo/5kok7qp55kpo7qqz5kqs7qr65jrg7rsx6QkTXnx2ksLb1jEFqa8WFXcP48uj7kJN1mCAHsrzAMT7vnhuUiacSXdHLraKKh56k9wg4U1i4nIAfnJX0zw6mhaXFVGnrXraPtxo0kGhowSfAA4i7WN0CgrKQlqJUKzysU0e6f29kK2O4T+v4mRbQdVMPrGgoFHnLsvePvE13w934D/prwreCrd4DmrjXvJNKnXxBB9CeqOeqiQdrZBYkEQZomSRqpbUsFXaEZNrGoetNVpa0/0hHbHVm0BIcIsL20a2krRVQJokMfVwq4AI2prTrbypB6/1tHaqkypmzryT3jdFNr8vOh8c+e679QBD0vqvMcS7IN8r6CQWwYozbgC0tvqzEoqybUEGCPlHjXWc1ul3Rss/9OMdfayefWCFZQ3R2DCGkysIz1aMAwtNSZ8hfDCCILFib7cdvMxAEtBH6QVS9FtR1882XQAqHhCXvvBX3/wUvLiTnR7X2M99DNVC3QM5GEIB0sLnDvL0WkppXfCQ5g9RFh+BHc+YLvNF8A+mcs+nzPF6XvREYDrUFC4fKOB/Teu2gkvQdj0D6wu9ag3wXwu8lPvCKhuAHKWO5bm8vLDOrBvx3UDOX700dgDwRDv36LKyB3AC9hVQjSvdULQeYbvP9D7/xp8ruf7/VlgLwWPwA2FLGffPq5ev8gIIiCgQgFcBgAMQCpMiID8b7JKCT026bCLQF4CBaulupVWJ1SK8LBRjS+TLYrNqvdcrveLzjsFXkTwqxjZ2AwDIMCEKAQNpOGBwAiQDgcgMbJgAKDzV3eHk/WABPESxPLACBKDx6L0ABiDYAgYRbVwAKDDxao0MJCA8BClI2PHoJYrOxsF8HZH+rVY4tklUDjw5MLQN/fCRyA4WviC6cNMiQAHALCnA0gAq9AqkNN3QptuPh46y1kQ66NQBSB8Ity5pVzs6bPdPUttja3N0pSQqVre/IsIGfwIEIxZLrgGHGAgAgDqSD/CiDAAI4IBbC+bYq4p4EBEk0cOMQkcoamZg4BNDQxyYfJbQdEHMAYA6UNkjSvFFhQhN2wK72CKQlJgsWIoAmX0rIlbwSdly5iNqBowN2fkDEKIDMZEucVneugjYK4YA5GHdFMKkjFkSlchE5bTYXaUYACrF7jhS1Zb5hZtHZhZnTrb8UBBUrsDjEX9zFkMAsRQpuFLTLmzJo3c+7s+TPo0IUaZWGwYJLo1OEmH6wcJq1S1apn5qht+7bHHBRzyO6NmTbu4MKD+y5uEILELATwmBi+e/hw1MZnsZ5u/Tr27Nq3c+/uPW717+LHky9v/jz69I7iqG/v/j38+PLn62JP//8+/vz69/NHGF60NZ4hYABp/XH3SG8IGsjZKLMwo5qCC3LxHxYMHPUFDw2GkRhTLUDj2jOhSLgZRC64JJl0XSTyYEIRjsjFbrEpJ2M0tLDo2SMuvlgfhgqcJoaGYBAYF4haKMDKjpC1s8eJX+ioxY1MPZlkOdJs0xSNYETJWY4pUrneF26YAYAoIhS0hAgD0ABcTUZFQYQIqfjSyQE+CTBANSJc0sIeFFlUZhGQGGUAMnWm+cIDfnwZly0EEHCiToPAEUNyeO3UQjt5CvBAczrwgOadNgC6wIlwWBjDOgBoeswJ67DlllENKUZMRp3EN9cqXrmlQgI+WJoqAagKof/pnpgAtycWv0YBahRuqJoJJtmIYNGkJKQyaAMN7aFsqQLYuiCFz3jb00Xe2kAFPTWuQhAAv2SxRCsBpaEqKougsAgbCrxhbg/7LsZCQC88tCijCcCBSQHO6AsHN36EuggLGhHjBzoJa8IDujzxy5IQYz68QjeOcBUqIKn02q4LCZTgksJZpufUTOikkmi7ivo6VUGOWsnHsPUSesVMDLD4sSpRQFCQsybM8DO+DCx8ZTGF4JHjVCuMOeaL4d6Qw5tF4DlQuj50KsLSOtgKrxIxEAAS14lgPYAQUxzhr5XSqC3nwAR3KIROBWirAzQQczSKAaxAseKjYGMhtzSkDsT/UeEiQ5OENEzcq8kJfzvm3m4HAHfULi40MY3YexhFUyKJyTD0YWObbiJfbxscB77aRiWyE40rvaPWppEmiEAIZJxhJet6gqQJ3xKTwLw2rLhGG0Hpsy8hrjVPs95LOdVcwoOI+4I1gw9TjCTAb1JDxllcFqyiHJHP6gslE9PP+SLPQ99cuMiJezRNEFU6z+ShCXiARR2HKdoVnBKt57HBDdCYQ9DkQAfSvIV9SdJanWxggpgIoSdp4gFt2hQR09TqCkNCirVWVUA/lUtPkHAaCZBhFTkdKXvaOwMOUCCWmoxAYuKrAqrwgA5P1cCDoVqMCw8xCY6wbSuVeVW7Loe7/x3OJ393UUvo2hURFABQhSvySAFxlwRQrcAmfEEhtXpIDVQZoGNke4sevGQgrXWGQ6Ahlw07UyTNbCmPUpKjdfYohj7yh46dCVBnBtSIv0GnkbhJid4EGRnhFUgzrnMkJnMAyOJMyTiS/AIlt5ZJR55uWtYxpB9TqcpVsrI9qGwlLGMpy1lCyD60vCUuc6lL8Nhyl778JTCDmaxeRoaQwnTlJknksmOGIUj9YuZS6AgRWCCFmoO8GCTB4EyEGDOYMXGANccwMs+UZZkE+xuStvDJWiglQ6JLZgP2p8Ec1AUvhNBUOruwzixETj7S3NSzFBcGxEFzO8FIRTaSqQuFPv+mnK3EGma2uU31KUAB0tld/K6kADwUQw/KS0g/4yNNAoTiAdM8GcCOlQI7cXARWiGErqqVCx9g6wqrGhkcgDMI5lGCB3C6EjMXUEmWrARTJUAV/DSFh0VkBFUQ6JbQCtMuVEVBW55zSLBc6CzfndMcSv0DqhzQlavY8y5tmeqlhFU/XxWgU97DQmJqGFAB+MF8GKOgdESig4zUTVNibdUBoBhS+EizV3WaCTWYpLigLcd5FyuBaQ4gsyH8lYtC0JAhcjIrVinFBBCYBjZ44K6CtiucV0iAYoIFi5BFERnkO80iEpuyGlwtAfI72cMKYgPU1khn00gC5RaFztd273v/sY3sbb2BMxYUMR5snedQbTATpaBDTY+NoiPSGSqVJXacrLWSC5KbjHy6p7Az+SssWvAAIaiObAW4G0HH+zlCxWFMLWCA7UzICvj9oXOQWG/9mJqAj/7SeM6zE1b6Cb9+Hg5zUuyJ0igHr9EhAsG9hR0CTPNe8u4IouPtwQH4gBce1k++4JgwCkiHYXdGsSorgWtFydsCu6IPrwst8YKRNLkTr2Cw7ymsKkYGiyXkgoA52cGsElG4yf6LY5CIICInZoxxskQxFopCnX70IAMLMxgoyMZMgIGV93mXYoFwcIktKL+Q+a8E7vpfJQC4CR9lz8Nkdh59S7xkqNHvfyuu/wFbeXtloVRUOgMQ4mnkt1Epe/TGiYDfd6Gx5hr4uLzETOAtpgG+i4FxhkPcwQCjwEFo2BdPbDQH20JCZQ+GhBUGwCYJywpN20mLBFhpYlKDiGMpKlEleHHLFlF4lR+sQ84WMueC0PnVmJBYyaKW6gh+BkAWH8MnrRaKPIsigkqw5Z5UTRavcy2CvzpPqqUk7KW/oOHiXIa04uljJ72AR3cbkN6beWUWHjAr1cDGIJ/LzQie40iBpxuYodxCvLuwaGKPsuEFz0/C53NJhzeSoQfBt70zrvGNjwfjHP84yEMuG4+LvOQmPzkvUa7ylbP8MSQHd8sJa3G5IJsyxBzQEf9jbqNsZu3hMdJCxMPB4hrpXEUjAGcY+BtRZMd3Fns0KYqm803TjnzmUOK5lrAeTauLBsgMy0LQxzHRouc7OQlNOtfJMXbHGmSPDqh52DVzUFURIO2ZiTs3td4iu38GyEWDYubq8QA4hGQBOsHDVoXqwXX9tAFrwuoARkX2KwgVC1aFRKaQOk6V+pUnRjH1tjdBVu+J5WsH9CtUPuWTdWVVLZ4fgaqEBZwZRIQbZtKWiwMlmsrzZPVAyXzoZXqt2rdLBRBJ8cbcWq60kC2mgBWR+cKm1sR/1vfnM0EqTKWrdsWKr7Syp/C1RXXjADlmV8JtWxWLADig4NU/yF0SqFD/JwsVaOge2tjkHTH+KkdstQ52TdB8F+UFBXEdV66UACScSBJ8F0HJXyj4lkBRgWv1TFWEVy4kSmzVm6mMnGk5oChIDHGxnyWY0NQoSm1pgWcdDO5MVqKo4IcNVoY019KIniq4wPxlCN/Y1gU6TMqsTCB4z9NYFnZtxz/RhIRZzn91UBzYAxBo2JFgFCKExIDZnwswTv4hkDxYGOHs1+Yh1YCQF0Z9GAsEVqhhTQsoYI8hCeJAYTZg2DwNGRCU0kPYYA60kTk8ghWGBpex4RaCGKkNWH49AoQJVO6NBXvUQR0+EQEgBykAGoY5YYiBTTwMIgLMF3Y9mt/kwOwEwRBq/4ffGQM/YBeRZd8SukDg0FkNboKIvECuAFqcSY9AFZ2X0V2YDcGYmdk4EZAAngsB4qKzNY2zAAvIpASNpSIoiIIb8mJHLE8CWeD+ZKAjVFK7gcYsJtQnPOD44OIfQtnt9IACKMpuWZkhqkMjMFndvIBp6EsjRsPuqIyIXKPQDJD7meMlOtj9/GG7RNcp+Zw5AN4kKIAmkIUpxsGxKYHvxdoggBBN3F8SXSGtWcWtaQX87MUajVvvpcmyhRoMLYCzsMUK+NWnqd5PsKNA0UYMxJ4MjAIHoVBBNIRKpQatLR5QAFHw1VcCaEobdWIcYQGrjaMo0Z6euMYDrCLbydkGGf/kSKbOI6xkE2Di9/nk1ZCNJz6cGKzbF8zbFWbli3RTOKxdLr2cFuhbGCwcQjASxdlGKVWEViaJWaJlbRCcbdRcIvEeUzQaeaQlXNYGXkKHXIIdVa4lYAbmMYGlYBamYbISYR6mYi7moiQmYz4mZPaHx3kl2PGdccBNZGamYBZhqGzTk7jIPtkUakCdr3kPPmHBaaLQGbDa/vwMF3DlG+7Hz/GR3oGHZWqmKnndNngmIIHmX/6BA/yIFmmConGUH9jlC3SUt+BLKFGBWFYOU4QhfjjF1/nTbeKmH/ndKtBU7Ynf9o1ErQyKoeScEgRLbKxIktUY/7AiXjnAKwJC9dT/10AW3uHVD6hYV7SwkHTeB67MIfAB1E2xn6vUnuQ1Hg1gn5VElbXYlK65lD1JHrOIH3YCU/n1iVIYQhOwoMN0DyE8DSVowUxsTok9zxCmSr0VX1ls4s5YSHy2Xw3MRP0MD9NAj77sJ/6wV5+AIMWchgNs1sg4I2VtYDQWZQ5qaFjsaMJA1ioIKQIdTSdOqC9xJlDgl10gYrRFkeZ8yN3wpHmu45ylC+8pSJgWgHv2C3zWzQAoikCiaeJYk9ucAdzYaBUV1TAwmApw4eTU4RB4jeiZjepFmJ4WguGQ4Tt0jRG4TpNAaZTyYzNyYz7qz0LdI/41DxY0QHCiRiIUJ6OZ/wsVKKfQrEFzVqFiKABprGlXoE9QMFD0yKl8WNEokBmZSVo6CIXitOI7zOOsHumUOVvwcNloKeoufWICnhpRIUKV6pBDwNCrEd8WrN96SGW3oWSqoIO37YRqIqVEoMP3RMOpNs4HpYR+6sZ0msMofFWqKd2oQQVCxqPALCVj0CRAOVtadNCgFOv+ASssOWZ3PEBfLk7AbNw04qvAalHM7eVwGKxw9KseJUV5pOVZDofCDiwR/qbEVqzF+oa+XqzGbmzKcazHfmzXUSzIjizJjkPGlizKpqw6iKzKtqzLruzLxqzMdsHJzqzNCmzN3qzOTmjO7qzPRmbP/qzQKmbQDv+t0QZm0R6t0l5h0i6t0+qcY+KdFiBHtokDzsUGhD2t1komVWrLMHSJQZzQOPiU1sHm1p7tedDR3PXEO61nONgRQrzdFljIvaKt3abtw9GlIIifskjrZdFA4bDUaVWC5PUts1TOtwKHzgAM+HxtxN4t5JJfwSVqElANDc6L8FSFxDSWcrACk+ZWkxbE8DjisyQWNe2AIzxu5K5uLXmB3ioG2NoB14zCe1WEPEGBFPAphSGq4lAhgN2A6rKu8KYGHalM9lHBaLkPucYGpbLEv2JDm2EhK6Yq6VbOrKojygyv9k7lF3jtT3KECpUFswrMrMyrFsUQ4h6FEVkX0QGkqEiXYvBur/xCRtPGgtjemDhYZYnNL/9OR/2KAdVW5jg8p+5wQVvq5Vs2XF4+LAMLB8Ji0gI3sAQjsG4o8ARfsAMn8ChFMAZL8AN3MAh/8G2IMAirJdCxbP+m8GCisAq38KK6MAxr3P/GMA1fEAvXMA6v0gznMA/vxw73MBDTxw8HMRH/2A0XMRKDyxEnMRPrxxA3MRR7hwCEAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     GVHD: graft-versus-host disease; KPS: Karnofsky Performance Status; ECOG: Eastern Cooperative Oncology Group; LPS: Lansky Performance Status; BSA: body surface area; ADL: activities of daily living; LFTs: liver function tests; AP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; ULN: upper limit of normal.",
"     <br>",
"      * AP may be elevated in growing children, and not reflective of liver dysfunction.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Pulmonary scoring should be performed using both the symptom and pulmonary function testing (PFT) scale whenever possible. When discrepancy exists between pulmonary symptom or PFT scores the higher value should be used for final scoring. Scoring using the Lung Function Score (LFS) is preferred, but if DLCO is not available, grading using FEV1 should be used. The LFS is a global assessment of lung function after the diagnosis of bronchiolitis obliterans has already been established. The percent predicted FEV1 and DLCO (adjusted for hematocrit but not alveolar volume) should be converted to a numeric score as follows: &gt;80 percent = 1; 70 to 79 percent = 2; 60 to 69 percent = 3; 50 to 59 percent = 4; 40 to 49 percent = 5; &lt;40 percent = 6. The LFS = FEV1 score + DLCO score, with a possible range of 2 to 12.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11:945. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_2_7209=[""].join("\n");
var outline_f7_2_7209=null;
var title_f7_2_7210="Mechanisms of action of selective estrogen receptor modulators";
var content_f7_2_7210=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mechanisms of action of selective estrogen receptor modulators",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/2/7210/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/2/7210/contributors\">",
"     Suzanne D Conzen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/2/7210/contributors\">",
"     Matthew Ellis, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/2/7210/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/2/7210/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/2/7210/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/2/7210/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/2/7210/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three classes of drugs are available that act as selective estrogen receptor modulators (SERMs):",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30181?source=see_link\">",
"     toremifene",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/1\">",
"     1",
"    </a>",
"    ]. All three agents are competitive inhibitors of estrogen binding to estrogen receptors (ERs), and all have mixed agonist and antagonist activity, depending on the target tissue. These mixed activities have led to the redesignation of this class of compounds from \"anti-estrogens\" to SERMs.",
"   </p>",
"   <p>",
"    The mixed",
"    <span class=\"nowrap\">",
"     antagonist/agonist",
"    </span>",
"    effect of SERMs on ERs can be illustrated by their physiological effects in postmenopausal women:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SERMs provide some protection against menopausal bone loss, presumably due to their partial agonist activity (",
"      <a class=\"graphic graphic_figure graphicRef56681 \" href=\"UTD.htm?32/36/33357\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef73629 \" href=\"UTD.htm?1/32/1551\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/2-5\">",
"       2-5",
"      </a>",
"      ]. However, the increase in bone density is substantially less than that seen with estrogen therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41481?source=see_link\">",
"       \"Selective estrogen receptor modulators for osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      SERMs lower serum total and low-density lipoprotein (LDL)-cholesterol concentrations (by 12 and 19 percent, respectively, in one report), although they do not increase serum HDL-cholesterol [",
"      <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/4,6,7\">",
"       4,6,7",
"      </a>",
"      ]. However, data confirming protection against cardiovascular disease for either drug or for estrogen are still controversial. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41576?source=see_link\">",
"       \"Managing the side effects of tamoxifen\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       Tamoxifen",
"      </a>",
"      's antagonist effect is particularly prominent with respect to breast cancer. Among women with ER-positive breast cancer, tamoxifen reduces the risk of recurrence and death when given as adjuvant therapy for early stage disease and can provide palliation in those with metastatic disease [",
"      <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. However, as will be described below, some ER-positive breast cancers display primary resistance to tamoxifen, and all advanced breast cancers eventually become refractory to tamoxifen treatment (secondary resistance). Tamoxifen may also prevent the development of contralateral breast cancer, both in women with a prior diagnosis of breast cancer and in those women at high risk of breast cancer (",
"      <a class=\"graphic graphic_figure graphicRef60219 \" href=\"UTD.htm?16/33/16926\">",
"       figure 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44246?source=see_link\">",
"       \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"       Raloxifene",
"      </a>",
"      has a similar protective effect against the development of invasive breast cancer, with a lower risk of thromboembolic events and cataracts but a higher risk of noninvasive (in situ) breast cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      also induce hot flashes (an estrogen antagonist effect). Of interest, while tamoxifen clearly induces endometrial hyperplasia (an estrogen agonist effect) and increases the risk of developing endometrial cancer (",
"      <a class=\"graphic graphic_table graphicRef69836 \" href=\"UTD.htm?21/11/21692\">",
"       table 1",
"      </a>",
"      ), raloxifene does not appear to have endometrioid agonistic effects; unlike tamoxifen, it does not increase the risk of uterine cancers. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41576?source=see_link\">",
"       \"Managing the side effects of tamoxifen\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44246?source=see_link\">",
"       \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    How",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    can have both antagonist and agonist actions on the ER in different tissues will be reviewed here, beginning with an overview of the function of the ER. The emphasis will be on the effects of tamoxifen on breast cancer. Additional material on the physiology of estrogen and estrogen receptors is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41672?source=see_link\">",
"     \"Molecular biology and physiology of estrogen action\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THE ESTROGEN RECEPTOR (ER)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most receptors of the steroid family, with the exception of the ER, are classically viewed as 'translocating receptors'. That is, they move from a principally cytoplasmic distribution in the absence of hormone to a predominantly nuclear localization in hormone-stimulated cells. However, the ER appears to be predominantly nuclear both in the presence and absence of hormone. The ER operates as a ligand-dependent transcription factor; attachment of estrogen hormone to the ER's ligand-binding domain results in either direct binding of the ER to estrogen response elements (ERE) in the promoter of target genes or to a protein-protein interaction with coactivators at their respective promoter sites [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. Subsequently, the hormone-receptor complex is able to bind to estrogen-specific response elements that activate or repress expression of genes whose protein products are responsible for the physiologic actions of the hormone.",
"   </p>",
"   <p>",
"    The ER shares many structural features with other members of the nuclear receptor superfamily with six components or \"domains\", A to F (",
"    <a class=\"graphic graphic_figure graphicRef59876 \" href=\"UTD.htm?13/58/14253\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Estradiol and SERMs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    bind to the ligand-binding site in the E domain, which also mediates ER dimerization. The sequence-specific DNA binding function of the ER requires dimerization and resides in domain C. Domain D contains a nuclear localization signal. Regions that promote transcription activation functions are present in domains",
"    <span class=\"nowrap\">",
"     A/B",
"    </span>",
"    (AF1) and E (AF2). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41672?source=see_link\">",
"     \"Molecular biology and physiology of estrogen action\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Corepressors and coactivators",
"    </span>",
"    &nbsp;&mdash;&nbsp;On a molecular level, we are only beginning to understand how an individual SERM can act as an ER agonist in one tissue and as an antagonist in another. However, it is likely that the change in receptor conformation that follows binding of the ER by a SERM results in variable interactions with co-factors that are required for ER-mediated gene regulation. These nuclear proteins, termed coactivators and corepressors, are able to interpret the difference between binding of different ligands (eg, estrogen or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    ) to the ER. Coactivators increase the transcriptional activity of the ER by promoting an interaction between the receptor and the transcriptional apparatus that provides the machinery for gene activation and subsequent mRNA transcription [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/13\">",
"     13",
"    </a>",
"    ]. In contrast, corepressors restrain ER activity, maintaining the receptor in a",
"    <span class=\"nowrap\">",
"     protein/DNA",
"    </span>",
"    complex that does not promote transcription [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ER coactivators are exquisitely sensitive to the conformational changes that occur in the ligand-binding domain (LBD) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/16-22\">",
"     16-22",
"    </a>",
"    ]. Unlike estrogens,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    distorts the LBD, generating an abnormal receptor conformation that disrupts coactivator binding outside the LBD [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/19,23-25\">",
"     19,23-25",
"    </a>",
"    ]. Subsequently corepressor molecules are recruited to the ER, holding it in an inactive state [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Changes in the relative ratios of coactivators and corepressors in breast cancer cells are implicated in the differential responsiveness of estrogen receptors to an agonist or an antagonist [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The influence of coactivators and corepressors on the tissue specificity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    and the development of tamoxifen resistance are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Estrogen receptor beta: a second ER isoform",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above characteristics describe ER-alpha. A second isoform, ER-beta, has been described that is highly homologous to ER-alpha in both the DNA binding and ligand binding domains [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. ER-beta binds estrogens with a similar affinity as ER-alpha and activates the expression of genes containing estrogen response elements (ERE) in an estrogen-dependent manner [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to the hormone and DNA binding domains, ER-alpha and ER-beta are not homologous in the N terminal",
"    <span class=\"nowrap\">",
"     A/B",
"    </span>",
"    (transactivation) domains. ER-beta does not contain a strong AF1 within its amino-terminus but, rather, contains a repressor domain that when removed, increases the overall transcriptional activity of the receptor. As a result, the transcriptional properties of ER-alpha and ER-beta are dissimilar. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41672?source=see_link\">",
"     \"Molecular biology and physiology of estrogen action\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transcriptional activity of ER-beta in response to estrogen is dependent upon the cell type, promoter, and the nature of the ligand.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    , which shows agonist activity in some tissues upon binding to ER-alpha, has no agonistic activity when it interacts with ER-beta. These differences appear to result from alterations in the amino-terminal",
"    <span class=\"nowrap\">",
"     A/B",
"    </span>",
"    receptor domain, particularly AF1 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/32\">",
"     32",
"    </a>",
"    ]. Unlike ER-alpha (see below), ER-beta does not have a strong AF1 domain, and its AF2 domain appears to function independently within the receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/33\">",
"     33",
"    </a>",
"    ]. In addition, the partial agonist activity of tamoxifen that is manifest through ER-alpha can be completely abolished upon coexpression of ER-beta [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. When coexpressed in tumor cells, ER-beta functions as a transdominant inhibitor of ER-alpha transcriptional activity at subsaturating hormone levels and decreases overall cellular sensitivity to estradiol.",
"   </p>",
"   <p>",
"    The discovery of ER-beta has added further complexity to the molecular biology of the ER and its interaction with estrogens and SERMs in different tissues. Further study of these interactions, particularly using molecular methods such as gene expression profiling, may help explain the differential actions of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    and other SERMs on different tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Currently, information on the clinical significance of ER-beta expression in breast cancer is limited. However, at least some data suggest that expression of ER-beta is an independent marker for benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    in women who have ER-alpha-negative tumors (in whom tamoxifen is usually not considered beneficial) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/37\">",
"     37",
"    </a>",
"    ]. These results raise the possibility that a subset of women who have ER-alpha-negative but ER-beta-positive breast cancer may in fact derive some benefit from adjuvant tamoxifen. However, these data are very speculative, and at present, assay of breast tumors for ER-beta is not routinely undertaken.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INTERACTION OF TAMOXIFEN WITH THE ER",
"    </span>",
"    &nbsp;&mdash;&nbsp;A simple model of ER-alpha function is provided in the figure (",
"    <a class=\"graphic graphic_figure graphicRef61233 \" href=\"UTD.htm?17/12/17615\">",
"     figure 5",
"    </a>",
"    ). After estrogen or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    binds to the ligand-binding domain, the ER is released from heat shock protein (HSP)-90 and ER dimerization occurs. Sequence-specific DNA-binding to an ERE follows. In the presence of estrogen, mRNA transcription is promoted though AF2. In the following figure, tamoxifen-bound ERs are shown as inactive, since tamoxifen inhibits AF2 function in breast cancer cells. However, this simple paradigm provides no insight into the tissue-specific mixed",
"    <span class=\"nowrap\">",
"     agonist/antagonist",
"    </span>",
"    actions of SERMs such as tamoxifen [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/12\">",
"     12",
"    </a>",
"    ]. As a result, more complex models are required (",
"    <a class=\"graphic graphic_figure graphicRef75840 \" href=\"UTD.htm?21/47/22256\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=see_link\">",
"     \"Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Tamoxifen resistance in breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research over the last two decades has identified two forms of resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    therapy: intrinsic (de novo) resistance, in which ER-negative and many ER-positive tumors do not respond to tamoxifen at the outset of therapy, and acquired resistance, where ER-positive tumors that initially responded to tamoxifen subsequently exploit the",
"    <span class=\"nowrap\">",
"     tamoxifen/ER",
"    </span>",
"    complex as a stimulatory rather than inhibitory growth signal [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Intrinsic resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;ER and PR expression are the best predictors of response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    ; tamoxifen is ineffective in patients with ER-negative, PR-negative breast cancer. However, 25 percent of",
"    <span class=\"nowrap\">",
"     ER+/PR+",
"    </span>",
"    tumors, two-thirds of",
"    <span class=\"nowrap\">",
"     ER+/PR-",
"    </span>",
"    and approximately one-half of",
"    <span class=\"nowrap\">",
"     ER-/PR+",
"    </span>",
"    tumors fail to respond to tamoxifen or develop early resistance to tamoxifen [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19194?source=see_link\">",
"     \"Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of factors may contribute to intrinsic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    resistance including: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Variable expression of the ER-alpha and beta isoforms",
"     </li>",
"     <li>",
"      Interference with binding of coactivators and corepressors",
"     </li>",
"     <li>",
"      Alternatively spliced ER mRNA variants",
"     </li>",
"     <li>",
"      Modulation of ER activity through increased expression of growth factors (eg, type 1 epidermal growth factor (EGF) receptor [EGFR1] and the type 2 EGFR, also called HER2)",
"     </li>",
"     <li>",
"      Inherited drug metabolizing CYP2D6 genotypes",
"     </li>",
"     <li>",
"      Mutations in the BRCA1 gene, which appears to modulate expression of ER-alpha. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These mechanisms are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H125175197\">",
"    <span class=\"h4\">",
"     Expression of ER isoforms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In laboratory models, altered levels of ER-alpha and beta can deregulate estrogenic and antiestrogenic activities in target cells [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/33\">",
"     33",
"    </a>",
"    ], and the relative changes in expression of ER",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    that occur during tumorigenesis parallel the marked changes in estrogen action that accompany this process [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/39\">",
"     39",
"    </a>",
"    ]. These preclinical findings suggest that altered expression of ER isoforms may represent one mechanism of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/34,40\">",
"     34,40",
"    </a>",
"    ]. However, the available data linking expression of ER-beta with clinical tamoxifen resistance are conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Thus, the role of ER-beta in tamoxifen resistance remains unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H125175204\">",
"    <span class=\"h4\">",
"     Tissue-specific availability of coactivators and corepressors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differential recruitment of coactivators and corepressors to the transcription complex depends upon differences between estrogen-bound ERs and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    -bound ERs. Tamoxifen distorts the LBD, generating a receptor conformation that disrupts coactivator binding outside the LBD [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/19,23-25\">",
"     19,23-25",
"    </a>",
"    ]. Subsequently, corepressor molecules are recruited to the ER, holding it in an inactive state [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/26\">",
"     26",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Since tamoxifen also induces ER dimerization and DNA binding, inactivation of the ER depends upon the net effect of tamoxifen on these functions and upon coactivator and corepressor interactions, which may differ between cell types and tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/19,21\">",
"     19,21",
"    </a>",
"    ]. As an example, a 160-kilodalton ER-associated protein, ERAP160, exhibits estradiol-dependent binding to the ER; the ability of the receptor to activate transcription parallels its ability to bind ERAP160 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/19\">",
"     19",
"    </a>",
"    ]. SERMs are unable to promote ERAP160 binding and can block the estrogen-dependent interaction of the ER and ERAP160 in a dose-dependent manner [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/19\">",
"     19",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    In addition, coactivator and corepressor proteins appear to play a major role in determining the tissue-specific",
"    <span class=\"nowrap\">",
"     agonist/antagonist",
"    </span>",
"    profile of tamoxifen [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/27\">",
"     27",
"    </a>",
"    ]. In some cells, tamoxifen-induced AF2 inhibition may be bypassed when enough coactivator function is recruited to the ligand-independent domain, AF1 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/43\">",
"     43",
"    </a>",
"    ]. In other cell types, available coactivator proteins might bind to and activate AF2 despite the presence of tamoxifen [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/21\">",
"     21",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    In the breast, tamoxifen (and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    ) induce recruitment of corepressors to ER target promoters. In endometrial cells, tamoxifen, but not raloxifene, recruits coactivators rather than corepressors to ER target genes that do not contain a classical ERE (c-myc and IGF-1). In addition, the estrogen agonist activity of tamoxifen in the endometrium requires a high level of steroid receptor coactivator 1 (SRC-1) expression [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/27\">",
"     27",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Differences in",
"    <span class=\"nowrap\">",
"     coactivator/corepressor",
"    </span>",
"    status among tumors may also help explain the variable response to tamoxifen in the primary treatment of ER-positive metastatic breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/28,38,44,45\">",
"     28,38,44,45",
"    </a>",
"    ]. In addition, corepressor and coactivator expression levels may influence the development of secondary resistance to tamoxifen. In animal models, prolonged tamoxifen exposure alters the balance between coactivators and corepressors in favor of the agonist, growth-promoting properties of tamoxifen; the net effect is stimulation of growth despite the continued presence of tamoxifen [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/46\">",
"     46",
"    </a>",
"    ]. This is accompanied by suppression of corepressor N-CoR levels in the tamoxifen-stimulated tumors when compared with their tamoxifen-sensitive counterparts [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H125175211\">",
"    <span class=\"h4\">",
"     Gene mutations and alternatively spliced variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the coding of the ER gene have been considered as another possible mechanism for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    resistance in breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/47\">",
"     47",
"    </a>",
"    ]. However, somatic ER mutations are rare, occurring in less than 1 percent of either ER-positive or ER-negative breast cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/48\">",
"     48",
"    </a>",
"    ]. Therefore, it seems unlikely that ER mutations substantially contribute to many clinical cases of tamoxifen resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/49\">",
"     49",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    In contrast, alternatively spliced ER mRNA variants have been frequently identified in both normal and malignant breast tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/50\">",
"     50",
"    </a>",
"    ]. These mRNA variants lack one or several exons due to exon \"skipping\". Some of these variants bind to DNA, but not estrogen, activating transcription in an estrogen-independent manner. These properties imply a role in estrogen-independent growth although they have not been investigated extensively as a cause of SERM resistance in human breast cancer. Interestingly, there appears to be a significant increase in expression of these exon-deleted variants in metastatic breast cancer when compared with the respective primary tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H125175218\">",
"    <span class=\"h4\">",
"     Modulation of ER expression through second messengers",
"    </span>",
"    &nbsp;&mdash;&nbsp;ER expression and function are also strongly influenced by non-genomic mechanisms such as estrogen-independent growth factor signaling [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/52\">",
"     52",
"    </a>",
"    ]. Both ER expression and function correlate with distinct patterns of growth factor receptor overexpression [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/53-61\">",
"     53-61",
"    </a>",
"    ]. As an example, ER-negative tumors (as well as those that are ER-positive but progesterone receptor-negative [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]) overexpress proteins of the epidermal growth factor receptor (EGFR) family, particularly EGFR and the HER2 protein [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/53-56,62\">",
"     53-56,62",
"    </a>",
"    ]. In experimental systems, ER expression is suppressed when either the HER2 receptor or EGFR is activated, leading to refractoriness to hormone therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/52,57-59\">",
"     52,57-59",
"    </a>",
"    ]. In addition, chronic activation of ER+ HER2-positive breast cancer cell lines with heregulin, a ligand for the HER2 family of receptors, leads to downregulation of ER expression and hormone independence [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    One report suggests that this effect may be mediated by a corepressor termed metastasis-associated protein 1 (MTA1) corepressor and that it can be inhibited by trichostatin A, opening the possibility of pharmacologic reversal of resistance to antiestrogen therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/59\">",
"     59",
"    </a>",
"    ]. Others suggest that the antagonist activity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    on the ER may be diminished via an interaction between HER2 and AIB1, an ER coactivator [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/64\">",
"     64",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Data linking nonestrogen growth factor signaling pathways to acquired tamoxifen resistance are discussed below. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Acquired resistance'",
"    </a>",
"    below.)",
"    <br/>",
"    <br/>",
"    It appears likely that an appropriate growth factor environment is necessary for efficient mitogenesis in breast cancer cells, with steroid hormone and growth factor signaling pathways \"cross talking\" to reinforce each others' signaling [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/52\">",
"     52",
"    </a>",
"    ]. One proposed model for both primary and secondary hormone resistance in breast cancer is that phenotypic changes in growth factor signaling pathways may perturb this balance of steroid hormone and growth factor interaction, providing a selective advantage for tumor cell proliferation. These changes may underlie in vivo endocrine unresponsiveness in breast cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H125175225\">",
"    <span class=\"h4\">",
"     Modulation of ER-alpha expression by BRCA1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Germline mutations in the BRCA1 and BRCA2 genes confer a genetic predisposition to breast and ovarian cancers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=see_link\">",
"     \"Genetic testing for hereditary breast and ovarian cancer syndrome\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    A least some data suggest that patients with inherited BRCA1 mutations derive less benefit from chemoprevention using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    than do those with BRCA2 mutations, although the available studies are conflicting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17418?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\", section on 'Breast cancer chemoprevention'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    It has been proposed that the selective benefit of tamoxifen in high-risk patients could be attributable to differences in ER-alpha expression. While most sporadic and BRCA2-associated breast cancers are ER-alpha positive, the majority of BRCA1-associated tumors do not express ER-alpha, possibly because the BRCA1 protein may be able to bind to and inactivate the ER-alpha promoter ESR1 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H125175232\">",
"    <span class=\"h4\">",
"     Altered tamoxifen metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    is converted to its active metabolites (endoxifen and 4-hydroxytamoxifen) by two rate-limiting enzymes, cytochrome P450 2D6 (CYP2D6) and UDP-glucuronyltransferase-2B7 (UGT2B7) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/66-69\">",
"     66-69",
"    </a>",
"    ]. Although several reports indicate that the inheritance of CYP2D6 polymorphisms may confer relative resistance to tamoxifen [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/70-77\">",
"     70-77",
"    </a>",
"    ], other data indicate that these polymorphisms do not impact either toxicity or breast cancer outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/78-81\">",
"     78-81",
"    </a>",
"    ]. Therefore, we do not evaluate for CYP2D6 genotype as a way to select patients for tamoxifen treatment because thus far there is no conclusive evidence that genotype affects breast cancer outcomes in tamoxifen-treated patients.",
"   </p>",
"   <p>",
"    The potential association between CYP2D6 genotype and outcomes for women on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    has been evaluated in several unplanned analyses of patients enrolled on prospective trials of tamoxifen for breast cancer prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/81\">",
"     81",
"    </a>",
"    ] and as adjuvant treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/77-80\">",
"     77-80",
"    </a>",
"    ]. Of note, among 15 women in one study who also submitted a buccal sample (for germline testing), concordance between tumor and germline genotype was 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IBIS-I &mdash; CYP2D6 genotyping was analyzed in 54 women treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      on the International Breast Cancer Intervention Study I (IBIS-I Prevention Trial) and later developed breast cancer (cases). Their results were compared to those from 211 women who took tamoxifen and did not develop breast cancer (controls) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/81\">",
"       81",
"      </a>",
"      ]. After adjustment for menopausal status, prior use of hormone replacement therapy, and smoking history, the main results were:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      There was no difference in the risk of breast cancer in intermediate (odds ratio [OR] 0.88, 95% CI 0.31-2.47) or poor metabolizers (OR 0.84, 95% CI 0.26-2.78) compared to extensive metabolizers.",
"     </li>",
"     <li>",
"      There was also no difference in the risk of hot flushes among intermediate (OR 1.19, 95% CI 0.48-2.95) or poor metabolizers (0.40, 95% CI 0.12-1.36).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NCCTG &mdash; CYP2D6 genotyping was performed on tumor tissue from 213 women (83 percent) who were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      only as part of a North Central Cancer Treatment Group (NCCTG) adjuvant breast cancer trial of tamoxifen with or without an additional year of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/34/41508?source=see_link\">",
"       fluoxymesterone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/78\">",
"       78",
"      </a>",
"      ]. After adjusting for tumor size and node status, compared to the homozygous or heterozygous wild-type (wt) CYP2D6 genotype",
"      <span class=\"nowrap\">",
"       (wt/wt",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       *4/wt),",
"      </span>",
"      women homozygous for the CYP2D6 polymorphism",
"      <span class=\"nowrap\">",
"       (*4/*4)",
"      </span>",
"      had:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      No significant difference in relapse free time (hazard ratio [HR] for recurrence 1.85, 95% CI 0.76-4.52), disease-free survival (HR 1.86, 95% CI 0.91-3.82), or overall survival (HR 1.12, 95% CI 0.50-2.50).",
"     </li>",
"     <li>",
"      A lower risk for moderate (grade 2) or severe (grade 3) hot flashes, though it was not statistically significant. The incidence was 0 percent for",
"      <span class=\"nowrap\">",
"       *4/*4,",
"      </span>",
"      23 percent for",
"      <span class=\"nowrap\">",
"       *4/wt,",
"      </span>",
"      and 20 percent for",
"      <span class=\"nowrap\">",
"       wt/wt",
"      </span>",
"      genotypes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BIG 1-98 &mdash; CYP2D6 genotyping was performed in 4393 (61 percent) women who were treated on the Breast International Group (BIG 1-98) adjuvant endocrine therapy trial [",
"      <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/79\">",
"       79",
"      </a>",
"      ]. The proportion of patients classified as poor, intermediate, or extensive metabolizers was 8, 30, and 62 percent, respectively. There was no association between CYP2D6 genotype and breast cancer free survival or the incidence of hot flashes among women treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      . Compared to extensive metabolizers, poor or intermediate metabolizers had:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      No significant difference in the risk of breast cancer recurrence (hazard ratio [HR] for recurrence 0.86, 95% CI 0.60-1.24).",
"     </li>",
"     <li>",
"      A higher risk for hot flashes (HR 1.24, 95% CI 0.96-1.59 for poor metabolizers; HR 1.23, 95% CI 1.05-1.43 for intermediate metabolizers).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ATAC &mdash; CYP2D6 and UGT2B7 genotypes were determined in approximately 1200 women (13 percent) who participated in the Anastrazole versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       Tamoxifen",
"      </a>",
"      Alone or in Combination (ATAC) trial. This information was then used to assign an activity score (0, 0.5, 1.0, 1.5, and 2.0) to correspond to their metabolic phenotype with the following results [",
"      <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/80\">",
"       80",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Compared to the wild-type phenotype (activity score=2.0), there was no significant association between recurrence and poor metabolizers (activity score=0; HR for any recurrence 0.99, 95% CI 0.48-2.08). There was no statistically significant association between CYP2D6 genotype and recurrence rate (overall or distant).",
"     </li>",
"     <li>",
"      Compared to wild-type",
"      <span class=\"nowrap\">",
"       (wt/wt),",
"      </span>",
"      there was no association between risk of recurrence and the CYP2D6 *4 polymorphism",
"      <span class=\"nowrap\">",
"       (*4/*4,",
"      </span>",
"      HR for any recurrence 0.98, 95% CI 0.45-2.14).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ABCSG 8 &mdash; An unplanned analysis was performed among 876 women who participated on the Austrian Breast Cancer Study Group (ABCSG) 8 Trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      for five years (arm A) versus tamoxifen for two years followed by anastrazole for three years (arm B) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/77\">",
"       77",
"      </a>",
"      ]. All patients underwent genotyping for alleles associated with poor (PM, *3, *4, *6), intermediate (IM, *10, *41), or extensive (EM, absence of these alleles) metabolism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For women treated in arm A, poor metabolizers",
"      <span class=\"nowrap\">",
"       (PM/PM)",
"      </span>",
"      had a significantly higher risk of a breast cancer event (defined as recurrence, contralateral breast or second non-breast cancer, or death) compared to extensive metabolizers",
"      <span class=\"nowrap\">",
"       (EM/EM,",
"      </span>",
"      odds ratio [OR] 2.45, 95% CI 1.05-5.73). The risk for intermediate metabolizers was also increased though this result was not statistically significant",
"      <span class=\"nowrap\">",
"       (EM/OM",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       PM/IM,",
"      </span>",
"      OR 1.67, 95% CI 0.95-2.93;",
"      <span class=\"nowrap\">",
"       EM/IM",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       IM/IM,",
"      </span>",
"      OR 1.23, 95% CI 0.58-2.61).",
"     </li>",
"     <li>",
"      For women treated in arm B, poor metabolizers had a higher risk of an event during the first two years of treatment, which was statistically nonsignificant (OR 2.6, p=0.46). However, this analysis was limited due to the small limited number of events during this period.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data reflect the controversy regarding the role of CYP2D6 genotypes and the metabolism of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , which extends to the concomitant administration of potent or moderate CYP2D6 inhibitors (eg, serotonin-selective reuptake inhibitor [SSRI] anti-depressants). Although we do not test for CYP2D6 genotype prior to the administration of tamoxifen, we prefer not to treat these patients with agents that inhibit CYP2D6. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=see_link&amp;anchor=H1030505#H1030505\">",
"     \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\", section on 'Issues in breast cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The main results of IBIS-I, ATAC, and BIG 1-98, and ABCSG-8 are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link&amp;anchor=H933462070#H933462070\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\", section on 'Tamoxifen'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44246?source=see_link&amp;anchor=H31421388#H31421388\">",
"     \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\", section on 'Tamoxifen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Acquired resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth factor pathways also appear to play a central role in acquired resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    . Signaling through EGFR and the HER2 receptor appears to bypass the estrogen requirement for breast cancer cell growth and may drive initially ER+ cells into an endocrine therapy-resistant state [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/64,82\">",
"     64,82",
"    </a>",
"    ]. It is postulated that activation of growth factor pathways such as these modulates ER activity via phosphorylation, which alters its function, especially its ability to interact with tamoxifen [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/60,83,84\">",
"     60,83,84",
"    </a>",
"    ]. The net result is that an ER-positive cell becomes \"hormone-independent\" and therefore resistant to tamoxifen.",
"   </p>",
"   <p>",
"    Emerging studies suggest that high levels of tumor EGFR expression may serve to identify those women for whom adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    provides little benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/85\">",
"     85",
"    </a>",
"    ]. However, EGFR expression might be associated with a poorer prognosis overall [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/86\">",
"     86",
"    </a>",
"    ], and whether alternative adjuvant strategies, either other forms of hormone therapy or chemotherapy, would alter the clinical course in these patients is uncertain. Prospective trials are required to address these issues.",
"   </p>",
"   <p>",
"    The impact of HER2 expression on the response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30058?source=see_link\">",
"     \"HER2 and predicting response to therapy in breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21370?source=see_link\">",
"     \"Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INTERACTION OF RALOXIFENE WITH ESTROGEN RECEPTOR ALPHA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The newer SERMs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    appear to have different tissue-specific effects from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    . The factors that determine the variable ER agonist and antagonist activity of raloxifene are not fully defined but are under active study [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/36\">",
"     36",
"    </a>",
"    ]. Like tamoxifen, raloxifene distorts the LBD of the ER, generating an abnormal receptor conformation that disrupts coactivator binding [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/35\">",
"     35",
"    </a>",
"    ]. As a result, there is likely to be significant cross-resistance between tamoxifen and raloxifene, resulting in a relative lack of activity of raloxifene in tamoxifen-refractory breast cancer. The differing effects of raloxifene and tamoxifen on the uterus may be related to structural differences in the two compounds that influence the conformations of the ligand-receptor complexes, thereby determining which estrogen-responsive genes are modulated in specific tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternatively, differences in tissue specificity compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    may be related to other unique aspects of the interaction of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    with the ER. As an example, the human transforming growth factor-beta3 gene is activated by the ER in the presence of estrogen metabolites or estrogen antagonists such as raloxifene [",
"    <a class=\"abstract\" href=\"UTD.htm?7/2/7210/abstract/88\">",
"     88",
"    </a>",
"    ]. Activation is mediated by a polypurine sequence, termed the raloxifene response element (RFE), and does not require the DNA binding domain of the estrogen receptor. Interaction of the estrogen receptor with the RFE appears to require a cellular adapter protein. The observation that individual estrogens and antagonists can modulate multiple DNA response elements may explain the tissue-selective estrogen agonist or antagonist activity of SERMs such as raloxifene.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=see_link\">",
"       \"Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/31/499?source=see_link\">",
"       \"Patient information: Medications for the prevention of breast cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30565089\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The selective estrogen receptor modulators (SERMs)",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30181?source=see_link\">",
"       toremifene",
"      </a>",
"      are competitive inhibitors of estrogen binding to estrogen receptors (ERs); all have mixed agonist and antagonist activity, depending on the target tissue. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among women with ER-positive breast cancer,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      reduces the risk of recurrence and death when given as adjuvant therapy for early stage disease and can provide palliation in those with metastatic disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      How an individual SERM can act as an ER agonist in one tissue and as an antagonist in another is not firmly established. However, it is likely that the change in receptor conformation that follows binding of the ER by a SERM results in variable interactions with co-factors that are required for ER-mediated gene regulation in different tissues. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Corepressors and coactivators'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Estrogen receptor beta: a second ER isoform'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Not all breast cancers respond to SERMs such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      . Resistance to tamoxifen therapy may be intrinsic (de novo), in which ER-negative and many ER-positive tumors do not respond to tamoxifen at the outset of therapy, or acquired, where ER-positive tumors that initially responded to tamoxifen subsequently exploit the",
"      <span class=\"nowrap\">",
"       tamoxifen/ER",
"      </span>",
"      complex as a stimulatory rather than inhibitory growth signal. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Tamoxifen resistance in breast cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of factors contribute to intrinsic resistance, including variable expression of the ER-alpha and beta isoforms, interference with binding of coactivators and corepressors, alternatively spliced ER mRNA variants, modulation of ER activity through increased expression of growth factors (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Intrinsic resistance'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       Tamoxifen",
"      </a>",
"      requires the cytochrome P450 CYP2D6 for conversion to its active metabolites. However, we do not evaluate for CYP2D6 genotype as a way to select patients for tamoxifen treatment. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Intrinsic resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The newer SERMs such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      appear to have different tissue-specific effects from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      . The differing effects of raloxifene and tamoxifen on the uterus may be related to structural differences that influence which estrogen-responsive genes are modulated in specific tissues. Tamoxifen induces endometrial hyperplasia, an estrogen agonist effect, and increases the risk of developing endometrial cancer. Raloxifene does not appear to have endometrioid agonistic effects; unlike tamoxifen, it does not increase the risk of uterine cancers. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Interaction of raloxifene with estrogen receptor alpha'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/1\">",
"      Cosman F, Lindsay R. Selective estrogen receptor modulators: clinical spectrum. Endocr Rev 1999; 20:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/2\">",
"      Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/3\">",
"      Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/4\">",
"      Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/5\">",
"      Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999; 281:2189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/6\">",
"      Grey AB, Stapleton JP, Evans MC, Reid IR. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab 1995; 80:3191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/7\">",
"      Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/8\">",
"      Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/9\">",
"      Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/10\">",
"      Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295:2727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/11\">",
"      Jensen EV, Jordan VC. The estrogen receptor: a model for molecular medicine. Clin Cancer Res 2003; 9:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/12\">",
"      MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 1998; 50:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/13\">",
"      Beato M, S&aacute;nchez-Pacheco A. Interaction of steroid hormone receptors with the transcription initiation complex. Endocr Rev 1996; 17:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/14\">",
"      Jordan VC. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 2004; 5:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/15\">",
"      Beato M, Candau R, Chavez S, et al. Interaction of steroid hormone receptors with transcription factors involves chromatin remodelling. J Steroid Biochem Mol Biol 1996; 56:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/16\">",
"      Kamei Y, Xu L, Heinzel T, et al. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 1996; 85:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/17\">",
"      Voegel JJ, Heine MJ, Zechel C, et al. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J 1996; 15:3667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/18\">",
"      Hong H, Kohli K, Garabedian MJ, Stallcup MR. GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors. Mol Cell Biol 1997; 17:2735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/19\">",
"      Halachmi S, Marden E, Martin G, et al. Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science 1994; 264:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/20\">",
"      O&ntilde;ate SA, Tsai SY, Tsai MJ, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995; 270:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/21\">",
"      Jackson TA, Richer JK, Bain DL, et al. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol 1997; 11:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/22\">",
"      Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 1995; 377:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/23\">",
"      Shiau AK, Barstad D, Loria PM, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998; 95:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/24\">",
"      Norris JD, Paige LA, Christensen DJ, et al. Peptide antagonists of the human estrogen receptor. Science 1999; 285:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/25\">",
"      Paige LA, Christensen DJ, Gr&oslash;n H, et al. Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. Proc Natl Acad Sci U S A 1999; 96:3999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/26\">",
"      Shibata H, Spencer TE, O&ntilde;ate SA, et al. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Recent Prog Horm Res 1997; 52:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/27\">",
"      Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002; 295:2465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/28\">",
"      Kumar R, Gururaj AE, Vadlamudi RK, Rayala SK. The clinical relevance of steroid hormone receptor corepressors. Clin Cancer Res 2005; 11:2822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/29\">",
"      Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996; 392:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/30\">",
"      Speirs V, Carder PJ, Lane S, et al. Oestrogen receptor beta: what it means for patients with breast cancer. Lancet Oncol 2004; 5:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/31\">",
"      Pace P, Taylor J, Suntharalingam S, et al. Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor alpha. J Biol Chem 1997; 272:25832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/32\">",
"      McInerney EM, Weis KE, Sun J, et al. Transcription activation by the human estrogen receptor subtype beta (ER beta) studied with ER beta and ER alpha receptor chimeras. Endocrinology 1998; 139:4513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/33\">",
"      Hall JM, McDonnell DP. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999; 140:5566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/34\">",
"      Paech K, Webb P, Kuiper GG, et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997; 277:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/35\">",
"      Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/36\">",
"      Frasor J, Stossi F, Danes JM, et al. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 2004; 64:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/37\">",
"      Gruvberger-Saal SK, Bendahl PO, Saal LH, et al. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res 2007; 13:1987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/38\">",
"      Smith CL, Nawaz Z, O'Malley BW. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 1997; 11:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/39\">",
"      Leygue E, Dotzlaw H, Watson PH, Murphy LC. Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis. Cancer Res 1998; 58:3197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/40\">",
"      Murphy LC, Leygue E, Niu Y, et al. Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer. Br J Cancer 2002; 87:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/41\">",
"      Speirs V, Malone C, Walton DS, et al. Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. Cancer Res 1999; 59:5421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/42\">",
"      Skliris GP, Leygue E, Curtis-Snell L, et al. Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. Br J Cancer 2006; 95:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/43\">",
"      McInerney EM, Katzenellenbogen BS. Different regions in activation function-1 of the human estrogen receptor required for antiestrogen- and estradiol-dependent transcription activation. J Biol Chem 1996; 271:24172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/44\">",
"      Lavinsky RM, Jepsen K, Heinzel T, et al. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A 1998; 95:2920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/45\">",
"      Girault I, Lerebours F, Amarir S, et al. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res 2003; 9:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/46\">",
"      Gottardis MM, Jordan VC. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 1988; 48:5183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/47\">",
"      Fuqua SA, Chamness GC, McGuire WL. Estrogen receptor mutations in breast cancer. J Cell Biochem 1993; 51:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/48\">",
"      Roodi N, Bailey LR, Kao WY, et al. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst 1995; 87:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/49\">",
"      Karnik PS, Kulkarni S, Liu XP, et al. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res 1994; 54:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/50\">",
"      Pfeffer U, Fecarotta E, Arena G, et al. Alternative splicing of the estrogen receptor primary transcript normally occurs in estrogen receptor positive tissues and cell lines. J Steroid Biochem Mol Biol 1996; 56:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/51\">",
"      Gallacchi P, Schoumacher F, Eppenberger-Castori S, et al. Increased expression of estrogen-receptor exon-5-deletion variant in relapse tissues of human breast cancer. Int J Cancer 1998; 79:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/52\">",
"      Nicholson RI, Gee JM. Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br J Cancer 2000; 82:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/53\">",
"      Harris AL, Nicholson S, Sainsbury R, et al. Epidermal growth factor receptor and other oncogenes as prognostic markers. J Natl Cancer Inst Monogr 1992; :181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/54\">",
"      Nicholson S, Richard J, Sainsbury C, et al. Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 1991; 63:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/55\">",
"      Lipton A, Leitzel K, Ali SM, et al. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 2005; 104:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/56\">",
"      T&ecirc;tu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994; 73:2359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/57\">",
"      Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1992; 24:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/58\">",
"      Liu Y, el-Ashry D, Chen D, et al. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res Treat 1995; 34:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/59\">",
"      Mazumdar A, Wang RA, Mishra SK, et al. Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol 2001; 3:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/60\">",
"      Pietras RJ, Arboleda J, Reese DM, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995; 10:2435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/61\">",
"      Mueller H, Kueng W, Schoumacher F, et al. Selective regulation of steroid receptor expression in MCF-7 breast cancer cells by a novel member of the heregulin family. Biochem Biophys Res Commun 1995; 217:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/62\">",
"      Arpino G, Weiss H, Lee AV, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005; 97:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/63\">",
"      Cui X, Schiff R, Arpino G, et al. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 2005; 23:7721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/64\">",
"      Osborne CK, Bardou V, Hopp TA, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003; 95:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/65\">",
"      Hosey AM, Gorski JJ, Murray MM, et al. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst 2007; 99:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/66\">",
"      Jordan VC. Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance. Breast Cancer Res Treat 1982; 2:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/67\">",
"      Johnson MD, Zuo H, Lee KH, et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004; 85:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/68\">",
"      Sun D, Sharma AK, Dellinger RW, et al. Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos 2007; 35:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/69\">",
"      Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004; 310:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/70\">",
"      Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/71\">",
"      Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003; 95:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/72\">",
"      Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007; 101:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/73\">",
"      Bonanni B, Macis D, Maisonneuve P, et al. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol 2006; 24:3708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/74\">",
"      Kiyotani K, Mushiroda T, Sasa M, et al. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci 2008; 99:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/75\">",
"      Wegman P, Vainikka L, St&aring;l O, et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 2005; 7:R284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/76\">",
"      Wegman P, Elingarami S, Carstensen J, et al. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 2007; 9:R7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/77\">",
"      Goetz MP, Suman VJ, Hoskin TL, et al. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res 2013; 19:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/78\">",
"      Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23:9312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/79\">",
"      Regan MM, Leyland-Jones B, Bouzyk M, et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 2012; 104:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/80\">",
"      Rae JM, Drury S, Hayes DF, et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 2012; 104:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/81\">",
"      Sestak I, Kealy R, Nikoloff M, et al. Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial. Br J Cancer 2012; 107:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/82\">",
"      El-Ashry D, Miller DL, Kharbanda S, et al. Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis. Oncogene 1997; 15:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/83\">",
"      Jordan VC. Pak up your breast tumor--and grow! J Natl Cancer Inst 2006; 98:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/84\">",
"      Holm C, Rayala S, Jirstr&ouml;m K, et al. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst 2006; 98:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/85\">",
"      Giltnane JM, Ryd&eacute;n L, Cregger M, et al. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. J Clin Oncol 2007; 25:3007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/86\">",
"      Arpino G, Green SJ, Allred DC, et al. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 2004; 10:5670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/87\">",
"      Grese TA, Sluka JP, Bryant HU, et al. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci U S A 1997; 94:14105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/2/7210/abstract/88\">",
"      Yang NN, Venugopalan M, Hardikar S, Glasebrook A. Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene. Science 1996; 273:1222.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 762 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-160F99BB66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_2_7210=[""].join("\n");
var outline_f7_2_7210=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30565089\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THE ESTROGEN RECEPTOR (ER)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Corepressors and coactivators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Estrogen receptor beta: a second ER isoform",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INTERACTION OF TAMOXIFEN WITH THE ER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Tamoxifen resistance in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Intrinsic resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H125175197\">",
"      Expression of ER isoforms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H125175204\">",
"      Tissue-specific availability of coactivators and corepressors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H125175211\">",
"      Gene mutations and alternatively spliced variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H125175218\">",
"      Modulation of ER expression through second messengers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H125175225\">",
"      Modulation of ER-alpha expression by BRCA1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H125175232\">",
"      Altered tamoxifen metabolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Acquired resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INTERACTION OF RALOXIFENE WITH ESTROGEN RECEPTOR ALPHA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30565089\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/762\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/762|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/36/33357\" title=\"figure 1\">",
"      Tamoxifen in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/32/1551\" title=\"figure 2\">",
"      Bone density with raloxifene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/33/16926\" title=\"figure 3\">",
"      Breast cancer with tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/58/14253\" title=\"figure 4\">",
"      Structure of ER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/12/17615\" title=\"figure 5\">",
"      Estrogen and tamoxifen binding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/47/22256\" title=\"figure 6\">",
"      SERM signal transduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/762|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/11/21692\" title=\"table 1\">",
"      Tamoxifen toxicities NSABP P1",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=related_link\">",
"      Genetic testing for hereditary breast and ovarian cancer syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30058?source=related_link\">",
"      HER2 and predicting response to therapy in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19194?source=related_link\">",
"      Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17418?source=related_link\">",
"      Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41576?source=related_link\">",
"      Managing the side effects of tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41672?source=related_link\">",
"      Molecular biology and physiology of estrogen action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=related_link\">",
"      Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=related_link\">",
"      Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/31/499?source=related_link\">",
"      Patient information: Medications for the prevention of breast cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44246?source=related_link\">",
"      Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41481?source=related_link\">",
"      Selective estrogen receptor modulators for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/55/21370?source=related_link\">",
"      Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=related_link\">",
"      Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_2_7211="Neurologic causes vulvar pain";
var content_f7_2_7211=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Neurologic triggers of vulvar pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Referred pain from the piriformis, pubococcygeus, obturator internus and externus muscles, or sacroiliac joint due to injury, spasm, dysfunction, or orthopedic conditions affecting these muscles and joints (eg, injury to back, hips, or knees, repetitive musculoskeletal or postural stressors)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Referred pain from a ruptured disc or scarring around sacral nerve roots after disc surgery or from spinal stenosis or significant spinal arthritis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Multiple sclerosis or neurofibromatosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pudendal nerve injury related to labor and delivery, recreational activities (horseback riding, biking), vaginal or transvaginal surgery",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Postherpetic neuralgia from herpes zoster",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pudendal nerve entrapment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sacral-menigeal (Tarlov's) cysts",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Bachmann G, Rosen RC. Vulvodynia and menopause. Menopause Management. March/April 2006, pages 14-21.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_2_7211=[""].join("\n");
var outline_f7_2_7211=null;
var title_f7_2_7212="ACC AHA CV risk noncard surgery";
var content_f7_2_7212=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Cardiac risk stratification for noncardiac surgical procedures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        High risk (reported risk of cardiac death or nonfatal myocardial infarction [MI] often)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Aortic and other major vascular surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Peripheral artery surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Intermediate risk (reported risk of cardiac death or nonfatal MI generally 1 to 5 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Carotid endarterectomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Head and neck surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Intraperitoneal and intrathoracic surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Orthopedic surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Prostate surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Low risk* (reported risk of cardiac death or nonfatal MI generally less than 1 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Ambulatory surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Endoscopic procedures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Superficial procedure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Cataract surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Breast surgery",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Do not generally require further preoperative cardiac testing.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. J Am Coll Cardiol 2007; 50:e159.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_2_7212=[""].join("\n");
var outline_f7_2_7212=null;
var title_f7_2_7213="Penile ulcer dark field";
var content_f7_2_7213=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Penile ulcer dark field",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_2_7213=[""].join("\n");
var outline_f7_2_7213=null;
var title_f7_2_7214="Paragard IUD PI";
var content_f7_2_7214=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F86255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F86255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Paragard IUD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This device is implanted into the uterus to prevent pregnancy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_2_7214=[""].join("\n");
var outline_f7_2_7214=null;
var title_f7_2_7215="Manroe normal neonatal neutrophil count";
var content_f7_2_7215=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F83825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F83825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 660px\">",
"   <div class=\"ttl\">",
"    Normal neutrophil count for healthy neonates from the Manroe study",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 640px; height: 524px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The total neutrophil count reference range in the first 60 hours of life. Stars represent single values; numbers represent the number of values at the same point. Heavy lines represent the envelope bounding these data.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Manroe BL, Weinberg AG, Rosenfeld CR, Browne R. The neonatal blood count in health and disease. I. Reference values for neutrophilic cells. J Pediatr 1979; 95:89. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_2_7215=[""].join("\n");
var outline_f7_2_7215=null;
